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GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation is presented in an alternative format. Following the 
General Introduction, a Literature Review on topics related to the dissertation 
research is presented. Six papers, including two published ones and four 
manuscripts, follow the Literature Review. Each paper is complete in itself with an 
abstract, introduction, materials and methods, results, discussion, and references 
cited. A General Summary follows the sixth paper and presents in brief the major 
finding and conclusions of the dissertation research. References cited in the 
General Introduction and Literature Review are listed following the General 
Summary. 
Background and Significance 
Cholesterol, as an essential constituent of biological membranes and an 
obligatory precursor in the synthesis of bile salts and steroid hormones, plays an 
important role in mammalian system. The problem is that, however, there is often 
too much cholesterol in the blood and other organs. For many years, it has been 
recognized that excess serum cholesterol is a major risk factor for atherosclerosis 
that results in coronary heart disease (Gotto et al. 1990), which remains a leading 
cause of human mortality in the United States and other developed countries 
(Thom et al. 1992; American Heart Association, 1994). Therefore, numerous 
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cholesterol-lowering agents have been discovered and synthesized to treat 
hypercholesterolemic individuals (Endo 1992). The side effects of those drugs, 
however, have caused concerns about their clinical use (Erkelens et al. 1988). 
Much effort also has been made in the development of chemical, physical, and 
biological technologies to decrease cholesterol contents of foods because dietary 
cholesterol intake affects serum cholesterol directly in many people (Fraser 1994). 
Biological methods (whole cell or enzymatic) are often the preferred method 
of food treatment because they are usually less harsh, form fewer by-products, are 
easier to control, and are considered "natural" by the consumer. Much of the 
research in decreasing cholesterol content of foods by biological methods has 
focused on the cholesterol oxidase that has been well characterized (Vrielink et al. 
1991). Unfortunately, attempts to use cholesterol-oxidizing bacteria to decrease the 
cholesterol content of foods has produced few positive results (Aihara et al. 1988; 
Johnson and Somkuti 1990). A novel method of using cholesterol reductase or 
cholesterol-reducing bacteria has been proposed to decrease cholesterol content of 
foods and to lower serum cholesterol concentration in humans (Dehal et al. 1991). 
The enzyme, cholesterol reductase, catalyzes the reduction of cholesterol to 
coprostanol. Coprostanol, unlike cholesterol, is absorbed poorly from the human 
intestine (Bhattacharyya 1986). Therefore, foods treated with cholesterol reductase 
or cholesterol reductase-producing bacteria should have little or no cholesterol 
available for absorption when the foods are consumed. Furthermore, introduction 
of cholesterol reductase or cholesterol reductase-producing bacteria into the small 
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intestine is hypothesized to decrease absorption of both the endogenous and 
exogenous cholesterol because of in situ conversion to coprostanol. 
Cholesterol-reducing bacteria have been isolated from the feces of rats 
(Eyssen et al. 1973), humans (Sadzikowslgr et al. 1977), and baboons (Brinkley et 
al. 1982). These previously isolated bacteria, however, had growth characteristics 
that made common laboratoiy manipulations difficult. Growth requirements 
included the need for plasmalogen, which is found in high concentrations in 
mammalian brain tissue, and the need for complete anaerobiosis. Further, those 
bacteria did not form colonies on solid plating media. Attempts to detect 
cholesterol reductase activity in extracts of those bacterial cells were unsuccessful 
(Bjorkhem et al. 1973). 
Recently, a unique cholesterol-reducing bacterium, designated Eubacterium 
coprostanoligenes ATCC 51222, that is much easier to grow in the laboratory was 
isolated (Freier et al. 1994). E. coprostanoligenes is a Gram-positive, anaerobic, 
nonfermentative bacterium that forms colonies on lecithin-containing solid media. 
It converts up to 90% of cholesterol to coprostanol in cholesterol-containing media, 
but it does not require plasmalogen or cholesterol for growth. Thus, E. 
coprostanoligenes seems more amenable than previously studied cholesterol-
reducing bacteria for applications in the food and pharmaceutical industries. The 
objectives of the present study are as follows: (1) optimization of conditions for 
growth and coprostanol production of E. coprostanoligenes, (2) development of 
assays to analyze the cholesterol-reducing activity of the bacterium, (3) 
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characterization of the new cholesterol-reducing bacterium, and (4) investigation of 
possibilities to use the bacterium for decreasing plasma cholesterol concentrations 
in animal models. The results from this study are necessary for the future use of E. 
coprostanoligenes as a probiotic. 
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LITERATURE REVIEW 
Absorption of Cholesterol and Other Related Sterols 
Cholesterol absorption has been a subject of great interest because of its 
close link with plasma cholesterol concentration. It has been found in many cases 
that the fractional absorption of cholesterol is related positively with plasma 
cholesterol concentrations and apolipoprotein E phenotype (Kesaniemi et al. 1987; 
Kesaniemi and Miettinen 1987). The relationship between dietary cholesterol and 
plasma cholesterol was highlighted by the case of an 88-year-old man who ate 25 
eggs per day and maintained a normal plasma cholesterol, which was explained 
partly by absorbing only 18% of his dietary cholesterol (Kern 1991) whereas usually 
34-57% of dietary cholesterol is absorbed from the human intestine (Grundy and 
Mok 1977). Studies on cholesterol feeding in hyper- and hypo-responding 
nonhuman primates also have indicated that cholesterol absorption and plasma 
cholesterol are related positively (Eggen 1976; Parks et al. 1977; St. Clair et al. 
1981). 
Sterols structurally related to cholesterol are absorbed differently. Some 
plant sterols inhibit the absorption of cholesterol (Mattson et al. 1977; Heinemann 
et al. 1991) and have demonstrated hypocholesterolemic properties (Lees et al. 
1977). Cholesterol is metabolized by intestinal bacteria into several derivatives, 
predominantly coprostanol, a saturated analog of cholesterol. The absorbability of 
coprostanol is of concern because a potential technology can be developed to 
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decrease cholesterol concentrations in foods and in human blood if coprostanol is 
not absorbed (Dehal et al. 1991). 
Sources of cholesterol 
Cholesterol available for absorption by the digestive tract includes 
cholesterol derived from the diet and from endogenous sources, predominantly bile 
and sloughed cells from the intestinal wall. A typical Western diet contains about 
335 mg cholesterol/d (Beitz and Knight, 1994). Bile contains about 400 mg 
cholesterol/100 ml (Nakayama 1969). At an average flow of 250 to 1100 ml/d, this 
adds 1 to 4 g of cholesterol each day to the adult human digestive tract (Whyte et 
al. 1973). Grundy and Metzger (1972) estimated that biliary outputs of cholesterol 
range from 800 to 1200 mg/d in normal adults. The amount of cholesterol released 
from sloughed cells varies greatly, depending on the wear and tear on the mucosa 
(Sabine 1977). Therefore, the cholesterol present within the intestinal lumen 
during any one day is typically more than two-thirds from endogenous sources and 
less than one-third from dietary sources. 
Sites of absorption 
The main sites for cholesterol absorption are the duodenum and jejunum in 
humans (Borgstrom 1960). In rats, after administration of a test dose of 
radiolabeled cholesterol, the most radioactivity is accumulated in the proximal half 
of the small intestine (Sylven and Nordstrom 1970). However, there is evidence 
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that the entire length of the small intestine has the capacity to absorb sterol from 
the lumen (Feldman and Henderson 1969). Cholesterol absorption occurs through 
the intestinal mucosal cells that cover the surface of the intestinal villi. The 
intestinal villus displays functional differences between the cells at the villus tip and 
those in the crypts. Sterol uptake is greatest in mucosal cells near the tip of the 
villus (Sylven and Nordstrom 1970). 
Forms of cholesterol 
Biliary cholesterol is entirely unesterified, but a portion of dietary 
cholesterol is esterified with fatty acids. Only free cholesterol, however, seems to 
be absorbed from intestinal lumen. Any cholesterol ester entering the intestine is 
hydrolyzed rapidly by pancreatic cholesterol esterase (Treadwell and Vahouney 
1968). Synthetic cholesterol esters, resistant to hydrolysis by pancreatic cholesterol 
esterase, are either poorly absorbed or not absorbed at all (Vahouny and Treadwell 
1964). Cholic acid or its taurine or glycine conjugate is an absolute requirement 
for enzymatic activity of rat pancreatic cholesterol esterase (Hyun et al. 1971; 
Jacobson et al. 1990). Before absorption, cholesterol must be solubilized by 
micelles containing conjugated bile acids and hydrolytic products of triacylglycerols 
and lecithin-fatly acids, monoacylglycerols, and lysolecithin (Hofmann and 
Borgstrom 1964). Cholesterol is only sparingly soluble in bile salt solutions (Carey 
and Small 1970). The addition of phospholipid or monoacylglycerol to bile salt 
solutions markedly increases the solubility of cholesterol. 
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Uptake of cholesterol 
To date, it is not known how cholesterol within the intestinal lumen moves 
from the lumen into the intestinal mucosal cells. Hofinann and Borgstrom (1962) 
suggested that the absorption of lipids, including cholesterol, occurs from micelles. 
However, both in vivo and in vitro studies indicate that micelles containing 
cholesterol are not taken up by the intestinal mucosa as intact aggregates 
(Simmonds et al. 1967; Hofinann and Yeoh 1971). Westergaard and Dietschy 
(1976) proposed that micelles promote cholesterol absorption by facilitating 
transport across the unstirred layer of water adjacent to the surface of the luminal 
cell. This transport occurs by simple diffusion. Movement of cholesterol through 
the unstirred layer, rather than penetration of the microvillus membrane, seems to 
be the rate-limiting step for its absorption. The micelle as a whole does not 
penetrate the cell membrane. Passage of cholesterol through the structural lipid of 
the membrane occurs by monomolecular passive diffusion. Several investigators, 
however, have looked for a protein mediator of cholesterol absorption. The 
discovery of such a protein would offer the unique opportunity to therapeutically 
interfere with cholesterol absorption by inhibition of the protein involved. An 
intrinsic membrane protein may indeed be involved in the absorption of cholesterol 
from mixed micelles by brush-border membrane vesicles (Thurnhofer et al. 1991). 
Further purification and characterization of the responsible protein(s) will confirm 
this new finding. 
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Events inside mucosal cells 
Once inside the mucosal cells, the absorbed cholesterol is mixed with that 
synthesized within the intestinal cells. Even though cholesterol is absorbed in the 
unesterified form, cholesterol secreted into intestinal lymph following a cholesterol-
rich meal is about 70-80% esterified (Treadwell and Vahouny 1968). It has been 
suggested that the cholesterol esterifying activity of the mucosa may be an 
important regulator of cholesterol absorption, because reesterification of absorbed 
free cholesterol within the mucosal cell would enhance the diffusion gradient for 
free cholesterol into the cell. Two enzymes are responsible for the esterification of 
cholesterol within intestinal mucosal cells: cholesterol esterase (CE, EC 3.1.1.13) 
and acyl coenzyme A.cholesterol acyltransferase (ACAT, EC 2.3.1.26). 
Cholesterol esterase activity requires millimolar concentrations of conjugated 
bile salts (Swell et al. 1950). The role of CE in cholesterol absorption has not been 
consistent. Murthy et al. (1961) indicated that a CE-like activity increased in rat 
intestinal mucosa with cholesterol feeding. Other investigators also showed that 
pancreatic juice or functioning CE activity within the mucosa was required for 
normal cholesterol absorption (Borja et al. 1964; Hyun et al. 1969). In contrast, 
some other studies showed that CE status has no effect on the proportion of 
exogenous cholesterol recovered as cholesteryl ester in lymph (Watt and Simmonds 
1981). By using Caco-2 cells, Huang and Hui (1990) found that there was no effect 
of CE on the association of radiolabeled cholesterol with these cells. 
Acyl CoAxholesterol acyltransferase is another enzyme that has been 
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implicated in intestinal mucosal cell esterification reactions. Unlike CE, ACAT is 
inhibited by bile salts (Norum et al. 1979) and is dependent on the CoA activation 
of fatly acids prior to esterification (Haugen and Norum 1976). Intestinal ACAT 
activity increases with cholesterol feeding and decreases with cholestyramine 
administration (Field and Salome 1982). Specific ACAT inhibitors usually decrease 
cholesterol absorption (Krause et al. 1992). The effectiveness of ACAT inhibitors 
in decreasing intestinal cholesterol absorption suggests a primary role for ACAT in 
the regulation of cholesterol absorption; the role of CE seems less established. 
Recently, Chang et al. (1993) successfully cloned and expressed human ACAT 
cDNA in mutant Chinese hamster ovary cells, which will allow more direct 
investigation about the role of ACAT in cholesterol absorption and other aspects 
of cholesterol metabolism. 
Transfer of cholesterol to Ivmph 
During cholesterol absorption, there is not a large accumulation of esterified 
cholesterol in the mucosal cells (Murthy et al. 1963), which indicates rapid 
disposition of the cholesterol esters as they are synthesized. This transfer of 
cholesterol esters and free cholesterol from mucosal cells into lymph is 
accompanied by the simultaneous transfer of protein, triacylglycerols, and 
phospholipids as stabilized fat particles, chylomicrons and very-low-density 
lipoproteins (VLDL) (Treadwell and Vahouny 1968). 
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Differential cholesterol absorption 
It is assumed generally that the digestive machinery does not distinguish 
between cholesterol derived from these three sources—diet, bile, and desquamated 
cells. There has been evidence, however, showing the differential absorption of 
cholesterol from dietary and biliary sources. Biliaiy cholesterol actually may be 
absorbed with greater efficiency than is dietary cholesterol. 
Intestinal perfusion studies have shown that efficiency of absorption of 
endogenous cholesterol is frequently in the range of 60-80% (Grundy and Mok 
1977). Absorption of dietary cholesterol is reported usually to be lower (Grundy 
and Ahrens 1969). Results from other studies using rats and chickens also support 
the concept of differential absorption of endogenous and exogenous sources of 
cholesterol (Dulery and Reisser 1982; Sklan et al. 1977). Hofinann and Borgstrom 
(1962 and 1964) explained that the difference might be caused by the physical 
states of endogenous and exogenous cholesterol. Biliary cholesterol enters the 
intestine in micellar solution. Ingested cholesterol mostly is dissolved in dietary 
triacylglycerols. To be absorbed, dietary cholesterol must be transformed into a 
micellar state. This extra step may not be 100% efficient; if it is not, absorption of 
exogenous cholesterol would be less than that of endogenous cholesterol. 
The studies of Samuel and McNamara (1983) also strongly suggest that 
micellarized sources of cholesterol are absorbed preferentially. They found that 
when exogenous cholesterol was administered in liquid formula, its absorption was 
significantly lower than that of endogenous cholesterol. When exogenous 
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cholesterol was dissolved and administered in monooleoylglycerol, however, its 
absorption was higher than that of endogenous cholesterol. These results indicate 
that the initial rate of cholesterol absorption is dependent on the physicochemical 
state of the cholesterol source. Data from studies of Samuel and McNamara 
(1983) also suggested that exogenous and endogenous cholesterol approach 
equilibrium as they travel down the absorptive gut. 
In a recent review on cholesterol absorption, Wilson and Rudel (1994) 
stated that even though the efficiency of absorption of micellar cholesterol in bile is 
potentially greater, cholesterol from endogenous and dietary sources usually is 
mixed completely in the intestine. As a result, they concluded that the percentage 
absorption of cholesterol from both sources is equal. Therefore, maneuvers 
designed to decrease cholesterol absorption as a mechanism to lower plasma 
cholesterol concentrations must consider both endogenous and exogenous 
cholesterol as the target. 
Specificity of sterol absorption 
Sterol absorption in the intestine seems very selective. Structurally related 
sterols that differ from cholesterol only in the structure of the side chain at carbon-
24 or in the degree of saturation of the sterol nucleus are absorbed less efficiently 
than cholesterol. Absorption of plant sterols, such as B-sitosterol, is normally poor 
and equal to only a few milligrams daily (Salen et al. 1970). Sitosterol differs from 
cholesterol only by the addition of an ethyl group on the side chain. Campesterol, 
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which has an additional methyl group on the side-chain, also is absorbed poorly. 
Cholestanol (5a;-cholestan-3B-ol), a saturated analog of cholesterol, is absorbed 
only half as efficiently as cholesterol (Treadwell and Vahouny 1968). Coprostanol 
(5B-cholestan-3i5-ol), another saturated analog of cholesterol, is a nonabsorbable 
sterol. 
The mechanism for this differential absorption is not fully understood yet. 
The most likely differences lie in rates of esterification of the noncholesterol sterols 
within enterocytes before incorporation into chylomicrons. Plant sterols can act as 
substrates for esterification in vitro, but all are esterified to a lesser extent than is 
cholesterol (Swell et al. 1954; Bhattacharyya 1979; Field and Mathur, 1983). 
Coprostanol and cholestanol differ only in the A/B ring configuration. Coprostanol 
is the A/B ring isomer of cholesterol, whereas cholestanol has an A/B ring 
configuration more similar to that of cholesterol. Bhattacharyya (1986) studied the 
differences in uptake and esterification of coprostanol and cholestanol by rat small 
intestine in vivo and in vitro with an attempt to explain the different absorbabilities 
of these two saturated cholesterol analogs. The results showed that coprostanol is 
nonabsorbable because its uptake by the intestinal mucosa and its esterification 
within the mucosal cells are extremely limited. In contrast, the uptake and 
esterification of cholestanol are not limited. Several possible reasons have been 
proposed for the lower uptake of coprostanol than that of cholestanol by the 
intestinal mucosa, although the two sterols differ so little from each other in 
structure. First, there may be differences in the solubility of the two sterols in 
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mixed micelles that could limit the availability of the sterol for uptake by the 
mucosal cells. No difference, however, was observed in concentrations of the two 
sterols per volume of mixed micellar layer isolated from the intestinal contents of 
sterol-fed animals (Bhattacharyya 1986). Second, the two sterols could form mixed 
micelles of different structures that could limit the partitioning of the sterols out of 
the mixed micelles into monomeric form, which, in turn, could limit the diffusion of 
the sterol and thus limit the uptake of the sterol by the mucosal cells. In vitro 
measurement of the rate of diffusion of the two sterols from mixed micellar 
solution individually across an artificial interface of phosphate buffer showed that 
the rate of diffusion of coprostanol was significantly lower than that of cholestanol 
(Bhattacharyya 1986). Third, the structural difference because of the cis- rather 
than trans-fusion of the ring A/B junction in coprostanol molecule leading to a 
difference in the 3-hydroxyl group from the axial to the equatorial position might 
have affected the incorporation into the phospholipid bilayer of the mucosal cell 
membrane, thereby affecting uptake. Therefore, it was concluded that not only the 
carbon numbers of sterols but the whole structure of sterol molecules seems to be 
an important determinant for its uptake and esterification, and probably 
absorption, in the small intestine (Bhattacharyya 1986). 
Nonabsorbability of coprostanol has led to development of a novel 
technology to decrease cholesterol contents of foods and in the blood of 
hypercholesterolemic individuals (Dehal et al. 1991). 
15 
Microbial Reduction of Cholesterol to Coprostanol 
Historical perspective 
Search for cholesterol-reducing microorganisms dates back to the nineteenth 
centuiy when it was recognized that cholesterol of exogenous or endogenous origin 
was eliminated with the feces mainly in the form of its saturated derivative, 
coprostanol (Bondzynski and Humnicki 1896-97). An important statement was 
made by Schoenheimer in the 11 December 1931 issue of SCIENCE that even the 
slightest structural changes in sterols influence their absorbability in the digestive 
tract (Schoenheimer 1931). He showed that cholesterol was absorbed easily, but 
coprostanol, known as koprosterol or coprosterol then, was absorbed much more 
difficultly. Soon after the discovery of this compound, it was suggested that 
coprostanol is formed by bacterial hydrogenation (reduction) of cholesterol in the 
intestine because coprostanol was not found in the tissue but always in large 
amount in the feces. However, early investigators were unable to reproduce 
cholesterol reduction to coprostanol by bacteria in vitro (Bondzynski and Humnicki 
1896-97; Schoenheimer et al. 1930; Beumer and Bischoff 1930). On the other 
hand, it was demonstrated that putrefaction of feces increased the degree of 
saturation of fecal sterols, which provided evidence for coprostanol production by 
bacterial action (Dam 1934). 
Later, a number of investigators succeeded in converting cholesterol into 
coprostanol with human feces in vitro (Rosenfeld et al. 1954; Snog-Kjaer et al. 
1956; Coleman and Baumann 1957). It was also found that coprostanol was absent 
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in the feces of germ-free animals (Danielson and Gustafsson 1959; Evrard et al. 
1964; Gustafsson et al. 1966; Kellogg and Wostmann 1969). In conventional 
animals, coprostanol formation was abolished by the administration of antibacterial 
agents (Rosenheim and Webster 1943; Wainfan et al. 1952; Coleman and Baumann 
1957; Kellogg et al. 1969.). Certain anaerobic bacteria from human feces were 
found responsible for cholesterol reduction (Snog-Kjaer et al. 1956). Schoenheimer 
hoped in 1931 that a cholesterol-reducing bacterium would be cultivated in the 
near future. It was not until 42 years later, however, when a pure culture of a 
cholesterol-reducing microorganism, Eubacteriiim ATCC 21408, was isolated 
(Eyssen et al. 1973). Since then, extensive research has been conducted to isolate 
more cholesterol-reducing microorganisms, to study their physiological and 
biochemical characteristics, and to investigated their potential applications in food 
and pharmaceutical industries. 
Cholesterol-reducing bacteria 
To date, a total of 13 cholesterol-reducing bacteria have been isolated and 
characterized (Eyssen et al. 1973; Sadzikowski et al. 1977; Mott and Brinkley. 1979; 
Brinkley et al. 1982; Fieier et al. 1994). All of these bacteria have been classified 
as strains of Eubacteriiim species. 
The first cholesterol-reducing bacterium, Eubacteriiim ATCC 21408, was 
isolated from rat cecal contents with use of a brain-thioglycollate medium under 
anaerobic conditions (Eyssen et al. 1973). E. ATCC 21408 was described as a 
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small, strictly anaerobic, and gram positive in veiy young cultures but became gram 
negative in cultures more than 3 d old. In young cultures, many diploforms were 
observed. 
E. ATCC 21408 failed to grow on many common culture media such as fluid 
thioglycollate medium, brain-heart infusion broth, trypticase soy broth, cooked 
meat medium, and the like. Growth on these media was not improved by addition 
of blood, serum, or yeast extract. Growth occurred, however, when those media 
were supplemented with 1-2 mg/ml of cholesterol in lecithin-containing media. 
Cholesterol could be replaced by A^-3B-hydroxy plant sterols such as 6-sitosterol, 
campesterol, and stigmasterol or certain steroid hormones such as testosterone. 
These media, however, supported growth only for a limited number of transfers. 
After approximately 10 transfers, these media no longer supported growth of this 
bacterium. Long-term propagation could only be carried out on media containing 
brain powder. It was concluded that the bacterium had an absolute requirement 
for cholesterol or a related unsaturated sterol and that growth stimulating activity 
of various A^-sterols was limited to those compounds that could be hydrogenated 
by E. ATCC 21408 (Eyssen et al. 1973). 
Growth of E. ATCC 21408 was very sparse on media containing 0.125 or 
0.25 mg cholesterol/ml, and all strains were lost on further subculture. With media 
containing cholesterol in amounts between 0.25-2.0 mg/ml, growth was directly 
proportional to the amount of sterol present. At least 1 mg sterol/ml was required 
for maintenance of the cultures, and maximal growth was not obtained unless the 
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medium contained 1.5-2 mg cholesterol/ml. The large amount of steroid required 
for maximal growth indicated that cholesterol was not acting as a true growth 
factor. It was assumed logically that the 5,6-double bond of cholesterol, plant 
sterols, and steroid hormones was acting as a hydrogen acceptor in the metabolism 
of the microorganism (Eyssen et al. 1973). 
E. ATCC 21408 grew optimally at 37 to 40°C and did not produce spores. 
Tests for production of indole, acetyl-methyl-carbinol, H2S, or catalase were 
negative, and nitrate was not reduced to nitrite. The microorganism was not 
motile, and it produced small amounts of acid and gas from glucose, lactose, and 
melibiose. No acid or gas was produced after growth in media supplemented with 
maltose, D-fructose, raffinose, mannose, trehalose, melezitose, xylose, or rhamnose. 
The bacterium was classified into the genus Eubacteiium because the general 
characteristics of this microorganism were compatible with those of the genus. The 
special growth requirements and the ability to produce coprostanol from 
cholesterol, however, differentiated this strain from any species listed in the genus 
Eubacteriiim in Bergy's manual at the time. 
In addition to cholesterol, E. ATCC 21408 reduced the 5,6-double bond of 
campesterol, 6-sitosterol, stigmasterol, 5-androsten-3B-ol-17-one, and 5-pregnen-
3,20i3-diol, exclusively yielding the corresponding SB-saturated derivatives. 
Similarly, the 4,5-double bond of allocholesterol was reduced to coprostanol. 
Neither the 7,8-double bond in 7-dehydrocholesterol or in lathosterol nor the 
22,23-double bond in the side chain of stigmasterol were reduced. In the absence 
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of a 3-hydroxy function (e.g. in cholest-5-ene), when the 3-hydroxyl function was in 
3a-position {e.g. in epicholesterol) or was substituted (e.g. in 36-chloro-cholest-5-
ene and in cholesteryl esters), no saturation of the double bond was observed. The 
bacterium also reduced 4-cholesten-3-one and coprostanone to coprostanol (Eyssen 
et al. 1973). 
Biohydrogenating activity of E. ATCC 21408 in vivo was investigated to 
determine its effect on serum cholesterol concentration and fecal sterol output 
(Eyssen and Parmentier 1974). It had been shown that conventional rats excreted 
50 to 100% more neutral sterols through the feces than did germ-free rats (Evrard 
et al., 1964; Kellogg and Wostmann 1969) and that cholesterol was more efficiently 
absorbed from the intestine of germ-free rats (Wostmann 1973). These findings led 
to an assumption that intestinal bacteria might interfere with the absorption of 
cholesterol and promote the fecal output of neutral sterols. To investigate whether 
transformation of cholesterol into the poorly absorbed coprostanol might explain 
these phenomena, gnotobiotic rats were associated with E. ATCC 21408. Because 
of its strictly anaerobic character, E. ATCC 21408 could not be established as a 
monoassociate in the intestine of germ-free rats where the prevailing oxidation-
reduction potential was slightly positive. To obtain a more negative oxidation-
reduction potential, the rats were exposed first to a Clostridium species. 
Gnotobiotic rats associated with E. ATCC 21408 plus Clostiidium Cl-8 converted 
cholesterol into coprostanol with an efficiency of approximately 70%. However, 
the extensive conversion of cholesterol into coprostanol did not result in an 
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increase in fecal C-27 sterol output. 
In another experiment, conventional and germ-free rats were fed a 1% 
cholesterol diet. After 2 wk of cholesterol feeding, conventional rats had 11% and 
28% less cholesterol in serum and liver, respectively, than did germ-free rats. The 
cholesterol concentrations in serum and liver of rats associated with C. Cl-8 plus E. 
ATCC 21408, however, were not lower than those of germ-free rats. It was 
concluded that conversion of cholesterol into poorly absorbed coprostanol was not 
the cause of the higher output of fecal C-27 sterols or the less efficient absorption 
of cholesterol in conventional rats (Eyssen and Parmentier 1974). It was explained 
by the observation that coprostanol formation predominantly occurred in the cecum 
and the large intestine, sites from which no cholesterol absorption takes place 
(Kellogg 1973). Other activities of the microflora were thought to be responsible 
for these phenomena. The microflora might contribute to fecal excretion of sterols 
by promoting sloughing of mucosal cells (Kellogg and Wostmann, 1969). On the 
other hand, the microflora also could interfere with absorption and excretion of 
cholesterol via an action on the bile acids. It was shown that the bile acid pools in 
the small intestine were three times larger in germ-free rats than in conventional 
rats and this might well explain the improved absorption of cholesterol in germ-free 
animals (Kellogg and Wostman 1969). 
The role of the cecum in maintaining the A^-steroid-reducing activity was 
investigated because E. ATCC 21408 was found exclusively in the cecum and the 
large intestine on microscopic examination of the intestinal contents of gnotobiotic 
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rats associated with C. Cl-8 plus E. ATCC 21408 (Eyssen and Pannentier 1974). In 
the study, 10 conventional rats were cecectomized. An equal number of animals 
were kept as unoperated controls, and a further 10 rats were sham-operated. 
Formation of coprostanol and B-reduction of 5,6-double bonds in B-sitosterol and 
campesterol were abolished completely within 2 d after cecectomy. Similar results 
were obtained after cecectomy of gnotobiotic rats associated with E. ATCC 21408 
and C. Cl-8 (Eyssen et al. 1972). It was concluded that E. ATCC 21408 was unable 
to grow in the intestine of cecectomized rats. One possible explanation was that in 
cecectomized animals normal peristalsis of the colon resulted in a rapid elimination 
of slowly growing indigenous microorganisms such as E. ATCC 21408. The 
Eubacteiium might require a site where stasis of intestinal contents occurs. This 
hypothesis was compatible with the observation that coprostanol formation could 
be restored in cecectomized rats by surgically producing a self-filling blind loop on 
the small intestine. It was pointed out that the observation could also explain why, 
in spite of the absence of a cecal sac similar to that of rodents, coprostanol 
formation takes place in the human colon where the intestinal contents are 
retained for 18 to 24 h. Crowther et al. (1973), however, determined that in 
humans the intestinal transit time was not crucial in maintaining cholesterol-
reducing bacteria. When healthy volunteers were fed a fat-free liquid diet, the 
percentage of neutral sterols excreted in the feces as coprostanol decreased. Fecal 
transit time in these volunteers was actually longer than that in controls. 
Wilkins and Hackman (1974) categorized people into two distinct patterns in 
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terms of cholesterol conversion to coprostanol: low conversion and high conversion. 
In a group of 31 volunteers, fecal samples from 8 people contained less than 30% 
of total sterols as coprostanol, whereas the fecal samples from the other 23 
volunteers contained greater than 60% of total sterols as coprostanol. Because all 
the volunteers were consuming similar diets and the patterns of sterol excretion 
were stable with time, it was thought that the differences were related to the 
bacterial flora of an individual rather than to difference in the colonic environment 
(Wilkins and Hackman 1974). 
Several investigators observed that feeding of diets containing large amounts 
of incompletely absorbed carbohydrates resulted in suppression of coprostanol 
formation (Wells and Cooper 1958; Kellogg and Wostmann 1966; Subbiah et al. 
1974). The effect of lactose on A^-steroid-reducing activity of E. ATCC 21408 was 
investigated (Eyssen et al. 1974). A group of 10 germ-free rats was associated with 
C CI-8 plus E. ATCC 21408. A second group was monoassociated with C. Cl-8, 
whereas a third group was kept germ-free. After 3 wk on the starch diet, five rats 
out of each group were given a diet containing 40% of lactose in the place of 
cornstarch. In rats associated with E. ATCC 21408, biohydrogenation of 
cholesterol was more than 80% inhibited 5 d after starting the lactose diet. 
Biohydrogenation of 6-sitosterol followed a similar curve. At the same time, the 
number of E. ATCC 21408 decreased significantly in lactose-fed rats. The pH of 
fecal contents decreased from a value of 6.8 in starch-fed rats to as low as pH 6.0 
in lactose-fed rats. The oxidation-reduction potential in the intestine was not 
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affected by the type of carbohydrate. When the rats were fed the lactose-
containing diet for more than 3 wk, however, production of coprostanol again 
increased to become stabilized after 5 to 6 wk at values 75-80% of those observed 
in starch-fed animals; the pH and the numbers of E. ATCC 21408 also increased to 
the values of those in starch-fed rats. Similar results were observed in starch- or 
lactose-fed conventional rats. The results suggested that the acid pH resulting from 
fermentation of unabsorbed lactose by the microflora was responsible for inhibition 
oiE. ATCC 21408. 
Addition of glucose or lactose to pure cultures of E. ATCC 21408 in vitro 
did not inhibit the cholesterol-reducing activity. In these cultures, the pH dropped 
slowly from pH 7.3 before incubation to pH 6.5 after a 72-h incubation. When 
grown in a basal brain-thioglycollate medium without added carbohydrates, 
production of coprostanol by E. ATCC 21408 was not inhibited by cocultivation 
with lactose-fermenting bacteria such as C. Cl-8, Escherichia coli, or Streptococcus 
faecalis. When glucose or lactose were added to these mixed cultures, however, the 
pH dropped to values below pH 6 within 24 h. Under these conditions, E. ATCC 
21408 failed to grow adequately and coprostanol was not produced. The inhibitory 
effect of the carbohydrate in mixed cultures, however, could be overcome by 
maintaining the pH of the culture medium above 6.5 throughout the incubation 
period, e.g., by addition of appropriate amounts of KOH every 6 h or by addition of 
CaC03 to the medium before incubation. It was concluded that the adverse effect 
of lactose diets on coprostanol formation in gnotobiotic and conventional rats was 
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an indirect effect mediated by the acids resulting from fermentation of unabsorbed 
lactose (Eyssen et al. 1974). 
Isolation of a cholesterol-reducing bacterium from human feces was first 
reported by Sadzikowski et al. (1977). The microorganism was isolated and 
cultivated in an anaerobic medium containing homogenized pork brains (naturally 
high in cholesterol). The human isolate was similar to E. ATCC 21408 from the 
cecum of rat (Eyssen et al. 1973). Both of them are small, gram-positive, anaerobic 
diplobacilli that require cholesterol for growth. Both organisms could use 
cholesteryl palmitate for limited growth, and the double bond of the cholesterol in 
the ester form was reduced, even though Eyssen et al. (1973) reported that E. 
ATCC 21408 did not reduce the double bond of cholesterol when cholesterol was 
present as an ester. The human isolate was not able to grow on a solid medium. 
The inability to form colonies necessitated laborious and unconventional isolation 
procedures—serial dilution procedures. It was noted that fecal samples with low 
initial coprostanol concentrations produced low amounts of coprostanol in vitro, 
and that the converse was true for samples with high concentrations. 
In an attempt to explain differences in coprostanol excretion between high 
and low converters observed by Wilkins and Hackman (1974), the human isolate 
and E. ATCC 21408 were incubated with several strains of bacteria to check for 
inhibition because cholesterol-reducing organisms from low converters seemed to 
be inhibited by certain members of the fecal flora. E. ATCC 21408 was inhibited 
significantly by the mixed flora isolated from a low converter. One organism, 
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identified as Fusobacteriiim russi, caused over 40% inhibition of coprostanol 
formation by E. ATCC 21408. The human isolate was inhibited only slightly by F. 
russi. It was concluded that differences in the amount of coprostanol in the feces of 
individuals may be because of differing susceptibilities of the cholesterol-reducing 
organisms to certain antagonistic bacteria of the fecal flora. It has been indicated 
that the cholesterol-reducing organisms seem uniquely adapted to a specialized 
niche in the environment of the colon. Most other intestinal bacteria are not 
capable of attacking the abundant cholesterol of feces; the cholesterol-reducing 
organisms, however, seems to have evolved a means of using cholesterol as a 
terminal electron acceptor (Eyssen et al. 1973). This cholesterol reduction could 
be advantageous because it might allow adenosine 5'-triphosphate (ATP) to be 
generated via a compound that is not used by the rest of the fecal flora 
(Sadzikowski et al. 1977). Besides the human isolate, Sadzikowski et al. (1977) also 
isolated a strain from rat cecal contents. 
In 1979, Mott and Brinkley isolated a cholesterol-reducing bacterium from 
baboon feces by techniques similar to those reported by previous investigators 
(Mott and Brinkley, 1979). The isolate closely resembled E. ATCC 21408 (Eyssen 
et al. 1973) and was designated Euhacteiium 403. To determine the growth factors 
for cholesterol-reducing Eubacterium, they extracted and isolated the lipid fractions 
of calf brain. The brain lipid fractions and pure lipid standards were tested in 
lecithin-cholesterol medium for their ability to support growth of E. 403. Lecithin-
cholesterol-medium is a brain-free medium that alone did not support growth of 
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the cholesterol-reducing bacterium. The results showed that both 
plasmenylethanolamine and 2-lyso-plasmenylethanolamine supported growth of E. 
403 in lecithin-cholesterol-medium. These plasmalogens or plasmenyl lipids are a 
class of glycerophospholipids characterized by an alkenyl ether linkage in the 1 
position. No growth occurred in lecithin-cholesterol-medium supplemented with 
acid-hydrolyzed Folch extract (Folch et al. 1957), as indicated by lack of 
coprostanol formation and absence of cells by Gram stain. Addition of acid-
hydrolyzed Folch extract to lecithin-cholesterol-medium-plus-
plasmenylethanolamine, however, enhanced coprostanol production, indicating that 
other brain lipids stimulated this activity. Acetic acid hydrolysis destroyed the 
growth-supporting activity of plasmenylethanolamine. Plasmenylethanolamine 
obtained from a commercial source also supported growth in lecithin-cholesterol-
medium; no other lipid standard, however, tested was active. Therefore, it was 
concluded that an intact alkenyl ether linkage is a growth requirement of the 
cholesterol-reducing Eubacteriiim in vitro. E. 403 actually catabolized the alkenyl 
ether linkage of plasmenylethanolamine during coprostanol formation (Mott and 
Brinkley, 1979). 
Later, Mott et al. (1980) further characterized cholesterol-reducing bacteria, 
including E. ATCC 21408 and E. 403, by conducting conventional biochemical tests 
and by testing different sterols and glycerolipids as potential growth factors. In 
media containing cholesterol and plasmenylethanolamine, the tests for nitrate 
reduction, indole production, and gelatin and starch hydrolyses were negative, and 
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no acid was produced from any of 22 different carbohydrates. The cholesterol-
reducing bacteria had 6-glycosidase activity because esculin was hydrolyzed to 
esculetin. It also was found that four other alkenyl ether residue-containing lipids 
also supported growth of E. 403 in lecithin-cholesterol-medium, in addition to 
plasmenylethanolamine and 2-lyso-plasmenylethanolamine. Lysoplasmanylcholine, 
a 1-alkyl glycerophospholipid that does not contain an alkenyl residue, did not 
support growth. Of six steroids tested, cholesterol, 4-cholesten-3-one, 4-cholesten-
313-ol (allocholesterol), and 5-androsten-36-ol-17-one supported growth of E. 403. 
All four steroids were reduced to the 3B-ol, 5B-H products. The steroids 5-
cholesten-3Q;-ol (epicholesterol) and 22,23-bisnor-5-cholenic acid-3B-ol were not 
reduced and did not support growth of the bacterium. At a high concentration (2.0 
mg/ml) of 4-cholesten-3-one in the medium, coprostanone was the major product 
after incubation, but at a low concentration (0.2 mg/ml), 4-cholestern-3-one was 
converted principally to coprostanol. The authors noted that members of the genus 
Eubacterium generally produced energy for growth by fermenting sugars to short-
chain acids. Like Eubacterium lentum, however, the cholesterol-reducing organisms 
did not produce acids from carbohydrate-containing media. Unlike E. lentum, 
cholesterol-reducing strains of Eubacterium did not derive energy from the arginine 
dihydrolase pathway (Mott et al. 1980). Therefore, it was concluded that the 
cholesterol-reducing bacteria resembled E. lentum, but, because they lacked the 
arginine dihydrolase pathway and had a unique requirement for certain sterols and 
alkenyl ether lipids, they could not be classified in any existing species within the 
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genus Eubacterium at the time. 
Isolation and characterization of the cholesterol-reducing strains of 
Eubacterium has been difficult because these organisms fail to grow on solid media. 
Brinkley et al. (1980) developed a cholesterol-brain agar medium that sustained the 
growth and colony formation of these bacteria under anaerobic conditions. 
Cholesterol was thought to be a limiting factor because it would not readily diffuse 
in agar. Therefore, 5% cholesterol was added to the lecithin-cholesterol medium 
containing plasmenylethanolamine (0.5 mg/ml of medium) and 1% agarose. 
Colonies of E. ATCC 21408 developed within 6 d on this medium when incubated 
under anaerobic conditions. Then, cholesterol concentrations of 1 to 10% in a 
brain agar medium was tested and 5% was found to be the optimal concentration. 
Deletion of amino acids or yeast extract from cholesterol-brain agar resulted in 
poorer growth, suggesting that free amino acids and vitamins are required for 
optimal growth of the cholesterol-reducing eubacteria. Trypan blue was added to 
improve the contrast between the small white colonies and the medium. This dye 
was not toxic and was not readily decolorized (reduced) by an anaerobic 
environment or by the cholesterol-reducing eubacteria. Many other anaerobes 
reduced the dye to a colorless form that aided in differentiation of the cholesterol-
reducing eubacteria from contaminants. 
Two colony types on cholesterol-brain agar were observed with both E. 
ATCC 21408 and E. 403. The colonies were composed of small, gram-positive 
bacilli and fibers; the fibers were seen protruding from both colony types when 
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observed microscopically. The unusual colony morphology and the presence of 
protruding fibers helped to differentiate these organisms from other bacteria. E. 
ATCC 21408 and 403 were subcultured repeatedly on cholesterol-brain agar by 
picking isolated colonies and streaking for isolation. No loss of viability was 
observed. Isolated colonies were transferred into standard brain medium and were 
confirmed as cholesterol-reducing organisms by the presence of coprostanol as a 
major product of growth (Brinkley et al. 1980). 
Brinkley et al. (1982) isolated nine new strains of cholesterol-reducing 
bacteria from baboons by plating dilutions of feces and intestinal contents directly 
to cholesterol-brain agar. All strains had similar colony and cell morphology and 
hydrolyzed the 6-glucosides esculin and amygdalin. Unlike the previously reported 
cholesterol-reducing bacteria, all of the nine new strains did not require cholesterol 
and an alkenyl ether lipid for growth. All strains reduced cholesterol to 
coprostanol in lecithin-cholesterol medium containing plasmenylethanolamine. 
Only two strains, 103 and 104, reduced cholesterol in the absence of 
plasmenylethanolamine. These two strain also produced succinate as an end 
product. Carbohydrate fermentation was variable; some strains produced weak 
acids (pH 5.5 to 6.0) from only a few different carbohydrates, whereas other strains 
produced strong acid reactions (pH < 5.5) from a wide variety of carbohydrates. 
All nine strains metabolized pyruvate and produced acetate and acetoin (3-liydroxy-
2-butanone). Succinate production by strains 103 and 104 was increased in the 
presence of pyruvate. Carbon dioxide production also was enhanced by pyruvate. 
30 
Hydrogen was not produced. All isolates were negative for indole production, 
nitrate reduction, urease production, and gelatin and starch hydrolysis. No 
products of the arginine dihydrolase pathway were detected, and lactate and 
threonine were not fermented. 
It was stated that cholesterol-reducing organisms were a much more diverse 
group of bacteria than previously described (Brinkley et al. 1982). The diversity 
seemed to be related to the metabolism of substrates for energy production. The 
most probable mechanism for ATP production was thought to be the 
dehydrogenation of pyruvate to acelyl-CoA. The role of cholesterol in growth of 
cholesterol-reducing bacteria again was questioned. Eyssen et al. (1973) suggested 
that cholesterol is the terminal electron acceptor, and all of the isolates previously 
reported required cholesterol for growth (Eyssen et al. 1973; Sadzikowski et al. 
1977; Mott and Brinkley, 1979). Because all of the nine isolates grew in the 
absence of cholesterol, an alternate electron acceptor must have been used by these 
strains when cholesterol was not available. The role of alkenyl ether lipids in 
cholesterol reduction also was questioned. An alkenyl ether lipid (e.g., 
plasmenylethanolamine) was required for the growth of E. ATCC 21408 and 403. 
These nine strains grew without cholesterol and plasmenylethanolamine, and strain 
103 and 104 reduced cholesterol in the absence of plasmenylethanolamine. It was 
indicated that most of their isolates belonged to the genus Eubacterium (Brinkley et 
al. 1982). Strains 103 and 104 did not fit the description for the genus Eubacterium 
because they produced significant amounts of succinate, a characteristic of 
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Actinomyces. Because these strains did not produce lactate or show any branching 
or other irregular cell morphology, however, they would be atypical of the genus 
Actinomyces. Because strains 103 and 104 shared so many characteristics with 
other isolates, it was suggested that all of these bacteria should remain in a single 
taxon (Brinkley et al. 1982). 
Recently, a novel cholesterol-reducing bacterium was isolated from a swine 
sewage lagoon (Freier et al. 1994). The new isolate has been designated as 
Eubacterium coprostanoligenes and deposited in the American Type Culture 
Collection as strain ATCC 51222. E. coprostanoligenes shares many properties with 
previously isolated cholesterol-reducing bacteria. The new isolate is a small, 
anaerobic, gram-positive coccobacillus. The bacterial cells are 0.5 to 0.7 iim in 
diameter and 0.7 to 1.0 iim in length and occur singly and in pairs. The cells are 
nonmotile and non-spore forming. Surface colonies on anaerobic lecithin agar 
plates are small, white, and circular with a powdery texture. Growth and 
coprostanol production are optimal at pH 7.0 to 7.5 and at 35°C to 39°C. The 
bacterium was described as an aerotolerant anaerobic chemoorganotroph. It 
reduces cholesterol to coprostanol but does not require cholesterol or plasmalogen 
for growth. Phosphatidylcholine is metabolized and is required for growth. Nitrate 
is not reduced, and indole is not produced. The bacterium does not hydrolyze 
starch and gelatin, but hydrolyzes esculin and indoxylacetate and produces 6-
glucosidase. It ferments amygdalin, lactose, and salicin and produces much acid, 
but it only weakly ferments L-arabinose, cellobiose, fructose, glucose, mannose, and 
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melibiose. The bacterial culture produces moderate amounts of H2 and small 
amounts of CO2. It produces acetic, formic, and succinic acids, but not alcohols. 
The genomic DNA of E. coprostanoligenes has a G + C content of 41 mol% 
(Freier et al. 1994). In contrast to the previous isolates, E. coprostanoligenes is 
much easier to grow in the laboratory. It forms colonies on lecithin-containing 
solid media and survives exposure to air for at least 48 h. The bacterium converts 
up to 90% of the cholesterol to coprostanol in cholesterol-containing medium. The 
cholesterol-reducing activity is possessed constitutively by the bacterium. Washed 
bacterial cells from cholesterol-free media efficiently reduced cholesterol to 
coprostanol under either anaerobic or aerobic conditions (Li et al. 1995). The 
cholesterol-reducing activity in bacterial cells decreased as a function of storage 
time at 22°C, 4°C, and -20°C. Hydrogen, pyruvate, and reducing agents increased 
the activity. Optimal cholesterol reduction occurred at pH 7.5 in a sodium 
phosphate buffer. E. coprostanoligenes seems more amenable than previously 
studied cholesterol-reducing bacteria for applications in food and pharmaceutical 
industries. 
Mechanisms of cholesterol reduction 
Long before a pure cholesterol-reducing bacterium was isolated, two 
hypotheses had been proposed for the mechanism of cholesterol reduction reaction: 
(1) a direct stereospecific reduction of the double bond (Bondzynski and Humnicki 
1896; Schoenheimer et al. 1930) and (2) a multistep conversion from cholesterol 
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involving the intermediates 4-choIesten-3-one and coprostanone (Rosenheim and 
Starling 1933; Schoenheimer et al. 1935; Rosenheim and Webster 1943). Since 
then, the debate on whether cholesterol is reduced biologically to coprostanol 
through a direct or an indirect pathway has been continuing. 
Radioactive cholesterol was used usually to study the mechanism of 
cholesterol reduction. With [3-^H, 4- '^^ C]-cholesterol, Rosenfeld et al. (1954) did in 
vivo experiments by feeding the dual-labeled cholesterol to human subjects and in 
vitro experiments by incubating the radioactive cholesterol with human fecal 
homogenates. They found that coprostanol isolated in both in vivo and in vitro 
studies contained deuterium and and that the dilutions of deuterium and 
are essentially of the same order. The retention of the isotopic label at C-3 
provided evidence that the hydroxyl group at C-3 was not involved in the process of 
cholesterol reduction to coprostanol. They argued that, if coprostanol arose from 
cholesterol principally by the multistep pathway, the deuterium atom at C-3 would 
be completely lost and the coprostanol would have contained only ^^C but no 
deuterium. Therefore, it was suggested that coprostanol is produced from 
cholesterol principally by a process not involving the hydroxyl group at C-3, but by 
direct saturation of the 5, 6 double bond of cholesterol. Later, however, Rosenfeld 
et al. (1956) found that coprostanol obtained from the biochemical reduction of 3a-
H-cholesterol contained an appreciable amount of isotope in ring B. It was 
concluded that some of the cholesterol molecules must have served as deuterium 
donors for other cholesterol molecules that were converted ultimately to 
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coprostanol. Then, by using 3a-^H-cholesterol, Rosenfeld and Gallagher (1964) 
again observed that cholesterol was reduced to coprostanol by fecal suspensions 
primarily with retention of tritium at C-3. However, they also found incorporation 
of isotope into other stable positions in coprostanol. It was suggested that 
cholesterol could be reduced by more than one bacterial species via different 
biochemical pathways. 
Bjorkhem and Gustafsson (1971) questioned the conclusion of Rosenfeld 
and Gallagher that the main pathway for the formation of coprostanol is direct 
reduction of cholesterol. They argued that the label in the C-3 position of 
cholesterol could be transferred to a cofactor in an oxidative step and that the 
labeled cofactor could transfer its label to the steroid in a reduction step. They 
investigated the importance of the two pathways for cholesterol reduction to 
coprostanol by cecal contents from rats. The reaction was carried out in 
deuterated water and with [4B-^H, 4-^'^C]- and [3a-^H, 4-^'^C]cholesterol as 
substrates. It was found that conversion of [3a-^H, 4-^^C]cholesterol into 
coprostanol occurred with loss of 50% of the tritium. The tritium retained in 
coprostanol was located in the C-3a position. Part of the retained tritium might 
have been introduced in a reductive step following an initial oxidative step. This 
hypothesis was supported by the finding that coprostanol formed from [4-
^'^CJcholesterol in the presence of [3a-^H]6-sitosterol contained significant amounts 
of tritium in the C-3Q: position. 
After conversion of part of [3a-^H, 4-^'^C]cholesterol into coprostanol, 
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unchanged cholesterol had a higher ratio than did the cholesterol added to 
the incubation mixture, indicating that oxidation of the 3i3-hydro3q'l group is at least 
partly rate-limiting in the over-all conversion of cholesterol into coprostanol 
(Bjorkhem and Gustafsson 1971). After cholesterol was incubated with cecal 
contents in the presence of deuterated water, the isolated coprostanol had a 
deuterium content of about 1.4 atoms at C-2, C-3, and C-4, about 0.5 atoms at C-5, 
and about 0.1 atoms at C-6, indicating extensive oxido-reduction at C-3 during or 
after conversion of cholesterol into coprostanol. 
Coprostanol isolated after incubation of [413-^H, 4-^^C]cholesterol retained 
60% of the tritium. Most of this tritium had been transferred to the C-6 position, 
showing that the conversion of cholesterol into coprostanol involves isomerization 
of the double bond to double bond. They also showed that incubation of A'^-
[4-^^C]cholesten-3-one with cecal contents resulted in efficient formation of 
coprostanol. Therefore, the authors concluded that the conversion of cholesterol 
into coprostanol proceeds to at least 50% by means of the intermediate formation 
of 4-cholesten-3-one (Bjorkhem and Gustafsson 1971). It was pointed out, 
however, that the reaction had been studied in a system consisting of a complex 
mixture of microorganisms. Thus, it was possible that different microorganisms 
might use different mechanisms to reduce cholesterol to coprostanol and that the 
contribution of the two mechanisms might be expected to vary. 
Isolation of a pure cholesterol-reducing microorganism, Eiibacterium ATCC 
21408, provided more specific information about the mechanism of cholesterol 
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reduction to coprostanol (Eyssen et al. 1973). Parmentier and Eyssen (1974) 
studied the mechanism of biohydrogenation of cholesterol to coprostanol by 
incubating E. ATCC 21408 with [3a-^H, 4-^'^C]cholesterol or [4B-^H, 4-
^^C]cholesterol in a brain-thioglycollate medium under anaerobic conditions. 
Conversion of [3a-^H, 4-^'^C]cholesterol to coprostanol by E. ATCC 21408 resulted 
in 65% loss of tritium. Part of the tritium, however, might have been lost after but 
not during reduction of cholesterol to coprostanol because incubation of preformed 
[3Q;-^H, 4-^'^C]coprostanol with E. ATCC 21408 had caused loss of 40% of the 
tritium at the C-3 position of coprostanol. Thus, it was stated that loss of tritium 
during conversion of [3Q;- HJcholesterol to coprostanol could not warrant the 
conclusion that reduction of the 5,6-double bond involved the formation of 3-oxo 
intermediates. 
To investigate whether biohydrogenation of cholesterol involved the 
formation of a 4,5-double bond, E. ATCC 21408 was incubated with [46-^H, 4-
^'^CJcholesterol (Parmentier and Eyssen 1974). The isolated coprostanol retained 
81% of the tritium originally present in cholesterol. It was found, however, that 
the label was not in the C-3 position but more than 90% of the tritium present in 
coprostanol was in the C-6 position. Therefore, it was concluded that more than 
70% of 46-^H of cholesterol was transferred by an intramolecular shift to the C-6 
position of coprostanol during the process of biohydrogenation, indicating that the 
reaction involved isomerization of the 5,6-double bond to a 4,5-double bond. The 
data supported the hj^jothesis that the major pathway for biohydrogenation of 
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cholesterol by E. ATCC 21408 involves the intermediate formation of 4-cholesten-
3-one followed by reduction of the latter to coprostanol (Parmentier and Eyssen 
1974; Eyssen and Parmentier 1974). 
Recently, Ren et al. (1995) studied the mechanism of cholesterol reduction 
to coprostanol by using Eubacteiium coprostanoligenes ATCC 51222. The 
bacterium was incubated with [4-^H, 4-^^C]cholesterol as a mixture of a and 13 
isomers. After 5 d of incubation, 90% of cholesterol was converted to coprostanol. 
No intermediates were found in the culture. The isolated coprostanol retained 97% 
of the tritium originally present in cholesterol. The majority of the label (64%), 
however, was located in the C-6 position, and only 36% of tritium remained in the 
C-4 position. It was shown that no solvent exchange occurred during proton 
transfer form C-4 to C-6 by the bacterium. Transferring of tritium from C-4 to the 
C-6 position indicated isomerization of a 5,6-double bond to a 4,5-double bond 
during the conversion of cholesterol to coprostanol. The data suggested that E. 
coprostanoligenes reduces cholesterol through an indirect pathway with the 
formation of 4-cholesten-3-one and coprostanone. 
In resting cell assays where washed cells of E. coprostanoligenes were 
incubated with micellar cholesterol in phosphate buffer at 37°C, both 4-cholesten-3-
one and coprostanone were produced in addition to coprostanol (Li et al. 1995b). 
Furthermore, 5-cholesten-3-one, 4-cholesten-3-one, and coprostanone were 
converted efficiently to coprostanol by E. coprostanoligenes. Therefore, it was 
concluded that the major pathway for reduction of cholesterol to coprostanol by E. 
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coprostanoligenes involves the intermediate formation of 4-cholesten-3-one and 
coprostanone followed by reduction of the latter to coprostanol (Ren et al. 1995). 
Potential applications 
Microbial reduction of cholesterol results in coprostanol that is absorbed 
poorly from the gastrointestinal system (Schoenheimer 1931; Bhattacharyya 1986). 
The nonabsorbability of coprostanol has led to the development of potential 
technology to lower cholesterol concentration in the blood of hypercholesterolemic 
individuals and to decrease cholesterol contents of foods (Dehal et al. 1990). By 
introducing cholesterol-reducing bacterium into the digestive tract, it is possible 
that little or no endogenous (e.g., biliary) and dietary cholesterol would be 
absorbed so that the cholesterol concentration in blood might be decreased. 
Treating foods with the bacteria may produce low-cholesterol or cholesterol-free 
foods so that consumers would have little or no concerns about the cholesterol in 
animal-derived foods. 
Early investigators have assumed that microbial conversion of cholesterol to 
coprostanol could affect sterol balance of the host (Iritani and Wells 1966). It was 
found that conventional animals excreted 50 to 100% more neutral sterols through 
feces than did germ-free animals (Evrard et al. 1964; Kellogg and Wostmann 1969; 
Eyssen et al. 1974). It was also observed that cholesterol was absorbed more 
efficiently from the intestine of germ-free animals and that germ-free animals had 2 
to 3 times greater liver cholesterol content than similar conventional animals when 
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moderate amounts of cholesterol were fed with the diet (Wostmann 1973). These 
findings indicate that intestinal bacteria interfere with the absorption of cholesterol 
and promote the fecal output of neutral sterols. 
Gnotobiotic rats associated with E. ATCC 21408, however, failed to promote 
the fecal output of neutral sterols (Eyssen and Parmentier 1974). The 
phenomenon was explained by the observation that coprostanol formation 
predominantly occurred in the cecum and the large intestine, an anatomical site 
from which no cholesterol absorption takes place. 
Recently, with the new cholesterol-reducing bacterium, E. coprostanoligenes 
ATCC 51222, Li et al. (1995a) investigated its effect on plasma cholesterol 
concentration in dietary-induced hypercholesterolemic rabbits. Experimental 
rabbits received 4 ml of E. coprostanoligenes suspension {ca 10® cells/ml) daily per 
OS for 10 d; control rabbits received the same dose of boiled bacterial suspension. 
It was found that plasma cholesterol concentration of experimental rabbits was 
26% lower (P < 0.001) than that of controls after bacterial treatment. The 
hypocholesterolemic effect of E. coprostanoligenes continued for at least 34 d after 
the last bacterial feeding. The sustained effect was explained by colonization of the 
bacterium in the digestive tracts. Also, coprostanol-to-cholesterol ratios in contents 
of digestive tracts (especially small intestines) of experimental rabbits were 
significantly greater than those of controls, which suggested that the colonized 
bacteria were reducing cholesterol to coprostanol actively in the intestine. When 
the intestinal contents were inoculated into the growth medium, E. 
40 
coprostanoligenes and its cholesterol-reducing activity were recovered from the 
experimental group but not from the control group. It was concluded that oral 
adminisfration of E. coprostanoligenes caused a significant hypocholesterolemic 
effect in rabbits and that this effect can be explained by the conversion of 
cholesterol to coprostanol in the intestine. This study was different from the study 
of Eyssen and Parmentier (1974) because, after oral administration of E. 
coprostanoligenes to rabbits, the bacteria were found to colonize and reduce 
cholesterol in the jejunum and ileum, which are major sites for cholesterol 
absorption. Similar hypocholesterolemic responses were observed by using milk as 
a carrier to deliver E. coprostanoligenes to the digestive tract of dietary-induced 
hypercholesterolemic rabbits (Madden 1995). Absence of an effect on serum 
cholesterol concentration and fecal sterol output with E. ATCC 21408 in 
gnotobiotic rats might result from the failure of colonizing the small intestine. 
Treatment of foods with cholesterol-reducing bacteria has provided another 
potential way to decrease cholesterol contents in foods (Dehal et al. 1991). It was 
observed that cholesterol reductase from plant sources converted some cholesterol 
in homogenized milk, homogenized cream, ground beef and pork, and fresh and 
dried egg yolks to coprostanol. However, the amount of conversion was small. 
With E. coprostanoligenes, preliminary data have shown that cholesterol in 
homogenized milk can be reduced significantly (» 10%) by incubation with the 
bacterium (unpublished data). Sonication of the milk made cholesterol therein 
more accessible to the bacterium. Incorporation of E. coprostanoligenes in yogurt 
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starter cultures resulted in lower cholesterol yogurt (unpublished data). 
Inoculation of E. copwstanoligenes into ground pork and mutton led to about 5% 
cholesterol reduction after 15 h of incubation (Madden 1995). Therefore, a 
microbial cholesterol-reducing system seems promising for future applications in 
food-processing industries. 
Cholesterol Oxidase and Cholesterol-Oxidizing Microorganisms 
Microbial cholesterol oxidases (EC 1.1.3.6) catalyze the transformation of 
cholesterol to 4-cholesten-3-one with concomitant reduction of molecular oxygen to 
hydrogen peroxide. This transformation is the initial step in the microbial 
catabolism of cholesterol. Cholesterol oxidase has been used widely for 
determination of serum cholesterol concentration in clinical specimens by coupling 
with peroxidase (Richmond 1973; Allain et al. 1974; Lolekha and Jantaveesirirat 
1992). The enzyme also has been used for steroid identification (Smith and Brooks 
1974) and as tools in cell biology for cholesterol quantification and for the 
subcellular localization of unesterified cholesterol (Heider and Boyett 1978; Lange 
and Ramos 1983; Patzer et al. 1978; Thurnhofer et al. 1986). Interest in 
cholesterol oxidases and cholesterol-oxidizing microorganisms is also partly because 
of their potential use in decreasing cholesterol content of foods, in particular 
fermented dairy products (Smith et al. 1991). Cholesterol degradation at the 
intestinal level by bacterial cultures can be used as probiotics. 
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Sources of cholesterol oxidase 
Since the report by Stadtman et al. in 1954 on crude enzyme preparations 
from Mycobacterium sp. (Stadtman et al. 1954), cholesterol oxidases have been 
described in a number of microorganisms, including Arthrobacter (Arima et al. 
1969), Norcardia sp. (Cheetham et al. 1980), Brevibacterium sp. (Uwajima et al. 
1973), Streptomyces sp. (Tomioka et al. 1976), Corynebacterium sp. (Shirokane et al. 
1977), Actinomyces sp. (Petrova et al. 1979), Streptoverticillium sp. (Inouye et al. 
1982), Schizophyllum sp. (Fukuyama and Miyake 1979), Rhodococcus sp. (Watanabe 
et al. 1986), and Pseudomonas sp. (Lee et al. 1989). Some of these microorganisms 
produce only membrane-bound cholesterol oxidase such as Nocardia (Cheetham et 
al. 1980), some produce only extracellular enzymes such as Brevibacterium, 
Streptomyces, and Streptoverticillium (Uwajima et al. 1973; Tomioka et al. 1976; 
Inouye et al. 1982; Fukuyama and Miyake 1979), and others produce both a 
secreted and a membrane-bound form such as some Rhodococcus strains (Aihara et 
al. 1986). 
Purification of cholesterol oxidase 
Cholesterol oxidase was first purified and crystallized from Brevibacterium 
sterolicum ATCC 21387 (Uwajima et al. 1973). B. sterolicum is a soil bacterium. It 
can grow on cholesterol as the sole source of carbon and energy and produces an 
extracellular form of cholesterol oxidase. Therefore, the enzyme was purified from 
the culture filtrate by a procedure involving ammonium sulfate fractionation. 
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DEAE-cellulose and hydroxyapatite column chromatographies, and Sephadex G-75 
gel filtration. Crystals of the enzyme were obtained from solutions of the purified 
preparation by the addition of ammonium sulfate. The crystals appeared as fine 
rods, with a bright yellow color. The crystalline cholesterol oxidase showed an 
absorption spectrum characteristic of a flavoprotein. Addition of sodium dithionite 
to the enzyme under anaerobic conditions produced a "bleaching" of the absorption 
peaks. Thus, these observations suggest that flavin is a prosthetic group of 
cholesterol oxidase and is responsible for its catalytic activity (Uwajima et al. 1973). 
This finding has been confirmed by later studies with cholesterol oxidase (Uwajima 
et al. 1974; Kamei et al. 1978; Kenney et al. 1979). It was found that most 
cholesterol oxidases contain one mole of tightly bound flavin adenine dinucleotide 
(FAD) per mole of protein as a prosthetic group. However, some of them, for 
example the enzyme from Nocardia eiythropolis, lack this cofactor (Richmond 
1973). The crystal structure of the enzyme from B. sterolicum was determined at 
1.8 A resolution (Vrielink et al. 1991). 
Richmond (1973) characterized, extracted, and purified a membrane-bound 
cholesterol oxidase from Nocardia sp. Disintegrating Nocardia sp. cells with 
mechanical techniques did not release much enzyme from the cell membrane. 
Incubation with a detergent, Triton X-100, effectively solubilized the membrane-
bound enzyme. Then, the enzyme was purified by a procedure involving 
ammonium sulfate precipitation and ion-exchange chromatography. Cholesterol 
oxidase from Nocardia sp. is very stable at 4°C and is also highly heat stable, which 
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allows it to be used analytically at temperatures as high as 50°C. It is active in 
aqueous ethanolic solutions containing as much as 30% of ethanol and in buffers 
ranging from pH 4.0 to pH 9.0. The en^mie is specific for 36-sterols and requires 
a double bond in the or positions. Shortening the cholesterol side chain 
markedly diminishes the affinity of the enzyme for these substrates. Cheetham et 
al. (1980) further developed the extraction method to obtain high yield of 
cholesterol oxidase from Nocardia rhodochroiis by treatment either with a 
detergent, Triton X-100, or with trypsin. It was found that the enzyme extracted 
with detergent, after removal of the detergent, could be reabsorbed by Nocardia, 
whereas enzyme extracted by using trypsin was water-soluble and could not be 
reabsorbed by cells. The results indicate that cholesterol oxidase from Nocardia is 
an intrinsic membrane-bound protein possessing a hydrophobic anchor region that 
can be removed by trypsin (Cheetham et al. 1980). 
Lately, Rhee et al. (1991) described the synthesis of a novel cholesterol 
affinity adsorbent and a very simple purification procedure that gives a high yield 
of homogeneous cholesterol oxidase from culture broth of a Pseudomonas sp. 
Rhodococcus equi ATCC 33706 possesses a membrane-bound and a secreted 
form of cholesterol oxidase. Johnson and Somkuti (1991) isolated both foims of 
the enzyme from the microorganism. They tested several detergents (n-oclyl 
glucoside, Tween-20, Tween-60, Tween-80, and Brij-35) in phosphate buffer for 
efficacy to release protein from membrane fragments and prevent aggregation of 
the secreted enzyme. It was found that 0.5% Brij-35 was most efficient for 
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releasing membrane-bound protein. n-Octyl glucoside decreased the activity of the 
membrane-bound enzyme and failed to release protein from the fragments. Octyl 
glucoside at a 2.0% concentration, however, prevented aggregation of the secreted 
enzyme. The membrane-bound enzyme was purified 38-fold by Bio-Gel A-1.5 m 
chromatography, whereas isolation from a Sephacryl S-200 column resulted in a 58-
fold purification of the extracellular enzyme. Cholesterol oxidase activity for both 
enzyme preparations was optimal at approximately 40°C; however, the pH optimum 
(8.0) for the membrane-bound enzyme was much broader for the secreted enzyme 
(pH 6.0-8.0). 
Recently, Kreit et al. (1994) reported the production and extraction of 
membrane-bound cholesterol oxidase from Rhodococcus sp. cells and proposed a 
topology model at the cytoplasmic membrane level for the cell-bound cholesterol 
oxidases of the noncardioform bacteria. Enzyme solubilization was achieved by cell 
treatment with Triton X-100 or other nonionic detergents that have low critical 
micelle concentration. They suggested that the enzyme active domain is located at 
the outer surface of the membrane and substrate catalysis in vivo occurs externally 
to the cytoplasm. This topology was indicated by the following: (a) The rapid 
release of A'^-S-keto derivatives by cell action on cholesterol or phytosterols seemed 
to show an easy and direct contact between the en2yme system and the substrate 
(b) The enzyme activity could be measured by using whole cells in a colormetric 
assay, indicating that substrate should not intersect the cytoplasmic membrane for 
catalysis (c) The enzyme could be extracted from whole cells with nonionic 
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detergents without cell disintegration, indicating an amphiphilic nature of the 
enzyme. It was concluded that this topology model might be a general one for the 
microbial enzyme (Kreit et al. 1994). 
Substrate specificity of cholesterol oxidase 
The substrate specificity of cholesterol oxidases has been studied with the 
enzyme from different microbial species (Richmond 1973; Smith and Brooks 1975; 
Smith and Brooks 1977; Kamei et al. 1978; Inouye et al. 1982; Uwajima et al. 
1974). The results of these studies indicated that the 3-hydroxy group in the B-
position of the sterol molecule is an absolute substrate requirement to allow 
enzymatic oxidation. Variations in the C(17)-linked side chain of the sterol affects 
oxidation rates. Alterations in the ring structure of the sterol are oxidized slower 
when compared with cholesterol. 
Cholesterol oxidase from Nocardia sp. catalyzed oxidation of 36-hydroxy-5-
cholene-24-oic acid, 5-pregnen-3B-ol, and androst-5-ene-3J3-ol but with a much 
slower rate than cholesterol, whereas 5Q!-cholestan-36-ol or 515-cholestan-3B-ol 
(coprostanol) was not oxidized by the enzyme (Richmond 1973). 
Recently, Slotte (1992) suggested that the physico-chemical state of the 
substrate might affect how efficiently the enzjone can bind its substrate. 
Therefore, he studied substrate specificity of cholesterol oxidase from Streptomyces 
cinnamomeus with cholesterol present in monomolecular monolayers at the 
air/water interface so that the orientation of the substrate molecules relative to the 
47 
enzyme could be controlled. Of the cholesterol analogs with structural alterations 
in the A- or B-ring that were examined, it was observed that removal of the 
double bond, to yield 5a-cholestan-36-ol, had no effect on the rate of oxidation. 
When the A^ double bond in cholesterol was instead at the A''^ position, the 
oxidation rate became 3-fold slower. A similar 3-fold decrease in the average 
oxidation rate was observed when the A^ double bond in cholesterol was instead at 
the A^ position (to yield 5a:-cholest-7-en-36-ol). 5,7-Cholestadien-3i3-ol, which had 
an additional double bond at A , was oxidized 5-fold slower than was cholesterol, 
whereas 36-hydroxy-5-cholesten-7-one and 5B-cholestan-36-ol (coprostanol) were 
not substrates for cholesterol oxidase. With C(17) side chain analogs of 
cholesterol, it was observed that the complete lack of the C(17) side chain (5-
androsten-3B-ol), or the insertion of a double bond at A^'^ (desmosterol), or even 
an ethyl group at C(24) (24b-ethyl-5,22-cholestadien-36-ol) had no appreciable 
effects on sterol oxidation rate, implying that the enzyme did not recognize the side 
chain in oriented sterol monolayers. 
The results were explained by three-dimensional, energy-minimized 
structures of the sterols with molecular modeling (Slotte 1992). It was shown that 
5a-cholestan-36-ol is structurally very similar to cholesterol (as is the oxidation 
rate), whereas the A-ring of 56-cholestan-36-ol (coprostanol) is markedly 
reoriented away from the plane of the sterol ring system. This A-ring distortion, 
together with the resulting reorientation of the 36-hydroxy group, makes this sterol 
essentially a non-substrate for cholesterol oxidase. The 3-D structure of 36-
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hydroxy-5-cholest-7-one is very similar to the structure of cholesterol, except for the 
keto-group extruding at C(7). This 7-keto derivative of cholesterol is not a 
substrate of cholesterol oxidase (Slotte 1992), suggesting that obtruding functional 
groups at positions in the B-ring will interfere with successful binding of the sterol 
molecule to the catalytic site of the enzyme. Sterol analogs that have obtruding 
methyl groups at position 4 in the A-ring, such as lanosterol, are also non-substrate 
molecules for cholesterol oxidase (Wortberg 1975). 
Mechanism of cholesterol oxidation 
The catalytic mechanism of cholesterol oxidase also has been studied (Smith 
and Brooks 1977; Kass and Sampson 1995). Cholesterol oxidase is a bifunctional 
enzyme. It catalyzes the oxidation of cholesterol to the temporary intermediate 5-
cholesten-3-one with the reduction of molecular oxygen to hydrogen peroxide 
(Stadtman et al. 1954; Uwajima et al. 1974) and the isomerization of the A^-bond 
(Smith and Brooks 1977) via a mechanism analogous to that of the A^-3-
ketosteroid isomerase from Pseudomonas testosterini (Batzold et al. 1976; 
Kuliopulos et al. 1987). 
5-Cholesten-3-one, however, is usually not accumulated in the oxidation of 
cholesterol to 4-cholesten-3-one. A faster rate of isomerization than of oxidation 
explains this phenomenon. The trapping of [4-^'*C]5-cholesten-3-one in a pool of 
unlabeled ketone after the incubation of [4-^^C]cholesterol with N. erythropolis 
cholesterol oxidase demonstrates that the sequence of oxidation followed by 
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isomerization does occur (Smith and Brooks 1977). Incubation of [4a-^H]-and [415-
^H]-cholesterol with cholesterol oxidase showed that the 46-hydrogen atom can be 
transferred to the 6fi-position. Incubations of cholesterol, 5-cholesten-3-one, and 4-
cholesten-3-one with the enzyme in H2O, however, led to some incorporation of 
into the 4-cholesten-3-one products, mostly at position 6B, suggesting that 
reverse isomerization can take place. It was found that both the isomerase and the 
oxidase activities of cholesterol oxidase were inhibited by the acetylenic 3-oxo seco-
steroids (5,10-seco-19-nor-5-cholestyne-3,10-dione), indicating either that there are 
two active sites on one protein or that there are two enzymes that are closely 
associated (Smith and Brooks 1977). 
Cholesterol oxidase from Brevihactenum steroliciim, however, was found to 
be a monomer (55 kD) with a single active site for both oxidation and 
isomerization and requires one FAD per active site (Uwajima et al. 1974; Li et al. 
1993). The three-dimensional structure of the B. steroliciim has been published (Li 
et al. 1993; Vrielink et al. 1991). Two structures have been solved, one in the 
absence of substrate and one with dehydroepiandrosterone, a moderately active 
substrate, in the active site. The enzyme has an active site sequestered from 
solvent by two loops that act as "lids". In addition, there is one charged residue in 
the active site, glutamate-361. This residue is positioned directly over the 13-face of 
the bound sterol. This observation led to the proposal that glutamate-361 is the 
base responsible for isomerization of the double bond into conjugation with the 
ketone of the intermediate (Li et al. 1993). Furthermore, it is presumed that the 
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isomerization reaction proceeds in a stepwise manner via an enol(ate) intermediate. 
The mechanism entails deprotonation of the axial 4-hydrogen by glutamate-361 and 
reprotonation by the conjugated acid at the axial position of carbon-6. This 
proposed mechanism is analogous to those determined for the cholesterol oxidase 
from N. eiythropolis (Smith and Brooks 1977) as well as ketoisomerases (Schwab 
and Henderson 1990). The degree of sequence similarity between the Nocardia 
and the Brevibactemim oxidases is unknown. They seem to have different physical 
properties. The Nocardia oxidase is a cytosolic protein, and there is no evidence 
for a flavin cofactor in the Nocardia oxidase (Smith and Brooks 1977). 
Furthermore, they have different substrate specificities (Smith and Brooks 1977). 
Recently, Kass and Sampson (1995) determined whether the isomerization 
reaction of B. sterolicum cholesterol oxidase is stereospecific, i.e., if the proposed 
mechanism is correct, by incubating [4Q:-^H]- and [4J3-^H]-cholesterol with 
cholesterol oxidase and analyzing the product composition. Additionally, they 
measured the degree of direct proton transfer between carbon-4 and carbon-6 to 
determine if the isomerization was catalyzed by one or two bases. Their results 
showed that [4a-*'H]-cholesterol was converted completely to 4-cholesten-3-one 
when it was incubated with the enzyme and that 84% of the deuterium label 
remained in the product as determined by mass spectrometry. ^H-NMR spectral 
analysis of the product revealed that no deuterium label was transferred to carbon-
6. All of the deuterium label remained at carbon-4. When [46-"H]-cholesterol was 
incubated with the enzyme, it also was converted completely to 4-cholesten-3-one. 
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It was found that 50% of the deuterium label remained in the product and that all 
of the deuterium label remained at carbon-4. Cholesterol was incubated in 
deuterated phosphate buffer with the enzyme that had not been preequilibrated 
with D2O and was converted completely to 4-cholesten-3-one. None of the product 
contained deuterium. When cholesterol was incubated in the same deuterated 
phosphate buffer with the enzyme that had been preequilibrated with D2O, 13% of 
the product contained deuterium and the label was in the 66 position. 
Therefore, it was concluded that the isomerization reaction catalyzed by B. 
steroliciim cholesterol oxidase proceeded via a stereospecific proton transfer from 
the 46-carbon to the 66-carbon to form 4-cholesten-3-one (Kass and Sampson 
1995). Fifty percent of the 46 deuterium label was transferred directly to the 66-
carbon; 50% of the label was lost to solvent. The 4a;-deuterium label remained on 
carbon-4. These results imply that there is one active site base that is positioned 
over the 6-face and is responsible for isomerization. Based on crystallographic 
evidence (Li et al 1993; Vrielink et al. 1990), glutamate-361 is most likely the 
general base. The observation of direct transfer of deuterium label indicates that 
the active site base must be quite mobile to accomplish both deprotonation and 
reprotonation (Kass and Sampson 1995). 
Very surprisingly, Molnar et al. (1993) found that bacterial cholesterol 
oxidases are able to act as flavoprotein-linked ketosteroid monooxygenases and 
catalyze the hydroxylation of cholesterol to 4-cholesten-6-ol-3-one. The new 
metabolite of cholesterol originally was found in reaction mixtures containing 
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cholesterol or 4-cholesten-3-one as a substrate and extra- or intracellular protein 
extracts from recombinant Streptomyces lividans and Escherichia coli strains carrying 
cloned DNA fragments of Streptomyces sp. SA-COO, the producer of Streptomyces 
cholesterol oxidase. Commercially purified cholesterol oxidase of a Streptomyces 
sp., as well as of Brevibacterium steroliciim and a Pseudomonas sp., and a highly 
purified recombinant Streptomyces cholesterol oxidase also were able to catalyze the 
6-hydroxylation reaction. Cholesterol oxidases of different bacterial origins, 
however, catalyze 6-hydrojtylation at different rates. With the same amounts of 
enzyme, the ratio of 4-cholesten-3-one and 4-cholesten-6-ol-3-one produced in the 
reactions showed wide variation, with the Pseudomonas enzyme producing mainly 
the 6-hydroxylated derivative while the Brevibacterium enzyme formed only trace 
amounts of this steroid. Hydrogen peroxide accumulating in the reaction mixtures 
as a consequence of the 36-hydroxysteroid oxidase activity of the enzyme was 
shown to have no role in the formation of the 6-hydroxylated derivative. The 
authors proposed a possible scheme for a branched reaction pathway for the 
concurrent formation of 4-cholesten-3-one and 4-choIesten-6-ol-3-one by 
cholesterol oxidase. At this point, cholesterol oxidase therefore can be considered 
as a trifunctional enzyme (Molnar et al. 1993). 
Cloning of cholesterol oxidase genes 
The study of cholesterol oxidase has progressed to the molecular level. 
Genes encoding cholesterol oxidase {cho) have been cloned from Streptomyces sp. 
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strain SA-COO (choA) (Murooka et al. 1986), Brevibacterium sterolicum ATCC 
21387 {choB) (Fujishiro et al. 1990), and Streptomyces sp. strain A19249 (choM) 
(Corbin et al. 1994). The expression of these genes in heterologous bacterial hosts 
has been observed (Brigidi et al. 1993; Corbin et al. 1994; Ohta et al. 1992; 
Solaiman and Somkuti 1991; Somkuti et al. 1991; Somkuti et al 1992). 
Murooka et al. (1986) cloned the cholesterol oxidase gene {choA) from 
Streptomyces sp. strain SA-COO into S. lividans with a multicopy plasmid, pIJ702, 
which resulted in an several-fold increase in cholesterol oxidase production. 
Deletion analysis of the recombinant plasmid, pCO-1, showed that the entire 
coding sequence of the choA gene was located within a 2.4 kb segment of the 
chromosomal DNA, which allows for production of about a 91,000 dalton protein. 
The results also showed that the choA gene on the plasmid could direct the 
synthesis of both extracellular and intracellular cholesterol oxidase (Murooka et al. 
1986). 
Ishizaki et al. (1989) determined the nucleotide sequence of a 2.1 kb 
fragment containing the choA gene, which codes secreted cholesterol oxidase. The 
data show that a single open reading frame encodes a mature cholesterol oxidase of 
504 amino acids with a calculated of 54,913. The leader peptides extend over 
42 amino acids and have the characteristics of a signal sequence, including basic 
amino acids near the amino terminus and a hydrophobic core near the signal 
cleavage site. Analysis of the total amino acid composition and amino acid 
sequencing of the first 21 amino acids from the N terminus of the purified 
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extracellular enzyme agree with data deduced from nucleotide sequencing data 
(Ishizaki et al. 1989). 
Horii et al. (1990) determined the nucleotide sequence of the promoter 
region of choA and found an open reading frame (choP) located between a 
potential promoter sequence and the structure gene for ChoA protein. Deletion 
analysis showed that the promoter region for choP is essential for expression of the 
choA gene. Northern (RNA) blot analysis of the transcript revealed a 2.9 kb 
transcript that is identical in size to the total sequence of the choP and choA genes. 
These results suggest that the two genes, choP and choA, are transcribed 
polycistronically under the control of the promoter that is upstream from the 
structural gene for choP. The choP gene encodes a protein of 381 amino acids 
with a calculated of 41,688. The nucleotide sequence of the choP gene has a 
high degree of similarity to the sequence of the genes for cytochrome P-450s from 
humans and Pseiidomonas species. A region of homology with the cytochrome P-
450s from different microorganisms was identified in the choP protein and may 
represent a region associated with a binding site for heme iron. It was speculated 
that the gene product of choP might be involved in the metabolism of cholesterol 
(Horii et al. 1990). The natural substrate for the choP protein or the inducer for 
the cho operon, however, has not been found. Molnar et al. (1991) deleted a 1.2 
kb fragment adjoining upstream of the choP-choA operon and subcloned the 
operon into a multi-copy shuttle vector composed of pIJ702 and pUC19 in 
Streptomyces lividans, which resulted in the overproduction of Streptomyces 
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cholesterol oxidase extracellularly about 70-fold more than that of the original 
producer, Streptomyces sp. SA-COO. The amount of overproduction of cholesterol 
oxidase was found to be dependent on the copy numbers of the plasmids as well as 
the presence of the sequences derived from pUC19. 
Fujishiro et al. (1990) cloned another cholesterol oxidase gene (choB) from 
Brevibacterium steroliciim ATCC 21387. The gene was selected from a pUC19-
based gene bank in E. coli MM294 by colony hybridization by using a synthetic 
DNA probe. The gene was shown to encode a protein having the same amino acid 
sequence as that determined from amino acid sequence analysis. The expression of 
choB in E. coli was not observed probably because of transcriptional failure 
(Fujishiro et al. 1990). 
Ohta et al. (1991) sequenced the choB gene and found that the nucleotide 
sequence contained an open reading frame with a G + C content of 64.9 mol% 
that would encode a protein of 552 amino acids. N-terminal amino acid sequence 
analysis of the extracellular enzyme of B. steroliciim confirmed that the mature 
enzyme consisted of 507 amino acids with a predicted of 54,902 and was 
preceded by a 45-amino acid signal sequence. Sequences of choA and choB were 
compared also by Ohta et al. (1991). The results show that the nucleotide 
sequence and deduced amino acid sequence of these two genes have identities of 
64% and 58%, respectively, indicating that the genes derived from a common 
ancestor. There are at least six highly conserved regions between the two enzymes 
that may play structurally or functionally important roles such as substrate binding 
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or catalysis. 
Recently, an insecticidally active cholesterol oxidase gene (choM) has been 
cloned and sequenced from Streptomyces sp. strain A19249 (Corbin et al. 1994). 
The primary translation product was predicted to be a 547 amino acid protein 
whose first 43 amino acids constitute a secretory signal peptide. 
Heterologous expression of cholesterol oxidase genes 
Ideas of developing a biotechnological approach to decrease the cholesterol 
content of milk have lead to attempts to engineer starter culture bacteria 
(lactococci, lactobacilli, and streptococci) genetically, to express the phenolypic 
traits that are related to cholesterol metabolism, and to use these cultures in the 
production of fermented dairy foods (yogurt and cheeses). 
Somkuti et al. (1991) transferred and expressed Streptomyces cholesterol 
oxidase gene in Streptococcus thermophilus, a thermophilic bacterium used primarily 
for lactic acid synthesis in dairy fermentation. The gene transfer involved 
construction of the recombinant plasmid pNC0937 from the Streptomyces sp. SA­
GOO cho gene and the bifunctional shuttle vector pNZ19. The transformants were 
confirmed by Southern hybridization experiments. The biosynthesis of a functional 
cholesterol oxidase in S. thennophiliis transformants was confirmed also by thin-
layer chromatographic analysis of reaction products following incubation of 
sonically disrupted cells with cholesterol. Unlike 5. lividans (Murooka et al. 1986), 
however, S. thermophilus did not secrete cholesterol oxidase into the culture 
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medium. The data provided evidence that the promoter sequence of the 
Streptomyces cho gene was recognized in S. thermophiliis. Instability of the 
insertion, however, was obvious, as indicated by the loss of cholesterol oxidase 
activity from transformants after repeated transfers. Agarose gels clearly showed 
that mutational events involved primarily the 2.4 kb component of pNC0937 that 
contained the cho gene. 
Later, Somkuti et al. (1992) also electrotransformed three strains of 
Lactobacillus casei with pNC0937. Transformation frequency was generally low 
and strain dependent. L. casei transformants, however, stably maintained 
pNC0937 with no indication of deletion mutational events. Transformants 
produced active cholesterol oxidase, although the enzyme that is extracellular in 
Streptomyces sp. was detectable only in sonicated cells of L. casei. 
Brigidi et al. (1993) studied the cloning and the expression of the cho from 
Streptomyces sp. into some species of Bacillus, in the intestinal species Lactobacillus 
reuteri and in E. coli. The cloning of the cho gene in those bacteria was successful. 
Only the transformants of E. coli, however, showed a significant intracellular 
en^me activity. The heterologous gene was stably maintained in Gram-positive 
transformants but no enzyme activity was detected, indicating that these hosts could 
not use the Streptomyces promoter. It was concluded that strong promoters known 
to function efficiently in Gram-positive bacteria and new cloning strategies have to 
be used to express the cho gene in intestinal and dairy lactobacilli (Brigidi et al. 
1993). 
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Recently, Corbin et al. (1994) expressed an insecticidally active cholesterol 
oxidase gene (choM) in E. coli and in plant protoplasts. Expression of the gene 
with the signal sequence in E. coli resulted in production of a protein that had 
enzymatic and insecticidal properties. Expression of the gene with or without the 
signal sequence in tobacco protoplasts resulted in production of an enzymatically 
active cholesterol oxidase. This study was the first description of expression of 
cholesterol oxidase in a plant cell expression system. Expression of the choM gene 
in stably transformed plants should provide significant insight into the utility of this 
gene as a novel insecticidal agent for transgenic plant technology. 
Potential applications 
There have been attempts to use cholesterol oxidases or cholesterol-
oxidizing bacteria to decrease the cholesterol content of foods. Aihara et al. (1988) 
investigated the degradation of egg yolk cholesterol with Rhodococcus equi No. 23, 
a strain isolated from butter. R. equi was incubated in a sterile egg yolk medium 
containing 0.3-1.7 mg cholesterol/ml. It was found that the cholesterol content 
decreased with increasing incubation time. With cholesterol less than 0.9 mg/ml in 
the medium, cholesterol was degraded completely after 3 d of incubation. With 
higher initial cholesterol concentration in the medium, however, the degradation of 
cholesterol was incomplete after 3 d. In addition to the residual cholesterol, small 
amounts of 4-cholesten-3-one could be detected but no other degradation products 
were detectable by TLC, indicating that the 4-cholesten-3-one formed was 
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converted rapidly into nonsteroid compounds with almost no accumulation of 
steroid intermediates in the culture medium. 
Johnson and Somkuti (1990) tested strains of the genera Rhodococciis, 
Norcardium, Brevibacterium, and Microbacterium for their ability to degrade 
cholesterol. It was found that the rate of cholesterol degradation by rhodococci 
was generally higher than that shown by Nocardia strains. With R. equi, it was 
observed that the actively growing cultures metabolized cholesterol without 
accumulation of large amounts of steroid intermediates, which was in agreement 
with other reports (Aihara et al. 1986; Watanabe et al. 1986). If the rate of cellular 
metabolism was decreased as in the case of resting cells, however, certain 
intermediate degradation products such as 4-cholesten-3-one and 1,4-cholestadiene-
3-one could be detected. When sonicated extracts of R. equi strains were tested for 
activity with free cholesterol or egg yolk as the substrate, all R. equi strains 
degraded free cholesterol at a higher rate. The rate of cholesterol degradation by 
cell-free extracts with egg yolk preparation was much lower. Some differences were 
seen among Rhodococcus strains in their ability to degrade egg yolk cholesterol 
even though rates of dissimilation of free cholesterol were similar. When the 
cholesterol in the cream preparation was used as the substrate, the degradation rate 
was even lower, indicating that cholesterol in cream preparations was even less 
accessible to the cholesterol dissimilating system of rhodococci than was cholesterol 
in egg yolk preparations. Therefore, it was concluded that the discoveiy of more 
efficient microbial enzymes and the development of procedures resulting in greater 
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substrate availability to enzymatic degradation are needed before further progress 
in reducing the cholesterol content of complexed food systems biologically can be 
made (Johnson and Somkuti 1990). 
Xiansheng et al. (1990) reported the cholesterol degradation and formation 
of oxidation products by cholesterol oxidase in a buffer system and in commercially 
homogenized pasteurized milk at a range of temperatures. Only one byproduct, 4-
cholesten-3-one, generated by cholesterol oxidase both in buffer and in milk was 
identified. In phosphate buffer, cholesterol (1 mg/ml) was oxidized to 4-cholesten-
3-one completely in less than 24 h at 25°C or 37°C. At 6°C, the enzyme was still 
active, but the reaction rate was slower. Interestingly in milk, the highest 
cholesterol degradation was achieved at the lowest temperatures tested, up to 50% 
being degraded in 8 h at both 7°C and 3°C. The result was explained by possible 
attachment of cholesterol oxidase to the fat globules (therefore more accessible to 
cholesterol) in milk at a low temperature. This feature offers the potential to use 
cholesterol oxidase in the same way as lactase is sometimes commercially applied to 
milk. Enzymes aseptically added after the heat treatment could decrease the 
cholesterol more than 50% before the milk reaches the consumer. 
Smith et al. (1991) further assessed reactivity of milk cholesterol with 
bacterial cholesterol oxidases from Pseudomonas, Streptomyces, and Rhodococcus. 
It was shown that P. fluorescens cholesterol oxidase oxidized cholesterol rapidly in 
homogenized/pasteurized milk or in sonicated raw milk but catalyzed cholesterol 
oxidation only slowly in intact raw milk. Pasteurization had little influence on 
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oxidation rates. Oxidases from Streptomyces and Rhodococciis species were 
significantly less active in milk than was the Pseudomonas enzyme. Cholesterol 
oxidation in homogenized milk depends on temperature and enzyme concentration. 
A maximum of 85% of the initial whole milk cholesterol (100-138 ng/ml) was 
oxidized in 96 h to a final cholesterol concentrations of 20-30 iig/ml. Sonicated 
skim milk cholesterol concentrations (initially 17-20 jig/ml) were decreased to 4-6 
jig/ml. In addition to sonication, other procedures have been developed to make 
the water-insoluble substrate, cholesterol, more accessible to the water-soluble 
cholesterol oxidase or cholesterol-oxidizing bacteria. For example, cyclodextrins 
have been used for enhancing the bioavailability of organic substrates to 
biocatalysts. 
Jadoun and Bar (1993) conducted cholesterol oxidation by resting 
Rhodococciis eiythropolis cells and soluble cholesterol oxidase in a cyclodextrin 
medium. It was found that both the enzyme and microbial oxidation of cholesterol 
were enhanced by the dimethylated B-cyclodextrin. The microbial transformation, 
however, was subject to a larger enhancement effect than was the enzymatic one, 
which was interpreted to indicate a stronger affinity of dimethylated 6-cyclodextrin-
complexed substrate for the microbial cells. 
In summary, studies have shown that it is possible is possible to remove or 
decrease cholesterol in foods by enzymes or enzyme-producing microorganisms. 
Cholesterol oxidase (alone) or bacteria that produce it, however, might not be 
suitable for removing food cholesterol because the hydrogen peroxide formed might 
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generate toxic compounds or undesirable flavor components (Smith et al. 1991). 
Further, the safely of the oxidized cholesterol products needs to be assured. 
Cholesterol-Lowering Agents 
Increased serum cholesterol concentrations are a major risk factor for 
coronaiy heart diseases. There is substantial evidence that lowering total and LDL-
cholesterol concentrations will decrease the incidence of coronary heart disease 
(Lipid Research Clinics Program 1988). To date, numerous cholesterol-lowering 
agents have been discovered and synthesized. 
3-Hvdroxv-3-methvlglutarvl coenzyme A (HMG-CoA) reductase inhibitors 
The HMG-CoA reductase inhibitors are the most commonly prescribed 
cholesterol-lowering drugs and are also the most recently introduced 
hypocholesterolemic agents. These inhibitors were initially discovered in Japan in 
1976 (Endo et al. 1976). The first potent inhibitor was named mevastatin (formerly 
called ML-236B or compactin). Subsequently, many mevastatin analogs were 
developed. By 1990, lovastatin (formerly called mevinolin), simvastatin, and 
pravastatin had been approved and marketed in many countries (Grundy 1988; 
Hunninghake 1992). The potency of lovastatin and pravastatin seems to be similar, 
and simvastatin is about twice as potent (Hoffman et al. 1986). These drugs are 
very efficient in lowering total cholesterol and LDL cholesterol concentrations, 
particularly in people resistant to diet-induced decreases in plasma cholesterol 
63 
concentrations. Beneficial effects from their administration in patients with 
coronary heart disease have been observed (Brown et al. 1990). 
HMG-CoA reductase is the rate-limiting enzyme in the de novo biosynthesis 
of cholesterol. The HMG-CoA reductase inhibitors are administered primarily to 
lower the plasma concentrations of total and LDL-cholesterol. These inhibitors 
share some molecular similarities with HMG-CoA, particularly the 3,5-dihydroxy 
heptanoic acid portion; other regions are also functionally essential (Endo 1992). 
These features lead to the result that the statins have a 10,000-fold greater affinity 
for HMG-CoA reductase than does the natural substrate, thus effectively blocking 
the conversion of HMG-CoA to mevalonic acid and thus also blocking cholesterol 
synthesis. 
Theoretically, an HMG-CoA reductase inhibitor lowers plasma cholesterol 
by two mechanisms: (a) an inhibition of the hepatic formation of plasma 
lipoproteins and (b) enhanced lipoprotein catabolism in the liver (Endo, et al. 
1979). Kovanen et al (1981) demonstrated in dogs that lowering of LDL-
cholesterol occurs via these two mechanisms. Bilheimer et al (1983), however, 
showed that the principal action of lovastatin is to increase the number of LDL 
receptors and to enhance LDL receptor-mediated catabolism of lipoprotein rather 
than to inhibit synthesis of lipoproteins. This conclusion was drawn from the 
observation that these drugs are extremely effective in patients with heterozygous 
familial hypercholesterolemia (FH). Cholesterol concentrations fall by 25-30% and 
35-40% with twice-daily doses of 20 mg and 40 mg lovastatin, respectively. In 
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receptor-negative patients with homo2ygous FH, however, no cholesterol-lowering 
has been observed during the treatment with lovastatin, even at very high doses 
(Uauy et al. 1988). 
Rates of synthesis of LDL receptors are correlated inversely with the 
amount of cholesterol in cells (Goldstein and Brown 1977). The mechanism 
responsible for up-regulating LDL receptors in receptor-deficient patients starts 
with inhibition of HMG-CoA reductase. The consequent reduction in hepatic 
cholesterol production results in an increase in receptor numbers, which "p"W" 
cholesterol out of blood, thereby lowing serum cholesterol concentration. Studies 
with experimental animals revealed that HMG-CoA reductase inhibitors increase 
messenger RNA for LDL receptors in the liver (Ma et al. 1986) and enhance the 
number of LDL receptors expressed on the surface of liver cells (Kovanen et al. 
1981). 
The HMG-CoA reductase inhibitors are considered generally as safe 
cholesterol-lowering drugs that decrease the death rate from heart attacks. 
Undesirable side effects, however, have been observed during clinical use of these 
drugs (Erkelens et al. 1988; Walkwe 1989). Some adverse clinical events include 
headache and gastrointestinal upset. Most common adverse laboratory events 
include elevation of serum transaminase activity and serum creatine kinase activity. 
Also, several studies have shown that HMG-CoA reductase inhibitors increase the 
risk of death from noncardiac mortality, including cancer and violent deaths, 
suggesting that over-all suivival is not improved (Muldoon et al. 1990; Oliver 1992; 
65 
Ravnskov 1992; Rossouw, et al. 1990). Recently, a report from the Scandinavian 
Simvastatin Survival Study Group (1994), however, has indicated that long-term 
treatment with simvastatin is safe and improved survival in 4444 coronary heart 
disease patients. 
Bile acid sequestrants and cholesterol absorption inhibitors 
Bile acid sequestrants are recommended as first-line therapy for decreasing 
LDL if dietary therapy is unsuccessful in lowering LDL-cholesterol concentrations 
sufficiently (Ad Hoc Committee 1984). They have been used routinely for lowering 
of elevated concentrations of LDL-cholesterol for more than two decades (National 
Cholesterol Education Program 1988). Two bile acid sequestering anion-exchange 
resins, cholestyramine (a quaternary ammonium salt of a copolymer of styrene and 
divinylbenzene) and colestipol (a tertiary amine, copolymer of diethylenetriamine 
and epichlorohydrin), although quite different in chemical structure, provide 
parallel and alternative approaches to normalization of plasma total and LDL-
cholesterol concentrations. The Lipid Research Clinics Coronary Primary 
Prevention Trials demonstrated that cholestyramine was effective in lowering LDL-
cholesterol concentrations and subsequently decreasing the incidence of coronary 
heart disease (Lipid Research Clinics Program 1984a and 1984b). 
Both cholestyramine and colestipol bind bile acids in exchange for chloride 
ions, an interaction that is irreversible and independent of temperature or pH. 
Cholestyramine, however, is more effective than colestipol in cholesterol-lowering 
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action. Because of their very large molecular size, resins are retained in the 
intestine where they sequester bile acids and thus promote their excretion in the 
feces. The augmented disposal of bile acid causes an increase in hepatic synthesis 
of bile acids by stimulating activity of the key liver enzyme cholesterol la-
hydroxylase. Increasing bile acid synthesis requires cholesterol as the precursor, 
which results in the depletion of the cholesterol pool in liver. Therefore, on one 
hand, the number of LDL receptors on liver cells is increased in order to capture 
more circulating LDL-cholesterol (thus lowering the plasma LDL-cholesterol 
concentration). On the other hand, the synthesis of cellular cholesterol is increased 
by up-regulating the activity of the HMG-CoA reductase (Kim et al. 1977). The 
increase of cholesterol synthesis by bile acid sequestrants partially offsets the 
beneficial effect of increased steroid excretion (Kim et al. 1977). Thus, the 
mechanism of action has two perceived defects. One is that LDL lowering is 
dependent on the capacity of new receptor synthesis, meaning that FH 
homozygotes are refractory, but these patients are rare. The other is that LDL 
lowering is limited by the accompanying rise in cholesterol synthesis, but this 
disadvantage can be remedied by combination therapy with HMG-CoA reductase 
inhibitors (Contermans and Erkelens 1992). Even though cholestyramine is highly 
effective in the treatment of many patients with high plasma cholesterol 
concentrations, it unfortunately is not tolerated by all patients. Therefore, in spite 
of its proven usefulness, the bile acid sequestrant is not an ideal cholesterol-
lowering agent (Endo 1994). 
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Neomycin is a cation aminoglycoside antibiotic that has a cholesterol-
lowering effect. It acts by precipitating cholesterol within the intestinal lumen and 
thus inhibiting its absorption (Samuel 1979). Side effects, including nausea, 
diarrhea, and renal toxicity, limit long-term administration. Other agents acting to 
inhibit cholesterol absorption are not of outstanding efficacy—possibly because 
there is always the potential for a compensatory increase in cholesterogenesis~but 
the unabsorbed plant sterol B-sitosterol and the hydrogenated derivative, sitostanol, 
may be beneficial on low-dose administration (Heinemann et al. 1986). 
Lifibrol (4-[4-[4-(l,l-dimethylethyl)phenyl]-2-hydroxybutoxy-benzoic acid) is 
a novel lipid-lowering agent. Lifibrol was initially studied in humans by Hasibeder 
et al. (1991). Lifibrol has primaiy effects on LDL-cholesterol, total cholesterol apo 
B, and Lp(a). The potency is similar to high doses of HMG-CoA reductase 
inhibitors or nicotinic acid and bile acid sequestrant combinations (Locker et al. 
1995). The effects on serum triacylglycerols and HDL-cholesterol are also similar 
to the HMG-CoA reductase inhibitors. The mechanism of action of lifibrol is 
complex and seems to involve several modes of action, including inhibition of 
cholesterol synthesis (but lifibrol is not a HMG-CoA reductase inhibitor), inhibition 
of sterol absorption, and enhanced sterol excretion, or possibly enhanced LDL-
receptor activity or bile acid negative feedback on HMG-CoA reductase. Lifibrol is 
well tolerated and could be useful in the therapy of primary hypercholesterolemia 
(Locker et al. 1995). 
Ikeda et al. (1992) found that tea catechins, in particular their gallate esters. 
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effectively decrease cholesterol absorption by decreasing solubility of cholesterol in 
mixed micelles. This observation accounts for the hypocholesterolemic effect of tea 
catechins. Recently, Burnett (1994) discovered a very potent class of cholesterol 
absorption inhibitors represented by azetidinone. The effect of this compound on 
serum cholesterol concentrations has not been reported yet. 
Fibric acid derivatives 
The fibrates include clofibrate and its analogs, gemfibrozil, bezafibrate, and 
fenofibrate. They are useful for lowering serum triacylglycerols and increasing 
HDL concentrations. The principal action of clofibrate is on triacylglycerols, i.e. 
VLDL. The other analogs are more potent, particularly with respect to the 
elevation of HDL-cholesterol. Some (e.g., gemfibrozil) also decrease LDL-
cholesterol concentrations in some patients (Fidge 1993). The mechanism of action 
of these fibric derivatives is still not fully understood. Their primary effect is a 
lowering of VLDL concentration. The concentration of other major lipoproteins, 
LDL or HDL, may also be altered, depending on which of the derivatives is used 
(Brewer 1992). 
Clofibrate is the ethyl ester of p-chlorophenoxyisobutyric acid. The ester 
form is necessary for absoiption from the intestine, but tissue and plasma esterases 
rapidly hydrolyze it to give the acid form, which is subsequently bound to albumin. 
Moreover, /?-chlorophenoxyisobutyric acid increases the lipoprotein lipase activity 
that accelerates the hydrolysis of VLDL-triacylglycerol and, consequently, the rate 
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of formation of LDL (Shepherd and Packard 1986). Other biochemical actions 
include decreases in plasma free fatty acid (FFA) concentrations, possibly by 
inhibition of adipocyte cyclic adenosine monophosphate (cAMP) generation, and a 
lowering of FFA output into the blood (Brewer 1992). In addition, the fibrates 
have been show to inhibit acyl coenzyme Axholesterol acyl transferase (ACAT) 
activity, thereby causing a decrease in the rate of cholesteryl ester formation and an 
associated rise in free cellular cholesterol concentration. This ACAT effect may 
explain both the increased biliaiy secretion of cholesterol and gallstone formation 
that sometimes accompany the use of these drugs. Also, fibrates inhibit HMG-
CoA reductase activity (Bernt et al. 1978), a surprising result because fibrates 
clearly are not competitive inhibitors of the eniqane. The resultant inhibition of 
cholesterol synthesis and subsequent up-regulation of the LDL receptor pathway 
results in more cholesterol being removed from the plasma. This reasoning 
explains why some of the drugs lower both cholesterol and triacylglycerol 
concentrations. 
Gemfibrozil is a member of the fibrate family that is tolerated better than 
clofibrate. It exerts additional influence on HDL metabolism by inducing synthesis 
of the nascent peptide (selectively increasing HDL3) and by preserving apo E levels 
so that the uptake of VLDL remnants (apo E-receptor mediated) is augmented 
(Saku et al. 1985; Newton and Krause. 1986). Bezafibrate and fenofibrate are 
newer potent hypolipidemic agents that lower both triacylglycerol and cholesterol 
concentrations. They also decrease hepatic VLDL secretion, possibly by enhancing 
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B-oxidation of liver fatty acids, thus depleting the FFA pool available for 
triacylglycerol production (Fidge 1993). In addition to a decrease in VLDL-
triacylglycerol concentration, these compounds also lead to a decrease in LDL-
cholesterol concentration. 
Antilipolvtics: nicotinic acid, acipimox. and acifran 
Nicotinic acid, unrelated to its vitamin effect, when administered in large 
doses, has a more pronounced impact on circulating triacylglycerol than on total 
cholesterol concentration, but there is a differential effect on lipoproteins such that 
VLDL declines and HDL rises. Nicotinic acid acts by inhibiting lipolysis, which is 
catalyzed by hormone-sensitive lipase, in white adipose tissue, probably by 
inhibiting adenylate cyclase activity (Saggerson, 1986). The inhibition of lipolysis in 
adipose tissue results in lower FFA availability for liver triacylglycerol production. 
The clinical use of nicotinic acid has been hampered by prostaglandin-mediated 
flushing, experienced after initial doses, which may be related to the rapidity of the 
attainment of nicotinic acid peak concentration in the circulation (Fears 1987). 
Therefore, several analogs have been developed. Among them are acipimox and 
acifran. 
Acipimox (5-methylpyrazine carboxylic acid-4-oxide) is more potent as a 
hypolipidemic agent (Sommariva et al. 1985). However, the half-life of acipimox in 
blood is shorter than that for nicotinic acid. Like nicotinic acid, acipimox produced 
a decrease in VLDL and an increase in HDL2 with an enhanced activity of 
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lipoprotein lipase. 
Acifran (AY-25712; 4,5-dihydro-5-methyl-4-oxo-5-phenyl-furan-2-carbo)q'lic 
acid) is also more potent than is nicotinic acid in laboratory animals (Cayen 1985). 
The half-life of plasma acifran is about the same as nicotinic acid. Acifran has 
been shown to cause a small decrease in total and LDL-cholesterol with a small 
increase in HDL-cholesterol. 
Antioxidants including probucol 
Oxidized lipoproteins have been of a great interest because they are 
suspected to cause increased atherogenicity (Beriy 1992). Oxidized LDL activates 
differentiation and migration of macrophages. The scavenger receptors on 
macrophages recognize oxidized LDL and allow for subsequent phagocytosis. When 
the macrophage becomes filled with oxidized LDL-cholesterol, it becomes the foam 
cell that is typically observed in early atherosclerotic lesions. Under the continuing 
influence of excessive oxidative stress, the foam cells necrose, and the toxic 
contents are spilled into the intimal space. This process stimulates an inflammatory 
response whereby the neutrophils and more macrophages are recruited to the site, 
with resultant neointimal and smooth muscle proliferation and eventual plaque 
formation (Steinberg et al. 1989). Most of the oxidation occurs when lipoproteins 
leave the plasma and enter extracellular environments that lack adequate 
concentrations of natural antioxidants (Fidge 1993). 
Antioxidants are chemical compounds with sparsely populated outer electron 
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shells that readily accommodate the unpaired electron characteristic of an oxygen 
free radical and thus neutralize this highly reactive species. Antioxidants that may 
be relevant to preventing the development of atherosclerosis in human include 
vitamin E (a-tocopherol), B-carotene, vitamin C (ascorbic acid), flavonoids, and 
selenium. It has been shown that vitamin E is probably the most effective 
antioxidant relative to preventing atherogenesis. Uptake of large doses of dietary 
vitamin E is associated with a decreased risk of coronary heart disease (Rimm et al. 
1993; O'Keefe et al. 1995). Vitamin E inhibits the oxidation of LDL-cholesterol 
both in vitro (Esterbauer et al. 1991) and in vivo (Riemersma et al. 1991). 
Probucol (2,2-bis[3,5-di-r-butyl-4-hydroxyphenylmercapto]propene) is a 
cholesterol lowering drug that decrease both LDL- and HDL-cholesterol 
concentrations but has no effect on VLDL-cholesterol or on triacylglycerol 
metabolism (Fears 1987). The mechanism of action is different from that of other 
hypolipidemic agents. Probucol increases the fecal excretion of bile acids and total 
fat but not sterol (Beynen 1986). It inhibits both hepatic cholesterogenesis and apo 
B synthesis. Even though probucol decreases the "good" (HDL) cholesterol, it has 
maintained an anti-atherogenic effect in several animal studies and in human trials 
(Walldius 1992). The presence of probucol in LDL prevents oxidation and impedes 
macrophage degradation (Parthasarathy et al. 1986), so that a direct anti-
atherosclerotic action may coexist with the quantitative effect on LDL. 
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Other potential cholesterol-lowering agents 
ACAT inhibitors: ACAT, acyl-coenzyme Axholesterol acyltransferase, plays a 
key role in the intracellular cholesterol esterification (Suckling and Stange 1985). 
Cholesterol esterification is an essential step in cholesterol absorption in the 
intestine, cholesterol secretion from the liver, and cholesterol accumulation and the 
foam cell formation in the vascular wall. Therefore, an ACAT inhibitor may 
exhibit both hypocholesterolemic and antiatherosclerotic effects by blocking 
cholesterol esterification. A number of ACAT inhibitors have been reported and 
are classified into two major chemical types, one being long-chain aliphatic 
carboxylic acid amide derivatives and the other being urea derivatives (Picard 
1993). Recently, Tawada et al. (1994) reported the synthesis of novel ACAT 
inhibitors known as 3-quinolylurea derivatives. These compounds were found to 
inhibit ACAT activity effectively in vitro and cause hypocholesterolemic effects in 
vivo. 
Sqtialene Synthase Inhibitors: Squalene synthase catalyzes the second 
committed step in cholesterol biosynthesis (Agnew 1985). In the reaction, two 
molecules of farnesyl pyrophosphate (FPP) are condensed in the presence of 6-
nicotinamide adenine dinucleotide phosphate (NADPH) and Mg""^ to form 
squalene. Therefore, squalene synthase has been the second potential therapeutic 
target for controlling cholesterol biosynthesis besides HMG-CoA reductase. There 
have been many reports of different classes of compounds that are potent inhibitors 
of squalene synthase. Three fungal metabolites, the zaragozic acids (sometimes 
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called squalestatins), have been show in vitro to be inhibitors of rat liver squalene 
synthase between nanomlar and picomolar concentrations as well as able to 
substantially decrease cholesterol biosynthesis in vivo (Hasumi et al. 1993; 
Bergstrom et al. 1993). A second class of "nanomolar" inhibitors are 
biophosphonates (Amin et al. 1992; Ciosek et al. 1993), and a third class, which 
are FPP analogs, are the isoprenoid (phosphinyhnethyl)phosphonates (Biller and 
Forster 1990; Biller et al. 1991). LoGrasso et al. (1994) compared the inhibition of 
yeast, rat, and human squalene synthase by zaragozic acid C and two FPP analogs. 
It was found that zaragozic acid C was a "nanomolar" inhibitor of all three 
isoenzymes. The isoprenoid phosphonate was a "micromolar" inhibitor of all three 
isoenzymes. An ether-linked phosphonate, however, was found to be 15- and 42-
fold more potent an inhibitor of the mammalian forms of squalene synthase than it 
was for yeast squalene synthase. The results suggest potential differences in active-
site binding residues in those isozymes (LoGrasso et al. 1994). Syntheses of 
squalestatin SI (also known as zaragozic acid A) and zaragozic acid C have been 
reported (Kelly and Roberts 1995). These syntheses are considerable achievements 
because natural compounds that are identified as having a desirable biological 
activity may have low activity in vivo, a poor therapeutic selectivity, or detrimental 
side effects that potentially preclude them from medical use. Many derivatives 
must be synthesized and their biological activity evaluated to identify one with the 
greatest potency and selectivity, and the least toxicity. Clinical use of squalene 
synthase inhibitors will not be possible until outstanding preclinical data are 
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available. 
Cyclophane: A cholesterol "cage" has been built recently that ultimately 
might be used to filter out excess cholesterol from the blood stream (Bradley 1994). 
Cyclophane is a ring-shaped molecule that can be tailored to large sizes by using 
organic synthesis. Two molecules of cyclophane, linked with acetylenes, create a 
molecule with a cavity 0.9 by 1.3 nanometers wide and 1.1 nanometers deep-just 
the right size for a cholesterol molecule. It was reported that when cholesterol was 
added to a cyclophane-water solution, cholesterol was accepted 190 times more 
than in normal water. Testosterone, a steroid hormone with a similar chemical 
structure as cholesterol, was trapped much less often, indicating the cage was fairly 
selective. It was believed that cyclophanes eventually could be incorporated into 
the membrane of a dialysis machine that would "vacuum" cholesterol from the 
bloodstream of patients with severe hypercholesterolemia in a "blood washing" 
procedure. However, much more needs to be learned about the selectivity of the 
cage before it is ready for clinical use. 
Cholesterol Vaccine: Although cholesterol is a common constituent of cells, 
antibodies directed specifically against cholesterol could be induced by 
immunization (Swartz et al. 1988). Protection against atherosclerosis with vaccines 
has been discussed (Travis 1993). Variations of this approach have been tested in 
animals (Bailey 1994). It was shown that when cholesterol-fed rabbits were 
immunized with synthetic antigens in which cholesterol-esters (as haptens) were 
covalently linked to various protein carriers, significant decreases in serum 
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cholesterol and up to 90% protection against atherosclerotic plaques were 
observed. Travis (1993), however, noted possible long-term adverse effects of the 
vaccination procedure. In experiments lasting up to 9 months, the 
hypocholesterolemic effects of immunization persisted, but the protective effects 
against atherosclerosis gradually declined, despite monthly booster shots. 
Nevertheless, it is believed that cholesterol vaccination could become a useful 
adjunct to diet or drug therapy if the procedure can be validated in a more 
appropriate model. Many technical obstacles, however, would need to be overcome 
before the scenario of a routine "cholesterol vaccination" could become a reality 
(Bailey 1994). 
Technologies to Decrease Cholesterol Content of Foods 
Cholesterol content of animal-derived foods is a concern of consumers 
because intake of cholesterol may result in an increase of plasma cholesterol 
concentration, which is a major risk factor for coronary heart disease. The primary 
therapeutic intervention for patients at high risk for development or progression of 
coronary heart disease is to prescribe a cholesterol-lowering diet (The Expert Panel 
1993). Therefore, much effort has been made to develop physical, chemical, and 
biological methods to remove or decrease the cholesterol content of animal-derived 
foods. 
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Physical processes 
Supercritical CO2 Extraction: Supercritical CO2 extractions are performed 
under high pressure above the critical temperature of the solvent (31°C for CO2). 
The intense pressure densifies the CO2 that then solubilizes a portion of the lipid 
components and removes them from the food matrix. This technology has been 
used to extract cholesterol and other lipids from spray-dried egg yolk powders 
(Froning et al. 1990; Rossi et al. 1990). Cholesterol and triacylglycerols were 
preferentially removed from egg powders, while retaining the phospholipids that 
contribute to the functionality of the product. Supercritical fluid extraction also 
can be applied to meats and meat byproducts. For example, Hardardottir and 
Kinsella (1988) extracted 97% of cholesterol and 78% of other lipids from trout 
muscle with this process. 
King et al. (1989) studied techniques for performing analytical extraction of 
lipids from meat products. They found that it was difficult to obtain efficient 
extraction of lipids from intact muscle because of the fibrous nature of the muscle 
structure and the high moisture content, both of which serve as barriers to 
penetration by CO2. Comminuting and dehydrating the muscle prior to extraction 
improved the efficiency of the extraction process. King et al (1993) recently, 
however, reported that supercritical fluid extraction could be used effectively to 
decrease the total lipid and cholesterol content of preformed meat products, 
without requiring comminution of the sample. Beef patties (raw, raw freeze-dried, 
cooked, and cooked freeze-dried) were used in the study. It was found that freeze-
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drying of the patties prior to supercritical CO2 extraction improved removal of total 
lipids and cholesterol. Freeze-diying enhanced cholesterol extraction, whereas 
precooking had limited effects (King et al. 1993). The process, however, is far 
more successful with dehydrated meat products because of the physical nature and 
low moisture contents of these products. Also, dehydrated meats are usually 
cooked products; so, protein denaturation during extraction is not a concern. 
Wehling et al. (1992) investigated (1) several factors that affect the 
extraction of lipid compounds from dehydrated beef and (2) different extraction 
conditions that affect the composition and sensory properties of the products. The 
results demonstrated that lipids were more easily extracted from chunks than from 
powders, allowing for the successful removal at lower temperatures and pressures. 
Extracted samples were lighter in color than the controls. The residual lipids in the 
extracted sample also contained higher relative percentage of linoleic and linolenic 
acids than did the lipids in the control samples, suggesting differential solubilities of 
lipids on the basis of fatty acid compositions. Taste panel evaluation of control and 
extracted powders found no significant differences in beef flavor, the presence of 
off-flavors, or overall acceptability (Wehling et al. 1992) 
Vacuum Steam Distillation: Substances can be fractionated selectively by 
using vacuum molecular distillation (Boudreau and Arul 1993). Cholesterol is a 
compound of low volatility but is more volatile than are the major triacylglycerols 
of milk fat. Superheated steam can be bubbled through the oil, and the oil can be 
heated directly to provide for the latent heat of vaporization of the distilling 
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compounds and to prevent the condensation of steam; thus, temperature and 
pressure can be varied independently. When the sum of the partial vapor pressures 
of water vapor and the distillates is equal to the total pressure, water vapor and the 
low volatile compounds such as cholesterol, free fatty acids, and aroma distill over. 
It has been reported that this process can be used to decrease cholesterol content 
by over 90% from butter oil or milk (Marschner and Fine 1989). The advantages 
of steam distillation include that the equipment is commercially available and less 
expensive to operate than that for supercritical fluid extraction. The daiiy industiy 
can offer consumers a series of functional new products such as low cholesterol 
milk, yogurt, ice cream, cheese, and butter. Cholesterol removal through the 
steam-stripping process, however, may cause the formation of toxic oxidation 
products of cholesterol, particularly 7-hydroxy and 25-hydroxy cholesterols and 
cholestanetriol (Boudreau and Arul 1993). 
Complexation processes 
Cyclodextrins: a-, 6-, and y-cyclodextrins, enzymatically derived from starch, 
are cyclic molecules that contain six, seven, and eight glucose units, respectively. 
They have a hydrophobic central cavity and form inclusion complexes with a large 
variety of hydrophobic and amphiphilic molecules including cholesterol (Abadie et 
al. 1994). 6-Cyclodextrin usually is selected for this application because its ring 
structure best fits the cholesterol molecules for selective encapsulation. The 
encapsulated cholesterol then can be separated from the cyclodextrin. B-
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Cyclodextrin has been used to remove cholesterol from animal fats, including milk 
cholesterol and egg cholesterol (Michael Foods 1992). Simply Eggs, liquid whole 
eggs with 80% less cholesterol than shelled eggs, were available on the shelf in 
food markets for a period of time but now are not produced because of a lack of 
sufficient commercial interest. Although cyclodextrin is used as a processing aid 
and not as an ingredient, FDA approval is needed because treated foods usually 
have a residual amount of cyclodextrin. Cyclodextrins, however, are approved for 
food use in Japan and several European nations. 
Saponins: Sidhu and Oakenful (1989) have developed a method that is based 
on complexation of cholesterol onto saponin or cyclodextrin chemically bound to an 
inert solid support. This method can remove up to 90% of the cholesterol from 
milk or cream. It was claimed that this technology does not affect the components 
of the fat globule membrane of milk apart from its cholesterol. Use of saponins 
for removing cholesterol from foods is the subject of a pending patent; therefore, 
the full details have not been revealed at this stage. 
Biological processes 
Biological processes to remove or decrease the cholesterol content of foods 
involve the use of enzymes or enzyme-producing microorganisms, which have been 
reviewed under the topics of Cholesterol-Reducing Bacteria and Cholesterol 
Oxidase and Cholesterol-Oxidizing Microorganisms previously. 
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OPTIMIZATION OF CONDITIONS FOR GROWTH AND 
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Abstract 
Conditions for growth and coprostanol production of Eubacterium 
coprostanoligenes ATCC 51222 were optimized in this study. The bacterium did not 
require cholesterol for growth, but it retained cholesterol-reducing activity in the 
absence of cholesterol. Lecithin was required for growth, but excess lecithin in 
media did not improve bacterial growth. Pyruvate, lactose, and most reducing 
agents improved bacterial growth and coprostanol production. The optimal pH 
range was 7.0 to 8.0 for both bacterial growth and coprostanol production. 
Addition of a buffer system in media did not seem necessary for bacterial growth 
but increased the coprostanol production. Optimal incubation temperature was 
37°C to 39°C. Most antibiotics inhibited bacterial growth with the exception of 
tetracycline at a final concentration of 50 |ig/ml. Resistance to tetracycline was 
dose-dependent. Ethanol as the solvent for dissolving tetracycline did not show any 
effect with a final concentration up to 1.3%. The mechanism for the tetracycline 
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resistance is unknown. No plasmid was found in the bacterium. Bile salts showed 
some inhibitory effects on bacterial growth. Knowledge of these growth conditions 
and effectors is necessary for future characterization and applications of E. 
coprostanoligenes. 
Introduction 
There has been a great interest in cholesterol because of its relationship with 
cardiovascular diseases. Excess serum cholesterol is a major risk factor for 
coronary heart disease, which remains a leading cause for human death in many 
developed countries including the United States (Thom et al. 1992; American 
Heart Association, 1994). Many cholesterol-lowering agents have been discovered 
and synthesized to treat hypercholesterolemic individuals (Endo 1992). Potential 
side effects of those drugs, however, have caused concerns about their clinical use 
(Erkelens et al. 1988). Also, many efforts have been made to develop physical, 
chemical, and biological technologies to decrease cholesterol contents of foods 
because dietary cholesterol intake affects serum cholesterol directly in many people 
(Eraser 1994; Pyorala 1987). 
Biological methods (whole cell or enzymatic) are often the preferred method 
of food treatment because they are usually less harsh, form fewer by-products, are 
easier to control, and are considered "natural" by consumer. Much of the research 
in decreasing cholesterol content of foods by biological methods has focused on the 
cholesterol oxidase that has been well characterized (Vrielink et al. 1991). 
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Unfortunately, attempts to use cholesterol-oxidizing bacteria to decrease the 
cholesterol content of foods has produced few positive results (Aihara et al. 1988, 
Johnson and Somkuti 1990). A novel method of using cholesterol reductase or 
cholesterol-reducing bacteria has been proposed to decrease cholesterol content of 
foods and to lower serum cholesterol concentrations in humans (Dehal et al. 1991). 
The enzyme, cholesterol reductase, catalyzes the reduction of cholesterol to 
coprostanol. Coprostanol, unlike cholesterol, is absorbed poorly jfrom the human 
intestine (Bhattacharyya 1986). Therefore, foods treated with cholesterol reductase 
or cholesterol reductase-producing bacteria will have less or no cholesterol 
available for absorption when the foods are consumed. Introduction of cholesterol 
reductase or cholesterol reductase-producing bacteria into the small intestine is 
hypothesized to decrease absorption of both the endogenous and exogenous 
cholesterol. 
Cholesterol-reducing bacteria have been isolated from feces of rats (Eyssen 
et al. 1973), humans (Sadzikowsky et al. 1977), and baboons (Brinkley et al. 1982). 
All these previously isolated bacteria, however, had characteristics that made 
common laboratory manipulations difficult. Recently, a unique cholesterol-
reducing bacterium, Eubacterium coprostanoUgenes ATCC 51222, was isolated and is 
much easier to culture in the laboratory (Freier et al. 1994). E. coprostanoUgenes is 
a Gram-positive, anaerobic, nonfermentative bacterium that forms colonies on petri 
plates and converts up to 90% of cholesterol to coprostanol in its growth media but 
does not require cholesterol for growth. Thus, E. coprostanoUgenes seems more 
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amenable than previously studied cholesterol-reducing bacteria for applications in 
the food and pharmaceutical industries. The present study was undertaken to 
optimize the growth conditions for culturing E. coprostanoligenes to achieve the 
maximal bacterial growth and coprostanol production. The information is 
necessary when proceeding toward further characterization and application of this 
cholesterol-reducing bacterium. 
Materials and Methods 
Cultivation of bacteria 
A standard growth medium to culture E. coprostanoligenes contains the 
following components per liter: 10 g casitone (Difco, Detroit, MI), 10 g yeast 
extract, 5 g lactose, 5 g sodium pyruvate, 0.5 g sodium thioglycolate, 0.1 g lecithin 
(type IV-S, Sigma), 0.1 g CaCl2*2 H2O, and 1 mg resazurin. Cholesterol (ash-free, 
Sigma Chemical Co., St. Louis, MO) was added at a concentration of 0.02% in the 
medium if coprostanol production was of concern. The pH of the medium was 
adjusted to 7.5 with 3 N KOH. The Hungate technique was used for the anaerobic 
preparation of media and handling of the culture (Holdeman et al. 1977). Fresh 
medium was inoculated with 1% of a 2-d culture and incubated at 37°C. 
Protein determination 
Bacterial cultures were harvested by centrifugation at 10,000 x g for 10 min 
at 4°C, usually after incubation for 2-4 d at 37°C. The cell pellets then were 
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washed once and suspended in 25 mM PIPES (piperazine-N,N'-bis-[2-
ethanesulfonic acid]) buffer (pH 7.5). Total cellular protein was determined by the 
Bradford method with microtiter plates (Redinbaugh and Campbell 1985). A 
portion of the cell suspension was mixed with an equal volume of 2 N NaOH and 
incubated at 37°C overnight to solubihze the protein. Bovine serum albumin, 
treated in the same manner, was used as a standard. Total cellular protein 
concentration was used as a indicator of bacterial growth. 
Determination of coprostanol production 
After incubation at 37°C for 2-4 d, aliquots of bacterial cultures in 
cholesterol-containing media were taken through the lipid extraction procedure 
(Bligh and Dyer 1959). The amounts of coprostanol produced and residual 
cholesterol were determined by gas-liquid chromatography by the method of Oles 
et al. (1990). The lipid extract from the samples was evaporated to dryness under 
nitrogen. Sterols in the residue were etherified with 1,3-bis-
(trimethylsilyl)trifluoroacetamide. A 5830A Hewlett Packard gas chromatograph 
was used. A 0.91 m x 4 mm internal diameter glass column, was packed with 3% 
SP-2250 on 100/120 Supelcoport (Supelco, Inc., PA). Operating conditions were; 
oven, 250-280°C; injector, 290°C; flame ionization detector, 290°C; nitrogen flow 
rate, 20 ml/min. 
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Results and Discussion 
Effects of cholesterol 
Cholesterol is not required for growth of E. coprostanoligenes (Freier et al. 
1994). But, cholesterol was added to the growth medium because cholesterol-
reducing activity of E. coprostanoligenes then could be determined in the same 
culture. The bacterium was cultured either in the presence or the absence of 
cholesterol, and the bacterial growth was determined (Figure 1). The results show 
that the growth rate and yield of E. coprostanoligenes were similar with or without 
cholesterol. Bacterial cells grown in cholesterol-free media retain cholesterol-
reducing activity when incubated with micellar cholesterol substrate in resting cell 
assays (Li et al. 1995). Therefore, cholesterol reductase seems to be synthesized 
constitutively in E. coprostanoligenes. Most previously isolated cholesterol-reducing 
bacteria require cholesterol and plasmalogen for growth and cholesterol-reducing 
activity (Eyssen et al. 1973; Sadzikowski et al. 1977; Mott and Brinkley 1979). 
Cholesterol was suggested as a terminal electron acceptor in the metabolism of the 
microorganism (Eyssen et al. 1973). Because E. coprostanoligenes does not require 
cholesterol for growth, an alternate electron acceptor must be used when 
cholesterol is not available. Therefore, the role of cholesterol in the metabolism of 
this microorganism needs to be investigated further. 
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Figure 1. Effect of cholesterol on bacterial growth. Cell protein is a measure 
of growth. Choi-Free and Choi refer to growth media without and 
with cholesterol, respectively. Data are expressed as the mean of five 
samples ± standard error. 
Effects of lecithin 
Lecithin is required for the growth of E. coprostanoligenes (Freier et al. 
1994). Effects of different concentrations of lecithin in the medium on bacterial 
growth was determined in this study (Figure 2). The bacterial growth rate was 
proportional to lecithin concentrations up to 0.05 mg/ml. The growth of E. 
coprostanoligenes was independent of lecithin concentrations over 0.05 mg/ml in the 
growth medium. E. coprostanoligenes has phospholipase activity and metabolizes 
lecithin, as indicated by the disappearance of lecithin and appearance of free fatty 
acids in the culture (Freier et al. 1994). 
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Figure 2. Effect of lecithin on bacterial growth. Cell protein is a measure of 
growth. Choi-Free and Choi refer to growth media without and with 
cholesterol, respectively. Each data point is an average of duplicate 
samples. 
Mott and Brinkley (1979) observed that most previously isolated strains of 
cholesterol-reducing bacteria required plasmenylethanolamine for growth and 
cholesterol reduction to coprostanol. The plasmalogen was metabolized by those 
bacteria into unidentified end products. The first isolate of cholesterol-reducing 
bacterium, Eubacterium sp. strain ATCC 21408, was shown to have 
sphingomyelinase activity (Eyssen et al. 1973). None of the metabolites of 
sphingomyelin, however, supported growth of the bacterium. The ways in which 
phospholipase and sphingomyelinase activities are related to the bacterial growth 
and cholesterol reduction remain unknown. When glycerol or fatty acids were 
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added along with cholesterol to a growth medium, E. coprostanoligenes did not 
grow or reduce cholesterol, although growth occurred in the presence of 
phosphatidylcholine (Freier et al. 1994). Therefore, the enzymatic hydrolysis of 
phosphatidylcholine seems necessary for growth and cholesterol reduction. 
Calcium chloride was found to stimulate coprostanol formation by E. 
coprostanoligenes. The mechanism for the stimulation might be related to the fact 
that Ca^"^ is an activator of phospholipase C (Freier et al. 1994). 
Effects of pyruvate 
Pyruvate increases coprostanol production by E. coprostanoligenes in 
cholesterol-containing media (Freier et al. 1994). In resting cell assays, pyruvate 
was found also to stimulate cholesterol reductase activity of the bacterium (Li et al. 
1995). The effect of different concentrations of pyruvate on the bacterial growth 
was determined in this study (Figure 3). The results show that cultures grew poorly 
without pyruvate in the medium. The yield of bacterial growth was proportional to 
the pyruvate concentrations up to 27 mM in the media. Greater concentrations of 
pyruvate did not improve the growth of E. coprostanoligenes. Freier et al. (1994) 
showed that pyruvate was metabolized by the bacterium because it disappeared 
from the growth medium and that, when pyruvate was added into the growth 
medium, significantly more acetic acid was produced. Pyruvate probably acts as a 
electron donor in cholesterol reduction. A similar observation was reported with 
16-dehydroprogesterone reductase activity of Eiibacteriiim sp. strain 144; pyruvate 
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Figure 3. Effect of pyruvate on bacterial growth. Cell protein is a measure of 
growth. Data are expressed as the mean of triplicate samples ± 
standard error. 
functioned as a electron donor for 16-dehydroprogesterone reductase in both whole 
cells and cell-free extracts of the bacterium (Watkins and Glass 1991). 
Effects of lactose 
E. coprostanoligenes ferments lactose to produce much acid (Freier et al. 
1994). Lactose was added to growth media to potentially increase the yield of 
bacterial growth. It was of concern, however, that the lower pH of the lactose-
containing culture might affect the bacterial growth and coprostanol production. 
Therefore, media with or without lactose were prepared, inoculated, and cultured. 
The bacterial growth, coprostanol production, and the pH values of the cultures 
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were determined (Figure 4). The bacterial yield was significantly higher in cultures 
with lactose than without lactose. The highest bacterial yield was achieved when 
both lactose and pyruvate were in the growth medium (Figure 5). Coprostanol 
production was also much higher in cultures containing lactose. After 48 h of 
incubation, the pH was 6.38 ± 0.12 (mean ± SE, n=8) in cultures with lactose and 
7.22 ± 0.01 (mean ± SE, n = 8) in cultures without lactose. Clearly, E. 
coprostanoligenes used energy produced from lactose fermentation for growth and 
cholesterol reduction. The lower pH of the culture can be used as a indicator for 
better bacterial growth, because, with the same medium, cultures with lower pH 
usually yield more bacteria than do the ones with higher pH. The effects of initial 
pH values in the growth medium on bacterial growth and coprostanol production 
will be shown and discussed later in this report. 
Lactose and other carbohydrates were thought to inhibit coprostanol 
formation by cholesterol-reducing bacteria (Kellogg and Wostmann 1966; Subbiah 
et al. 1974; Wells and Cooper 1958) in vivo. With a pure culture of E. ATCC 
21408, however, Eyssen et al. (1974) found that addition of lactose or glucose in 
the culture did not inhibit cholesterol-reducing activity of this bacterium and that 
the pH value dropped slowly from 7.3 before incubation to 6.5 after a 72-h 
incubation. But, when the cholesterol-reducing bacterium was cultured with 
lactose-fermenting bacteria such as Clostridium Cl-8, Escherichia coli, or 
Streptococcus faecalis, the pH of these mixed cultures dropped to values below 6 
within 24 h, E. ATCC 21408 failed to grow adequately, and coprostanol 
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Figure 4. Effect of lactose on bacterial growth (cell protein) and coprostanol 
production. Coprostanol production was measured as percentage of 
cholesterol in growth medium that was converted to coprostanol. 
Med+Lac and Med-Lac refer to media with and without lactose, 
respectively. Data are expressed as the mean of quadruple samples ± 
standard error. 
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Figure. 5 Effect of lactose and pyruvate on bacterial growth. Cell protein is a 
measure of growth. Data are expressed as the mean of quadruple 
samples ± standard error. 
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production was inhibited. The inhibitory effect of the carbohydrate in mixed 
cultures could be overcome by maintaining the pH of the culture medium above 6.5 
throughout the incubation period. In the present study, lactose not only did not 
show inhibitory effects but stimulated growth and coprostanol production of E. 
coprostanoligenes. 
Effects of reducing agents 
Reducing agents are particularly effective in stabilizing microbial enzymes 
that are derived from a reducing environment (Linn 1990). Some reducing agents 
such as dithiothreitol sometimes, however, cause inactivation of enzyme activities 
(Cayama and Apitz-Castro 1973; Gomez-Moreno and Palacian 1974; Trotta et al. 
1974). 
Sodium thioglycolate usually is added in the growth medium to culture E. 
coprostanoligenes. Effects of sodium thioglycolate and other reducing agents 
including 6-mercaptoethanol, dithiothreitol, glutathione (reduced form), and L-
cysteine on bacterial growth and coprostanol production were determined (Table 
1). Sodium thioglycolate and B-mercaptoethanol stimulated the bacterial growth, 
dithiothreitol and glutathione had no effect, and L-cysteine inhibited bacterial 
growth. Coprostanol production was increased by sodium thioglycolate, 13-
mercaptoethanol, and glutathione but not by the other reducing agents. In resting 
cell assays, all the reducing agents except L-cysteine were stimulatory to cholesterol 
reductase activity of E. coprostanoligenes (Li et al. 1995). 
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Table 1. Effect of reducing agents on bacterial growth and coprostanol 
production. 
Reducing Agents Cell Protein (ng/ml)® Coprostanol (%)^ 
Control 331 ± 11 47.4 ± 1.3 
Sodium thioglycolate 497 ± 38 56.6 ± 1.6 
B-Mercaptoethanol 414 ± 14 50.1 ± 1.1 
Dithiothreitol 339 ± 16 47.2 ± 0.5 
Glutathione (reduced form) 306 ± 13 52.3 ± 0.7 
L-Cysteine 64 ± 9 39.0 ± 4.0 
" Mean of triplicate samples ± standard error. Cell protein is a measure of 
bacterial growth. Coprostanol production was measured as percentage of 
cholesterol in growth medium that was converted to coprostanol. 
Effects of initial pH values 
Growth media with different initial pH values were prepared by addition of 
appropriate amounts of KOH or HCl. After incubation at 37°C for 2 d, the 
bacterial growth and coprostanol production were determined (Figure 6). Initial 
pH at 7.0 in the growth medium was the optimal pH for the bacterial growth. 
Growth was significant with the initial pH values between 6.5 and 8.5, whereas 
growth was sparse with the initial pH below 6.5 or above 8.5. Coprostanol 
production increased with the increase of initial pH values of growth media up to 
7.0, remained stable between pH 7.0 and 8.5, and decreased when the initial pH 
value was above 8.5. When PIPES buffer (25 mM) was added into the growth 
medium at pH 7.5, bacterial growth was not improved but coprostanol production 
was increased significantly (Figure 7). In resting cell assays, the optimal pH for 
cholesterol reductase activity of E. coprostanoligenes was 7.5 with both PIPES buffer 
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Protein ^Coprostanol 
Figure 6. Effect of initial pH values of media on bacterial growth (cell protein) 
and coprostanol production. Coprostanol production was measured 
as percentage of cholesterol in growth medium that was converted to 
coprostanol. Data are expressed as the mean of triplicate samples ± 
standard error. 
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Figure 7. Effect of PIPES buffer in media on bacterial growth (cell protein) 
and coprostanol production. Coprostanol production was measured 
as percentage of cholesterol in growth medium that was converted to 
coprostanol. Med and Med+Buffer refer to growth media without 
and with PIPES buffer. Data are expressed as the mean of triplicate 
samples ± standard error. 
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and sodium phosphate buffer (Li et al. 1995). With different buffer systems, 
however, cholesterol reductase activity responded differently to the pH values. 
Effects of incubation temperatures 
Effects of different incubation temperatures on bacterial growth and 
coprostanol production were determined (Figure 8). The highest bacterial yield 
was achieved at 39°C. At 3TC, the bacterium growth was about 25% less. At 41°C, 
the bacterial yield was only half of that at 39°C. When incubation temperatures 
were above 41°C or below 35°C, no significant growth occurred. Similar results 
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Figure 8. Effect of incubation temperatures on bacterial growth (cell protein) 
and coprostanol production. Coprostanol production was measured 
as percentage of cholesterol in growth medium that was converted to 
coprostanol. Data are expressed as the mean of triplicate samples ± 
standard error. 
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were observed with coprostanol production except that the optimal temperature for 
coprostanol production was 37°C instead of 39°C. Therefore, the temperature 
range for optimal bacterial growth and coprostanol production seems to be from 
37°C to 39°C. 
Effects of antibiotics 
Antibiotics, including ampicillin, kanamycin, streptomycin, tetracycline, and 
chloramphenicol, were tested for their effects on the growth and coprostanol 
production of E. coprostanoligenes (Figure 9). All of these antibiotics except 
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Figure 9. Effect of antibiotics on bacterial coprostanol production. Coprostanol 
production was measured as percentage of cholesterol in growth 
medium that was converted to coprostanol. Amp = ampicillin, Kan 
= kanamycin, Str = streptomycin, Tet = tetracycline, and Chi = 
chloramphenicol. The final concentrations of antibiotics in media 
were 50 jig/ml. Incubation times are presented as 48 h and 96h. 
Data are expressed as the average of duplicate samples. 
98 
tetracycline inhibited bacterial growth and coprostanol production at a final 
concentration of 50 iig/ml. After 48 h of incubation, cultures with tetracycline 
produced less coprostanol than did the controls; however, by 96 h, the cultures with 
tetracycline produced the same amount of coprostanol as did the controls. 
This tetracycline resistance of E. coprostanoligenes was investigated further 
for dose and incubation time responses. To determine effects of ethanol, which 
was used as a solvent for tetracycline, the same concentrations of ethanol as in 
tetracycline cultures were added to the cultures without the antibiotics. 
Coprostanol productions in those cultures were determined (Figure 10). After 24 h 
of incubation, coprostanol production in cultures was not affected by ethanol 
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Figure 10. Effect of ethanol and tetracycline on bacterial coprostanol 
production. Coprostanol production was measured as percentage of 
cholesterol in growth medium that was converted to coprostanol. 
EtOH = ethanol and Tet = tetracycline. Final concentrations of 
EtOH and Tet in cultures are presented in parentheses. Data are 
expressed as the average of duplicate samples. 
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but was lower with tetracycline than that in the controls. After 48 h of incubation, 
coprostanol production increased significantly in cultures with tetracycline at 50 
|ig/ml, and became similar to that of the control after 72 h of incubation. Cultures 
with higher tetracycline (75 or 100 iig/ml), however, produced less coprostanol than 
did the control even after 96 h of incubation. Ethanol showed no effect on 
coprostanol production. The relationship between cholesterol reduction and 
tetracycline resistance was investigated. An attempt was made to search for a 
plasmid that might be responsible for tetracycline resistance and cholesterol-
reducing activity. Accordingly, no plasmid was found in E. coprostanoligenes. The 
mechanism for tetracycline resistance of this bacterium, therefore, remains 
unknown. 
Effects of bile salts 
A primary bile salt, sodium taurocholate, and a secondaiy bile salt, sodium 
taurodeoxycholate, were added to the growth medium. An in vivo situation was 
mimicked by adding appropriate amounts of bile salts to reach the physiological 
concentrations of bile salts in human intestines. In bile, the concentration of bile 
salts is about 50 mM (Muraca et al. 1991). Cholate was added in the growth 
medium with a final concentration at 10 mM because a 5-fold dilution was assumed 
by the intestinal lumen fluid. Deoxycholate is formed by bacterial actions that 
occurs mostly in the large intestine after bile acid reabsorption; therefore, its 
concentration was set at 2.5 mM. Effects of these two bile salts on bacterial growth 
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Figure 11. Effect of bile salts on bacterial growth. Cell protein is a measure of 
growth. Media with cholate and deoxycholate are presented as 
+Cholate and + Deoxycholate, respectively. Data are expressed as 
the mean of triplicate samples ± standard error. 
were determined (Figure 11). In the presence of bile salts, bacteria did not grow as 
well as did the control. The primary bile salt, cholate, showed a stronger inhibitory 
effect on growth than did the secondary bile sate, deoxycholate. When the 
concentration of cholate was decreased to 2.5 mM as that of deoxycholate, bacterial 
growth still was inhibited by cholate, indicating that the effect was not caused by 
higher concentration of cholate. Thus, effects of bile salts on bacterial growth need 
to be considered when bacterial doses are determined for animal feeding studies. 
In summary, E. coprostanoligenes did not require cholesterol for growth and 
retained cholesterol-reducing activity in the absence of cholesterol. Lecithin was 
required for growth but excess lecithin in media did not improve bacterial growth. 
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Pyruvate, lactose, and most reducing agents improved bacterial growth and 
coprostanol production. The optimal pH range for bacterial growth and 
coprostanol production was 7.0 to 8.0. Addition of a buffer system to media 
was not necessary for bacterial growth but increased coprostanol production. The 
optimal incubation temperature was 37°C to 39°C. Most antibiotics inhibited 
bacterial growth and coprostanol production with the exception of tetracycline at a 
final concentration of 50 jig/ml. The resistance to tetracycline was dose-dependent. 
Ethanol as the solvent for dissolving tetracycline did not affect growth or 
coprostanol production at a final concentration up to 1.3%. The mechanism for 
tetracycline resistance is unknown. No plasmid was found in the bacterium. Bile 
salts slightly inhibited bacterial growth. The information on optimal conditions is 
necessary for future characterizations and applications of E. coprostanoligenes. 
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A RESTING CELL ASSAY FOR CHOLESTEROL REDUCTASE ACTIVITY 
IN EUBACTERIUM COPROSTANOLIGENES ATCC 51222 
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Abstract 
A resting cell assay was established to evaluate the cholesterol reductase 
(CR) activity of Eubacterium coprostanoligenes ATCC 51222. Cell suspensions from 
cholesterol-free media rapidly reduced cholesterol to coprostanol. Optimal assay 
conditions in a 1-ml reaction mixture were determined to be up to 1 h of 
incubation and up to 0.25 mg of bacterial protein per assay with at least 1 mM of 
cholesterol as substrate. The CR activity in cells decreased as a function of storage 
time at 22°C, 4°C, and -20°C. Filling the headspace of the reaction mixture with 
H2 increased the CR activity about 20%. Optimal CR activity occurred at pH 7.5 
in sodium phosphate buffer. Pyruvate and reducing agents in the buffer increased 
the CR activity. This study has validated assay conditions for determination of CR 
activity in resting cells of E. coprostanoligenes. 
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Introduction 
It was established in the 1930s that cholesterol is reduced enzymatically to 
the saturated product coprostanol by intestinal bacteria (Schoenheimer 1931). The 
enzyme responsible for the reaction is now named cholesterol reductase (CR) 
(Dehal et al. 1991). Depending on diet composition, coprostanol can represent 
more than 50% of total fecal sterols of humans. Coprostanol, unlike cholesterol, is 
absorbed poorly by the human intestine (Bhattacharyya 1986), and any increase in 
formation of coprostanol could decrease absorption of cholesterol. Cholesterol-
reducing bacteria have been isolated from the feces of rats (Eyssen et al. 1973), 
humans (Sadzikowsky et al. 1977) and baboons (Brinkley et al. 1982). These 
previously isolated bacteria, however, had growth characteristics that made common 
laboratory manipulations difficult. Growth requirements included the need for 
plasmalogen, which is found only in high concentrations in mammalian brain tissue, 
and the need for complete anaerobiosis. Further, those bacteria did not form 
colonies on solid plating media. Attempts to detect CR activity in extracts of those 
bacterial cells were unsuccessful (Bjorkhem et al. 1973). Recently, a unique 
cholesterol-reducing bacterium, designated Eubacterium coprostanoligenes ATCC 
51222, that is much easier to grow in the laboratory was isolated (Freier et al. 
1994). E. coprostanoligenes is a Gram-positive, anaerobic, nonfermentative 
bacterium that forms colonies on lecithin-containing solid media. It converts up to 
90% of cholesterol to coprostanol in cholesterol-containing media, but it does not 
require plasmalogen or cholesterol for growth. Thus, E. coprostanoligenes seems 
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more amenable than previously studied cholesterol-reducing bacteria for 
applications in the food and pharmaceutical industries. An active, stable, cell-free 
enzyme preparation of E. copwstanoligenes would be even more ideal. The present 
study was undertaken to validate an assay for the CR activity of resting cells of E. 
copwstanoligenes as we attempt to define conditions leading to maximal production 
of CR activity. 
Materials and Methods 
Growth of bacteria 
E. coprostanoligenes ATCC 51222 was grown in a cholesterol-free medium 
that contained the following components per liter: 10 g casitone (Difco, Detroit, 
MI), 10 g yeast extract, 5 g lactose, 5 g sodium pyruvate, 1 g CaCl2 *2 H2O, 0.5 g 
sodium thioglycolate, 0.1 g lecithin (type IV-S, Sigma) and 1 mg resazurin. The pH 
was adjusted to 7.5 with 3 N KOH. The Hungate technique was used for the 
anaerobic preparation of media and handling of cultures (Holdeman et al. 1977). 
Fresh medium was inoculated with 1% of a 48-h culture and incubated at 37°C for 
48 h. 
Preparation of cell suspensions 
After incubation for 48 h at 37°C, cultures were harvested by centrifugation 
at 10,000 X g for 10 minutes at 4°C. The cell pellets then were suspended in 25 
mM PIPES ( piperazine-N,N'-bis-[2-ethanesulfonic acid]) buffer (pH 7.5) 
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containing 5 mM sodium thioglycolate and 45 mM sodium pyruvate. No 
precaution was taken to maintain anaerobiosis during preparation of cell 
suspensions. 
Preparation of micellar cholesterol substrate 
Cholesterol (58 mg), [la, 2Q!-^H]-cholesterol (20 jiCi) and lecithin (148.8 
mg) were dissolved in chloroform (20 ml). The solution was evaporated to dryness 
at about 35°C. After the addition of PIPES buffer (20 ml) and glass beads, the 
solution was mixed vigorously in a vortex mixer until all lipid was dispersed. The 
lipid dispersion was sonicated for 5 minutes in ice by a sonifier. Residue was 
removed by centrifugation at 1,800 x g for 10 minutes, and the micellar solution 
was stored at 4°C. It contained 7.5 mM cholesterol (133 iiCi/mmole) and 10 mM 
lecithin. These preparation procedures were modified from Dehal et al. (1991). 
Resting cell assay for CR activity 
The standard assay contained 1 ml of bacterial cell suspension (~ 0.4 mg 
cell protein) in 25 mM PIPES buffer at pH 7.5, 45 mM sodium pyruvate, 5 mM 
sodium thioglycolate, 1.33 mM lecithin and 1 mM micellar cholesterol. Control 
assay mixtures contained bacterial suspension that had been boiled for 10 min. The 
assay was started by addition of micellar cholesterol. Each assay was conducted in 
triplicate, and results are expressed as mean ± standard error (SE). Student's t 
test was employed to analyze the difference among treatments. Probability (P) less 
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than 0.05 was considered significant. After incubation at 37°C for 1 h with shaking, 
the assay mixture was extracted with 1:1:0.8 chloroform:methanohH20 (Bligh and 
Dyer 1959). The organic extract was concentrated under N2 to about 100 [il. 
Sterols were separated on thin-layer chromatography (TLC) plates by using a 3:1 
solvent system of hexane:ethyl acetate (v/v). Bands corresponding to cholesterol 
and coprostanol were scraped into scintillation vials, and radioactivity was 
determined by using a Beckman LS-1701 liquid scintillation counter. Under these 
assay conditions, one unit (U) of activity is equal to 1 nmole of coprostanol 
produced per hour, and specific activity is equal to U/mg protein. 
Protein determination 
Total cellular protein was determined by the Bradford method with 
microtiter plates (Redinbaugh and Campbell 1985). A portion of the cell 
suspension was mixed with 2 N NaOH and incubated at 37°C overnight to 
solubilize the protein. Bovine serum albumin, treated in the same manner, was 
used as a standard. 
Results 
Effects of storage temperature and time on CR activity 
E. coprostanoligenes is an anaerobic bacterium and grows only in a pre-
reduced, anaerobically sterilized (PRAS) medium. It can, however, survive 
exposure to air for at least 48 h (Freier et al. 1994). Therefore, no precautions 
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were taken to maintain anaerobiosis during preparation of the cell suspensions. 
Assays for CR activity are not always conducted immediately after a suspension of 
bacterial cells is prepared. Therefore, effects of temperature (22, 4 and -20°C) and 
time (2 and 24 h) for storing cell suspensions after harvesting cells were determined 
(Figure 1). The CR activity of resting cells decreased over time at all temperatures 
tested. The decrease was especially evident at -20°C. Therefore, the resting cell 
assays were conducted immediately after a suspension of bacterial cells was 
prepared for all subsequent assays. 
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Figure 1. Effects of storage temperature and time on CR activity. After 
bacterial cells were harvested from the growth medium, the CR 
activity assays were conducted immediately (•) or after cell 
suspension were kept at room temperature (22°C), 4°C or -20°C for 2 
h ([[i) or 24 h (®). Standard assay conditions (see Materials and 
Methods) were used in this experiment. Data are expressed as the 
mean of triplicate assays + standard error. 
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Figure 2. Effects of the composition of headspace gases on CR activity. The 
headspace of the reaction mixture was filled with air, N2 or H2. 
Standard assay conditions (see Materials and Methods) were used in 
this experiment. Data are expressed as the mean of triplicate assays 
+ standard error. 
Effects of composition of headspace gases on CR activity 
H2 and CO2 are produced as headspace gases by E. coprostanoligenes during 
growth in PRAS medium (Freier et al. 1994). To determine effects of gas 
environment on CR activity of resting cells, the headspace above the reaction 
mixture was filled with either air (control), N2 or H2. Data from the experiment 
are shown in Figure 2. Filling the headspace with H2 significantly increased the 
CR activity above that with air (P < 0.01). Compared with the air control, filling 
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with N2 also increased CR activity, but the increase was not as significant as with 
H2 because of the variation in CR activity from N2 treatment (P = 0.10). The 
headspace was not filled with N2 or H2 for all subsequent assays. 
Effects of buffers and pH on CR activity 
Usually, PIPES buffer at pH 7.5 was used in the resting cell assay. To 
determine the effects of different buffers and pH values on CR activity, the 
following buffers were tested within their effective buffering ranges: sodium 
acetate buffer (pH 4.5 to 6.0), PIPES buffer (pH 6.0 to 7.5), sodium phosphate 
buffer (pH 6.0 to 7.5) and TAPS (tris-[hydroxymethyl]-methylaminopropane 
sulfonic acid) buffer (pH 7.5 to 9.0). No CR activity was observed below pH 5.0 
(Figure 3). Maximal CR activity was obtained at pH 7.5 with phosphate buffer. 
With PIPES buffer, pH 7.5 also was optimal for CR activity. With TAPS buffer, 
however, CR activity was substantial at pH values of 8.5 and 9.0. 
Effect of pyruvate on CR activity 
Addition of pyruvate to a growth medium containing cholesterol stimulated 
coprostanol production by E. coprostanoligenes{Fx&iQv et al. 1994). The effect of 
pyruvate on CR activity of resting cells was determined in the present study (Figure 
4). The CR activity increased with increasing pyruvate concentration in the 
reaction mixture up to about 36 mM. 
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Figure 3. Effect of buffers (v, sodium acetate; •, sodium phosphate; o, PIPES; 
A, TAPS) and pH on CR activity. Buffers were used at a final 
concentration of 25 mM. The pH was adjusted by KOH or HCl. The 
other assay conditions were as described in the text (see Materials 
and Methods). Data are expressed as the mean of triplicate assays ± 
standard error. 
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Figure 4. Effect of pyruvate on CR activity. Except pyruvate concentrations, 
standard assay conditions (see Materials and Methods) were used in 
this experiment. Data are expressed as the mean of triplicate assays 
± standard error. 
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Effects of reducing agents on CR activity 
Sodium thioglycolate normally was used as a reducing agent in the buffer for 
the resting cell assay, and it caused about 20% increase in the CR activity. Other 
reducing agents, including B-mercaptoethanol, dithiothreitol, glutathione (reduced 
form) and L-cysteine, were compared for their effects on CR activity of E. 
coprostanoligenes (Table 1). Among them, 6-mercaptoethanol and sodium 
thioglycolate had the greatest stimulatory effect (P < 0.01); however, all the 
reducing agents except L-cysteine were stimulatory to CR activity (P < 0.05). 
Table 1. Effect of reducing agents on CR activity 
Reducing agent^ CR (U/mg protein)'' 
Control 363 ± 7.9^= 
Sodium thioglycolate 439 ± 8.2*^ 
6-Mercaptoethanol 449 ± 4.1^^ 
Dithiothreitol 413 ± 24.0^^ 
Glutathione (reduced form) 412 ± 16.1'^ 
L-Cysteine 380 ± 9.9^^ 
® The final concentration of reducing agents was 5 mM in 25 mM PIPES 
buffer at pH 7.5. The control contained no reducing agents. Except reducing 
agents, the standard assay conditions (see Materials and Methods) were used in 
this experiment. 
Mean of triplicate assays ± standard error. 
Means with different superscripts are different (P < 0.05). 
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Validation of the restin|g cell assay for CR activity in E. coprostanoligenes 
Validation of the assay was achieved by measuring the effects of incubation 
time, cell protein and cholesterol concentrations on CR activity of resting cells 
(Figure 5a-c). The time course of cholesterol conversion to coprostanol is shown in 
Figure 5a. The reaction was linear up to 1 h of incubation. The dependence of 
CR activity on bacterial cell protein concentration is illustrated in Figure 5b. 
Coprostanol production as a function of increasing cell protein was linear up to 
0.25 mg bacterial cell protein in the assay. Figure 5c shows the relationship 
between cholesterol substrate concentration and coprostanol production. Maximal 
CR activity was achieved at about 1 mM of cholesterol in the reaction mixture. 
Discussion 
The present study provides the follow-up data on factors that affect the 
conversion of cholesterol to coprostanol by resting cells of E. coprostanoligenes after 
the initial report on isolation of the bacterium (Freier et al. 1994). Cell suspension 
of E. coprostanoligenes catalyzed a rapid enzymatic reduction of cholesterol to 
coprostanol, with a rate as high as 1200 nmole/h -mg protein. There were no 
significant differences in the CR activities of cultures from growth medium with or 
without cholesterol (data not shown). Resting cells from cholesterol-free medium 
possessed CR activity, which indicates that CR is synthesized constitutively and not 
inducibly by E. coprostanoligenes. 
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Figure 5a-c. Effects of incubation time, cell protein and cholesterol concentration 
on CR activity, a. Incubation time. The reaction mixture contained 
0.4 mg bacterial cell protein and 1 mM cholesterol substrate, b. 
Bacterial cell protein concentration. The reaction mixture was 
incubated for 1 h with 1 mM cholesterol substrate, c. Cholesterol 
substrate concentration. The reaction mixture contained 0.4 mg 
bacterial cell protein and was incubated for 1 h. Except conditions 
indicated above, other assay conditions were as described in the text 
(see Materials and Methods). Data are expressed as the mean of 
triplicate assays ± standard error. 
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The CR activity declined over time after cells were harvested from cultures. 
This decline in activity occurred even though E. coprostanoligenes survives exposure 
to air for up to 48 h and even though there is no significant difference in CR 
activity of resting cells whether the cell suspension was prepared aerobically or 
anaerobically. The instability of CR activity is similar to that of both mammalian 
and microbial S-oxo-A'^-steroid 5/3-reductase activity (Bjorkhem et al. 1973). 
Keeping cells at -20°C for 24 h almost completely destroyed their cholesterol-
reducing ability. Loss of cell membrane integrity through freezing and thawing 
might account for this loss of CR activity because a great loss of CR activity 
occurred when E. coprostanoligenes was disrupted by sonication, passage though a 
French pressure cell or enzymatic digestion (unpublished data). 
The CR activity of E. coprostanoligenes was increased by filling the 
headspace of the reaction vessel with H2 in the resting cell assay (P < 0.01). 
Hydrogen gas has been reported to stimulate 16-dehydroprogesterone and 
progesterone reductases of Eubacterium sp. strain 144 (Glass and Burley 1985) and 
the deoxycorticosterone-21-dehydroxylase activity of £. lentum VPI 11122 (Feighner 
and Hylemon 1980). Hydrogen gas was thought to be an exogenous electron donor 
for the reduction reaction because hydrogenase activity was detected in both 
organisms. Whether hydrogenase activity is present in E. coprostanoligenes was not 
determined. 
Effects of buffers and pH on CR activity were intriguing. Optimal CR 
activity occurred at pH 7.5 in both sodium phosphate and PIPES buffers. Higher 
118 
pH values could not be tested with the same buffer systems because of their 
ineffective buffering capacity over pH 7.5. In TAPS buffer, however, CR activity 
was inhibited at pH 7.5 but recovered at higher pH. The dramatically different 
responses to different buffers and pH values also were reported in other studies 
about steroid double bond-reductases in Eubacteriiim (Glass et al. 1991; Watkins 
and Glass 1991). Evidently, different chemical compositions of the buffer systems 
contribute to the difference in enzyme activities at the same pH. We suggest use 
of sodium phosphate buffer at pH 7.5 in further studies of CR activity in E. 
coprostanoligenes. 
Pyruvate increases coprostanol production by E. coprostanoligenes in 
cholesterol-containing growth media (Freier et al. 1994). In the present study, 
pyruvate also stimulated the CR activity of E. coprostanoligenes in the resting cell 
assay. Pyruvate might act as a cofactor in cholesterol reduction because pyruvate 
stimulated 16-dehydroprogesterone reductase activity in both resting cells and cell 
extracts of Eubacteriiim sp. strain 144 (Glass and Burley 1985; Watkins and Glass 
1991). More definitive data on the interrelationships of pyruvate and CR will 
become available when activity can be assayed in cell extracts of E. 
coprostanoligenes. 
The mechanism of cholesterol reduction has been investigated by a number 
of researchers. Two pathways, direct and indirect, have been proposed for the 
conversion (Figure 6). The direct pathway was supported by the fact that no 
significant change in the labelling pattern of suitably marked cholesterol took place 
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Figure 6. Proposed reaction pathways for enzymatic conversion of cholesterol 
to coprostanol (Bjorkhem and Gustafsson 1971). I. Direct pathway. 
II. Indirect pathway: 1, oxidation; 2, nonenzymatic isomerization; 3, 
reduction; 4, reduction. 
(Rosenfeld and Gallagher 1964). This pathway, however, was later questioned on 
the ground that intermediate cofactors may be involved in removing and restoring 
the label (Bjorkhem and Gustafsson 1971). Work with Eiibacterium sp. ATCC 
21408 confirmed the presence of the intermediates, A'^-cholestenone and 
coprostanone, during the cholesterol-to-coprostanol conversion (Parmentier and 
Eyssen 1974). Ren (1991) observed that E. coprostanoligenes also reduced 
cholesterol by an indirect pathway. In the present study, substantial amounts of 4-
cholesten-3-one and trivial amounts of coprostanone were detected in addition to 
coprostanol in the resting cell assay (data not shown). No intermediates were 
detected in the actively growing culture, however, when cholesterol was included in 
the growth medium. Coprostanol was the only measurable end product of 
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cholesterol reduction by E. coprostanoligenes in 24-h cultures (Freier et al. 1994). 
The exact mechanism of cholesterol reduction by E. coprostanoligenes can be 
studied only after pure preparations of CR become available. 
Results of the present study indicate that CR activity in E. coprostanoligenes 
can be maximized by careful selection of assay conditions. We have validated the 
assay conditions for determination of CR activity in resting cells of E. 
coprostanoligenes. Knowledge of optimal assay conditions are required to proceed 
toward purification of CR from this bacterium. 
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CHARACTERIZATION OF A CHOLESTEROL-REDUCING ANAEROBE, 
EUBACTERIUM COPROSTANOLIGENES ATCC 51222 
A paper prepared for submission to Journal of Bacteriology 
Ling Li, Timothy A. Freier, Paul A. Hartman, and Donald C. Beitz 
Abstract 
The present study characterized Eiibacterium coprostanoligenes ATCC 51222 
from its electron microscopic structure and DNA composition to the mechanism of 
cholesterol reduction, substrate specificity, and effects of several cofactors and 
inhibitors. E. coprostanoligenes was shown to be a Gram-positive coccobacilloid 
bacterium. The cells were 0.5 to 0.7 |jim in diameter and 0.7 to 1.0 ^m in length 
and occurred both singly and in pairs. The bacterium reduced cholesterol to form 
coprostanol through an indirect pathway, and it seems to have a broad specificity 
for substrates. The bacterium converted all detected reaction intermediates to 
coprostanol, and it metabolized pregnenolone, progesterone, androstenediol, and 
etienic acid. In resting cell assays, either NADH or FAD increased cholesterol 
reductase activity, but activity was inhibited when NADH and FAD were added 
together. lodoacetate, NaCN, and NaN3 did not affect enzyme activity 
significantly, whereas EDTA inhibited activity, and HgCl2 abolished activity 
completely. The en^me activity was found to be associated with bacterial cells. 
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and attempts to achieve active cell-free extracts were not successful because a great 
loss of activity occurred after the bacterial cells were disrupted. Addition of 
different cofactors did not recover the cholesterol reductase activity. The genomic 
expression library of E. coprostanoligenes was constructed in an expression vector, 
bacteriophage X vector A.gtll. Several efforts were made to develop a screening 
technique for detection of positive clones for cholesterol reductase. The 
cholesterol oxidase gene (cho) was considered a possible probe, but the preliminary 
experiment did not show hybridization of the gene with the genomic DNA of E. 
coprostanoligenes. Studies are still in progress to develop ways to isolate the 
enzyme or the gene. 
Introduction 
A novel cholesterol-reducing anaerobic bacterium, Eubacterium 
coprostanoligenes ATCC 51222, has been isolated recently (Freier et al. 1994). This 
bacterium is of great interest because of its potential use to decrease serum 
cholesterol concentrations in hypercholesterolemic individuals and to decrease 
cholesterol contents of foods. Elevated plasma cholesterol is a major risk factor for 
atherosclerosis that results in coronary heart disease (CHD), which remains a 
leading cause of human mortality in Western countries (Thorn et al. 1992). Dietary 
cholesterol has been of concern because of its potential to increase serum 
cholesterol concentration (Fraser 1994). Lowering plasma cholesterol 
concentrations has been shown to decrease the risk of CHD death and nonfatal 
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CHD events (Scandinavian Simvastatin Survival Study Group 1994). Decreasing of 
daily intake of dietary fat and cholesterol has been recommended to decrease 
plasma cholesterol and CHD risk in populations (Report of the Nutrition 
Committee 1993). 
Cholesterol-reducing bacteria convert cholesterol to coprostanol, which is 
absorbed poorly from the gastrointestinal tract (Bhattacharyya 1986). Therefore, a 
novel method has been proposed to decrease cholesterol contents of foods and to 
lower elevated plasma cholesterol concentration by using cholesterol reductase or 
cholesterol-reducing bacteria (Dehal 1991). Cholesterol-reducing bacteria have 
been isolated from feces of rats (Eyssen et al. 1973), humans (Sadzikowsky et al. 
1977), and baboons (Brinkley et al. 1982). All these previously isolated bacteria, 
however, had characteristics that made common laboratory manipulations difficult. 
The recent isolate, E. coprostanoligenes, has many unique characteristics that make 
the bacterium more amenable for future applications in food processing and 
pharmaceutical industries (Freier et al. 1994). E. coprostanoligenes reduces more 
than 90% of cholesterol to coprostanol in growth media but does not require 
cholesterol for growth. It grows under anaerobic conditions but does not require 
anaerobiosis for cholesterol reduction. A resting cell assay has been developed to 
analyze the cholesterol reductase activity of E. coprostanoligenes (Li et al. 1995b). 
Oral administration of E. coprostanoligenes has caused a significant decrease of 
plasma cholesterol concentrations in hypercholesterolemic rabbits (Li et al. 1995a). 
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Although foods treated directly with E. coprostanoligenes may not be readily 
accepted for human consumption, a pure preparation of cholesterol reductase from 
the bacterium would be more ideal to the treatment of foods and 
hypercholesterolemic individuals. Mass production of cholesterol reductase for 
commercial use would be more feasible economically if the gene(s) encoding 
cholesterol reductase from E. coprostanoligenes could be inserted into faster 
growing Saccharomyces cerevisiae, Escherichia coli, or other appropriate hosts. 
Another cholesterol metabolizing enzyme, cholesterol oxidase, converts cholesterol 
to 4-cholesten-3-one through 5-cholesten-3-one as an intermediate (Smith and 
Brooks 1977). Cholesterol reductase catalyzes the same reactions initially (Ren 
1991). The cholesterol oxidase genes (c/zo) have been isolated from Streptomyces 
and Brevibacterium species (Murooka et al. 1986; Fujishiro et al. 1990). Extensive 
homology was found between cho genes from these two microorganisms (Ohta et 
al. 1991), and it was concluded that the genes are clearly from a common ancestor. 
It is hypothesized in this study that the genes encoding cholesterol reductase and 
cholesterol oxidase would share some homology because cholesterol reductase and 
cholesterol oxidase both must bind cholesterol and show similar catalytic functions. 
This hypothesis provides a potential method to isolate the cholesterol reductase 
gene from E. coprostanoligenes by using a cho gene as a probe. 
The present study was conducted to characterize further the properties of E. 
coprostanoligenes. The mechanism, substrate specificity, and cofactors and 
inhibitors of cholesterol reduction were investigated. Attempts were made to 
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develop active cell-free preparations and to isolate the cholesterol reductase 
gene(s) from the bacterium. Such information is necessary for manipulating the 
cholesterol-reducing system of E. coprostanoligenes for potential use in commercial 
biotransformation processes. 
Materials and Methods 
Bacterial cultivation 
A growth medium to culture E. coprostanoligenes contained the following 
components per liter: 10 g casitone (Difco, Detroit, MI), 10 g yeast extract, 5 g 
lactose, 5 g sodium pyruvate, 0.5 g sodium thioglycolate, 0.1 g lecithin (type IV-S, 
Sigma), 0.1 g CaCh '^ H2O, and 1 mg resazurin. Cholesterol (ash-free, Sigma 
Chemical Co., St. Louis, MO) was added at a concentration of 0.02% in the 
medium if coprostanol production in the actively growing culture was of concern. 
Other steroids, including 5-cholesten-3-one, 4-cholesten-3-one, coprostanone, 
pregnenolone (4-pregnen-3j3-ol-20-one), progesterone (4-pregnen-3, 20-dione), 
androstenediol (5-androsten-3]8, 17j3-diol), and etienic acid (5-androsten-3)8-ol 17)3-
carboxylic acid), were added in media instead of cholesterol for determination of 
substrate specificity. The pH of the medium was adjusted to 7.5 with 3 N KOH. 
The Hungate technique was used for the anaerobic preparation of media and 
handling of the culture (Holdeman et al. 1977). Fresh medium was inoculated with 
1% of a 2-d culture and incubated at 37°C for 2 to 5 d. 
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Electron microscopy 
After 2 d of incubation at 37°C, bacterial cultures were harvested by 
centrifugation at 10,000 x g for 15 min at 4°C. The cell pellets then were washed 
three times and suspended in 25 mM PIPES (piperazine-N,N'-bis-[2-ethanesulfonic 
acid]) buffer (pH 7.5). The bacterial suspensions were fixed in 4% 
paraformaldehyde-3% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) overnight 
at 4°C, washed three times in the same buffer, and postfixed at 4°C for 1 h in the 
same buffer containing 1% osmium tetroxide. The prepared cells were washed 
three times in buffer, placed in a microcentrifuge tube containing 1% agar (liquid), 
and pelleted. The pellet was dehydrated with a graded series of ethanol and 
embedded in LR white resin with constant agitation. The resin was polymerized 
overnight in a oven at 65°C. Sections were cut with a Reichert Ultracut E 
ultramicrotome, placed on 200-mesh copper grids, poststained in a solution 
containing uranyl acetate and lead citrate, and viewed with a JEOL model 1200EX 
scanning transmission electron microscope operated at 80 kV. 
Determination of coprostanol production in jgrowing cultures 
After incubation at 37°C for up to 5 d, an aliquot of the bacterial cultures in 
cholesterol-containing media was taken through the lipid extraction procedure 
(Bligh and Dyer 1959). The amounts of residual cholesterol and coprostanol 
produced were determined by gas-liquid chromatography (GLC) by the method of 
Oles et al. (1990) with 5Q;-cholestane as an internal standard. The lipid extract 
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from the samples was evaporated to dryness under a stream of N2. Sterols in the 
residue were etherified with l,3-bis-(trimethylsilyl)trifluoroacetamide and assayed 
with a 5830A Hewlett Packard gas chromatograph. The glass column, 0.91 m x 4 
mm internal diameter, was packed with 3% SP-2250 on 100/120 Supelcoport 
(Supeico Inc., PA). Operating conditions were: oven, 250-280°C; injector, 290°C; 
flame ionization detector, 290°C; nitrogen flow rate, 20 ml/min. Thin-layer 
chromatography (TLC) was performed also to determine the products of 
cholesterol reduction. Sterols in lipid extracts were separated by TLC with 
standards chromatographed on each plate by using hexane:ethyl acetate (75:25 v/v) 
as a solvent. After spraying with a 0.2% ethanolic solution of 2,7-
dichlorofluorescein, sterols were identified under ultraviolet light. 
Resting cell assays 
Assays were conducted as described by Li et al. (1995b). Namely, bacteria 
were cultured in cholesterol-free media for 2 d at 37°C before being harvested by 
centrifugation. Then, the washed bacterial cells were suspended in 25 mM sodium 
phosphate buffer at pH 7.5 with 45 mM sodium pyruvate and 5 mM sodium 
thioglycolate. Different cofactors and metabolic inhibitors were added to reaction 
mixtures respectively to determine their effect on cholesterol reductase activity of 
the bacterium. Control assay mixtures contained bacterial suspension that had 
been boiled for 10 min. Assays were started by addition of the [la, 2a-^H]-micellar 
cholesterol substrate. After incubation at 37°C, assay mixtures were extracted, and 
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organic extracts were concentrated under a stream of N2 to about 100 nl. Sterols 
were separated by TLC with standards chromatographed on each plate. 
Corresponding bands were scraped into scintillation vials for determination of 
radioactivity. 
Preparation of cell-free extract 
Possible extracellular cholesterol reductase from E. coprostanoligenes cultures 
was prepared by precipitating the supernatant of 2-d cultures with 40% and then 
65% ammonium sulfate. Precipitates were dissolved in 25 mM sodium phosphate 
buffer (pH 7.5) containing 45 mM sodium pyruvate and 5 mM sodium 
thioglycolate. Both the supernatant and the precipitate solution were dialyzed 
against the phosphate buffer overnight at 4°C. Cholesterol reductase activity in the 
preparation was determined by incubation with [la, 2a-^H]-micellar cholesterol as 
substrate. A crude cell-free extract was prepared by disrupting bacterial cells with 
sonication, passage through a French pressure cell, freezing and thawing, liquid N2 
freezing and pulverizing in a mortar and pestle, or enzymatic digestion, followed by 
centrifugation at 10,000 x g for 20 min at 4°C. The supernatant was considered as 
the crude cell-free extract. The effect of disruption on cholesterol reductase 
activity was determined. Precautions were taken to keep anaerobiosis in the 
procedures by flushing the samples with N2. 
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Protein determination 
Total bacterial protein was determined by the Bradford method with 
microtiter plates (Redinbaugh and Campbell 1985). A portion of the cell 
suspension or enzyme preparations was mixed with an equal volume of 2 N NaOH 
and incubated at 37°C overnight to solubilize the protein. Bovine serum albumin, 
treated in the same manner, was used as a standard. 
Isolation of genomic DNA 
The genomic DNA of E. coprostanoligenes was isolated and purified by a 
procedure modified from Jarrell et al. (1992). The bacterial pellet was treated with 
liquid N2. After the liquid N2 had evaporated, the frozen cells were ground 
vigorously to a fine powder with a pestle, and 5 to 10 ml of TE buffer (10 mM 
Tris-HCl, 1 mM EDTA, pH 7.5) containing 0.25 M sucrose were added 
immediately. When the slurry had thawed, sodium dodecyl sulfate (SDS; from a 
10% w/v solution) was added to a final concentration of 1%. Proteinase K (Sigma, 
MO) (50 ng/ml) was added and the mixtures were incubated at 60°C for 30 min. 
Sodium chloride was added from a 5 M stock solution to a final concentration of 
0.5 M, and the lysates were put on ice. After 1 h, the lysates were cleared by 
centrifugation at 10,000 x g for 15 min at 4°C. The supernatant was decanted 
carefully, and the nucleic acids were precipitated with an equal volume of cold 
isopropanol. The DNA was collected by centrifugation and then dissolved in TE 
buffer at 60°C. After RNase treatment (50 ng/ml for 30 min at 37°C with DNase-
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free RNase A), the DNA was extracted twice with an equal volume of phenol-
chlorofonn-isoamyl alcohol (25:24:1; v:v:v), followed by two extractions with 
chloroform. After addition of NaCl to 0.5 M, the DNA was precipitated with 2.5 
volumes of cold ethanol, collected by centrifugation, and dissolved in TE buffer. 
Determination of DNA base composition 
Genomic DNA was dissolved in 0.1 X SSC buffer (15 mM of NaCl and 1.5 
mM of sodium citrate, pH 7.0). The melting temperature (Tm) of the DNA was 
determined by the thermal denaturation method with genomic DNA of E. coli as a 
control. The guanine plus cytosine (G + C) content was calculated with the 
formula as follows: (G + C)% = (Tm - 53.9) x 2.44 (Mandel and Marmur 1968). 
Preparation of cho gene probe and Southern hybridization 
Lactobacillus casei LC102 carrying plasmid pNC0937, which contains the 
Streptomyces cho gene, was kindly provided by G. A. Somkuti at the USDA, ARS, 
North Atlantic Area Eastern Regional Research Center, Philadelphia, 
Pennsylvania. L. casei was cultured in Lactobacilli MRS broth (Difco) with 20 mM 
DL-threonine and chloramphenicol (15 p.g/ml) at 37°C under 5% C02. Plasmid 
DNA was isolated from L. casei by the procedures of Somkuti and Steinberg 
(1986). Plasmid pNC0937 was confirmed by agarose gel electrophoresis and 
purified further by QIAGEN plasmid protocol (QIAGEN Inc., CA). pNC0937 is 
a 8.1-kb plasmid containing a cho gene within a 2.4-kb Pst I fragment (Somkuti, et 
133 
al. 1992). The plasmid was digested with Pst I, and the cho fragment was separated 
by agarose gel electrophoresis and recovered by using the QIAEX gel extraction kit 
(QIAGEN Inc., CA). The preparation of cho DNA was used to synthesize the ^"P-
labeled probe by using Random Primed DNA Labeling Kit (Boehringer Mannheim 
Biochemica Co., IN). 
In addition to DNA from E. coprostanoligenes, genomic DNA was isolated 
from E. coli DH5a, Eubacteriiim sp. VPI 12708, and Brevibacteiium steroliciim 
ATCC 21387. The genomic DNA preparations were digested completely with 
EcoR I and electrophoresed on a 0.7% agarose gel along with preparations of 
pNC0937, pNC0937 Pst I digest, and DNA molecular weight markers. The DNA 
was transferred and immobilized on a nylon membrane by using a capillary transfer 
method. Southern hybridization of the ^^P-labeled cho probe to the immobilized 
DNA was conducted as described by Sambrook et al. (1989). After washing away 
the unhybridized ^"P-label probes, the membrane was exposed to a Phosphor-
Imager (Molecular Dynamics) to determine the results of hybridization. 
Construction of genomic expression library 
Genomic DNA of £. coprostanoligenes was digested with EcoR I for 5, 10, 
20, 30, 40, 60, 80, 100, 120, and 240 min to obtain random sizes of DNA fragments. 
The partial digests were pooled and electrophoresed on a 0.6% low-melting 
temperature agarose gel, appropriate bands of DNA were sliced out, and DNA was 
purified from the gel slices (Sambrook et al. 1989). The DNA fragments of sizes 
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between 5 to 7 kb were used for library construction in the expression vector, 
bacteriophage X vector Xgtll, that accepts DNA inserts up to 12 kb. The DNA 
fragments were ligated with dephosphoiylated Agtll arms (Promega Co., WI) with 
T4 ligase. Packaging of ligated DNA was fulfilled by incubating the ligation 
mixture with the Packagene Extract (Promega Co., WI). An aliquot of packaged 
phage was used for titration, which was conducted by using E. coli strain Y1090 as 
a host on LB plates with IPTG (isopropyl-U-D-thiogalactopyranoside) and X-gal (5-
bromo-4-chloro-3-indolyl-i3-D-galactopyranoside) in the top agar. The number of 
plaques was counted, and the titers of the phage then were calculated. The rest of 
the packaged phage was mixed with chloroform and dimethylsulfoxide and stored at 
-70°C for future use. 
Results 
Ultrastructure and genomic DNA composition 
Transmission electron micrographs (Figure lA-B) showed that E. 
coprostanoligenes had a typical cell wall structure of Gram-positive bacteria. The 
bacterium was about 0.5 to 0.7 nm in diameter and 0.7 to 1.0 jxm in length. Many 
cells existed in diploform, which was more obvious in the scanning electron 
micrograph (Figure IC). The melting temperature for the genomic DNA was 
about 71°C, and the G + C content was calculated to be 41% (Figure 2). 
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Figure 1. Electron photomicrographs of E. coprostanoligenes. (A) Bar = 0.1 
Jim. (B) Bar = 0.2 (im. (C) Bar = 1.0 jim. 
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Figure 2. Thermal denaturation of genomic DNA of E. coprostanoligenes. Tm 
refers to the melting point of genomic DNA. (G + C)% refers to the 
guanine plus cytosine percentage content of genomic DNA. 
Mechanism of cholesterol reduction and substrate specificity 
When E. coprostanoligenes was grown in cholesterol-containing media, the 
only sterols in cultures were the final product, coprostanol, and residual cholesterol 
determined both by GLC (Figure 3) and TLC (Figure 4). In resting cell assays 
with [la, 2a!-^H]-micellar cholesterol as substrate, however, in addition to a 
coprostanol band, 4-cholesten-3-one and coprostanone bands were observed clearly 
on TLC plates, although no 5-cholesten-3-one band was found (Figure 5). The 
corresponding bands were scraped and counted for radioactivity in a scintillation 
counter, and the final product, coprostanol, and the intermediates were quantified 
(Figure 6). Interestingly, the production rate for 4-cholesten-3-one was higher than 
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that of coprostanol, and coprostanone seemed not to accumulate in the reaction. 
When 5-cholesten-3-one, 4-cholesten-3-one, and coprostanone were added to the 
growth media, they all were converted to coprostanol by the bacterium (Figure 7). 
In addition to these cholesterol analogs, E. coprostanoligenes also metabolized 
pregnenolone, progesterone, androstenediol, and etienic acid (Figure 8A-B). 
Effects of cofactors and inhibitors 
Several potential cofactors and inhibitors were incorporated into resting cell 
assays to determine their effects on cholesterol reductase activity (Table 1). In 
addition to the final product, coprostanol, production of intermediates were shown 
also in the table. Among the cofactors used, NADH (B-nicotinamide adenine 
dinucleotide, reduced form) led to the highest cholesterol reductase activity, 
followed by FAD (flavin adenine dinucleotide) and NADP"*" (6-nicotinamide 
adenine dinucleotide phosphate). When NADH and FAD were added together in 
the reaction mixture, an inhibitoiy effect was observed on cholesterol reductase 
activity. NADPH and NAD did not affect cholesterol reductase activity 
significantly. Among the inhibitors used, NaN3, NaCN, and iodoacetate did not 
affect cholesterol reductase activity of E. coprostanoligenes. EDTA 
(ethylenediaminetetraacetate) showed a strong inhibitory effect. HgCl2 abolished 
the en25ane activity completely. 
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Figure 3. Chromatograms of GLC analysis. (A) Cholesterol-containing 
medium before bacterial inoculation. (B) One-day incubation with 
bacteria. (C) Two-day incubation with bacteria. 
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Figure 4. TLC analysis of E. coprostanoligenes culture in cholesterol-containing 
medium. The TLC plate was sprayed with ethanolic solution of 2,7-
dichlorofluorescein, sterols were visualized under ultraviolet light. 
Lane 1 and 2, uninoculated culture; Lane 3 and 4, inoculated culture 
incubated for 5 d; Lane 5, standards. 
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Figure 5. TLC analysis of products from the resting cell assays with E. 
coprostanoligenes. The TLC plate was sprayed with ethanolic solution 
of 2,7-dichlorofluorescein, sterols were visualized under ultraviolet 
light. Lane 1 and 2, assays with killed (boiled) bacteria (controls); 
Lane 3, standards; Lane 4 and 5, assays with live bacteria. 
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Figure 6. Products of cholesterol reductase of E. coprostanoligenes in resting 
cell assays. Data are expressed as the mean of triplicate assays ± 
standard error. 
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Figure 7. TLC analysis of E. coprostanoligenes cultures with cholesterol and 
other steroids in the growth medium. The incubation time was 5 d. 
The TLC plate was sprayed with ethanolic solution of 2,7-
dichlorofluorescein, sterols were visualized under ultraviolet light. 
Lane 1 and 2, uninoculated and inoculated cholesterol-containing 
culture, respectively; Lane 3 and 4, uninoculated and inoculated 5-
cholesten-3-one-containing culture, respectively; Lane 5 and 6, 
uninoculated and inoculated 4-cholesten-3-one-containing culture, 
respectively; Lane 7 and 8, uninoculated and inoculated 
coprostanone-containing culture; Lane 9, standards. 
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Figure 8. TLC analysis of E. coprostanoligenes cultures with different steroids. 
Plates were sprayed with ethanolic solution of 2,7-dichlorofluorescein, 
steroids were visualized under ultraviolet light (A) Lane 1 and 3, 
pregnenolone and progesterone standards; Lane 2 and 4, cultures 
with pregnenolone and progesterone. (B) Lane 1 and 3, 
androstenediol and etienic acid standards; Lane 2 and 4, cultures with 
androstenediol and etienic acid. 
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Table 1. Effects of cofactors and inhibitors on cholesterol reductase activity®. 
Product (runole/h.mg protein) 
Treatment Recovery^ 
Coprostanol 4-Chol-3-one Coprostanone 
Control 592 ± 29 582 13 289 37 105 ± 4 
Cofactors 
NADH 680 ± 2 234 20 374 6 92 ± 2 
FAD 629 ± 5 589 ± 3 285 ± 22 108 ± 0 
NADP+ 612 ± 4 481 ± 15 183 ± 2 103 ± 1 
NADPH 599 ± 17 559 10 215 8 102 ± 2 
FAD+NADPH 595 70 505 47 226 23 95 6 
NAD+ 584 ± 15 483 18 253 28 101 ± 2 
FAD+NADH 350 ± 28 246 18 233 10 94 ± 3 
Inhibitors 
NaNg 615 ± 17 487 12 198 3 96 ± 1 
NaCN 579 ± 24 583 13 203 3 98 ± 2 
lodoacetate 525 ± 13 601 ± 7 155 3 99 ± 2 
EDTA 181 ± 16 207 ± 15 34 2 110 ± 1 
HgCl2 3 ± 1 1 1 7 0 110 ± 1 
" Data are expressed as the mean of triplicate assays ± standard error. 
Recovery (%) = (amount of residual cholesterol + amount of 
products)/amount of added cholesterol substrate x 100. 
Enzyme activity in extracellular fluid and cell-free extract 
No cholesterol reductase activity was found in extracellular broth before or 
after ammonium sulfate precipitations. Cholesterol reductase activity was 
associated with the bacterial cells. Great loss of cholesterol reductase activity 
occurred after the bacterial cells were disrupted by sonication, passage through a 
145 
French pressure cell, freezing and thawing, liquid N2 freezing and pulverizing, or 
enzymatic digestion. Repeated trials resulted in the same observation. Crude cell-
free extracts, prepared after two passages through a French pressure cell (16,000 
psi), were studied further with addition of a variety of cofactors (Table 2). The 
cholesterol reductase activity decreased about 100 times as the cells are broken, 
and the activity could not be recovered by addition of cofactors. 
Table 2. Cholesterol reductase activity in cell-free extract. 
Sample Coprostanol (nmole/h.mg protein)^ 
Before disruption'' 1060.7 
After disruption 11.1 
Crude cell-free extract 2.3 
Extract + H2 3.5 
Extract + FAD 4.0 
Extract + FAD + Ho 5.0 
Extract + NADH 2.1 
Extract + NAD"*" 5.7 
Extract + NADPH 3.9 
Extract -I- FAD + NADPH 4.6 
" Data are the average of two assays. 
Bacterial cells were disrupted by two passages through a French pressure cell. 
Southern hybridization 
After hybridization with ^^P-label cho gene, strong signals were observed for 
pNC0937 DNA and its 2.4-kb Pst I fragment. Weak signals were seen in the lane 
with DNA from B. sterolicum ATCC 21387. No signals, however, were detected in 
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lanes with genomic DNA of E. coprostanoligenes, E. sp. VPI 12708, or E. coli 
DH5a. 
Construction of genomic expression library 
With incorporation of IPTG and X-gal in the top agar, a blue-white color 
screen was possible to distinguish between the background nonrecombinant and 
recombinant phage. The nonrecombinant Agtll phage had B-galactosidase activity 
that converts X-gal into a blue product under the induction of IPTG. The 
recombinants had received an insert in the phage genome and caused an insertional 
inactivation of B-galactosidase activity; thus, they could not convert X-gal to 
produce a blue product. Therefore, recombinants showed as white plaques, 
whereas nonrecombinants were blue. The titers for recombinants and 
nonrecombinants were 5 x 10^ pfu/ml and 1 x 10'^ pfu/ml, respectively. 
Discussion 
E. coprostanoligenes cells appeared shorter than the cells of most 
Eubacterium spp. (Moore and Holdeman 1986). Many bacterial cells existed in 
diploforms in the cultures. Eyssen et al. (1973) reported similar observations with 
Eubacterium ATCC 21408 in young cultures. These cells might be in the process of 
dividing. The range for G + C content of DNA is 30 to 55% for Eubacterium spp. 
(Moore and Holdeman 1986). The G + C content (41%) of E. coprostanoligenes 
DNA was in the middle of this range. 
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The conversion of cholesterol to coprostanol by intestinal microorganisms 
has been reported to occur by two pathways (Figure 9). One, indirect pathway, 
involves the intermediary formation of 4-cholesten-3-one and coprostanone 
(Bjorkhem and Gustafsson 1971; Eyssen and Parmentier 1974; Parmentier and 
Eyssen 1974). In the other pathway, cholesterol is transformed into coprostanol by 
the direct reduction of the 5-6 double bond (Rosenfeld and Gallagher 1964). 
2 
HO-
5-ChoIesten-3-one Cholesterol 4-Cholesten-3-one 
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II 
Coprostanol Coprostanone 
Figure 9. Proposed reaction pathways for enzymatic conversion of cholesterol 
to coprostanol (Bjorkhem and Gustafsson 1971).^ I. Direct pathway. 
II. Indirect pathway: 1, oxidation; 2, isomerization; 3, reduction; 4, 
reduction. 
In the beginning of the study with E. coprostanoligenes, it was thought that 
the bacterium reduces cholesterol to coprostanol in a direct pathway because no 
intermediates were observed in cultures with cholesterol. Later, by incubating the 
bacterium with a mixture of a and 6 isomers of [4-^H, 4-^'*C]-cholesterol, it was 
found that the final product, coprostanol, retained 97% of the tritium originally 
148 
present in cholesterol; the majority of this tritium (64%), however, was in the C-6 
position in coprostanol, which showed that the conversion of cholesterol to 
coprostanol by E. coprostanoligenes involved the intermediate formation of 4-
cholesten-3-one followed by the reduction of the latter to coprostanol (Ren et al. 
1995). After the establishment of a resting cell assay for cholesterol reductase 
activity, it was possible to provide direct evidence of the cholesterol reduction 
pathway in E. coprostanoligenes. 
In the current study, intermediates in cholesterol reduction were observed 
on TLC plates and quantified by determination of radioactivity. Isomerization of 5-
cholesten-3-one to 4-cholesten-3-one must have been very rapid because no 5-
cholesten-3-one accumulated in the reaction. Reduction of 4-cholesten-3-one to 
coprostanone might be a rate-limiting step in this pathway because 4-cholesten-3-
one was formed in even greater amounts than was the final product, coprostanol. 
Reduction of coprostanone to coprostanol was rather fast because only little 
coprostanone accumulated in the reaction. E. coprostanoligenes converted 5-
cholesten-3-one, 4-cholesten-3-one, and coprostanone, respectively, to coprostanol, 
validating the existence of the indirect pathway for cholesterol reduction in this 
bacterium and indicating that the bacterium has a broad substrate specificity. The 
broad specificity of the enzyme system on substrates was shown further by its ability 
to metabolize pregnenolone, progesterone, androstenediol, and etienic acid. These 
characteristics may be useful for future application of E. coprostanoligenes in the 
pharmaceutical industry. 
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Both NADH and NADPH have been suggested as cofactors for cholesterol 
reductase of plant origin (Dehal et al. 1991). In the current study, NADH also 
stimulated the cholesterol reductase activity in cells of E. coprostanoligenes. NADH 
increased coprostanol formation, probably through increasing the rate of 4-
cholesten-3-one reduction because much less 4-cholesten-3-one accumulated in 
reactions in the presence of NADH (Figure 10). 
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Figure 10. Effect of NADH on cholesterol reductase activity in resting cell 
assays. The data are expressed as the mean of triplicate assays ± 
standard error. 
FAD is a prosthetic group of most cholesterol oxidases that catalyze 
conversion of cholesterol to 4-cholesten-3-one (Kenney et al. 1979). Interestingly, 
FAD also showed a stimulatory effect on cholesterol reductase. The cholesterol 
reductase system could have used FAD as a cofactor for the first step in the 
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pathway, that is oxidation of cholesterol to 4-cholesten-3-one as in the cholesterol 
oxidase system. 
When NADH and FAD were used together, however, cholesterol reductase 
activity was lower than that of the control. This observation might be explained by 
the possibility that NADH could have reduced FAD to form FADH2 and NAD 
(Figure 11). Further, FADH2 might have inhibited the production of 4-cholesten-
3-one from cholesterol, and NAD might have inhibited the reduction of 4-
cholesten-3-one to coprostanol. Therefore, the resultant effect would be less of the 
final product, coprostanol, produced in the reaction. This explanation assumes that 
NADH dehydrogenase is present in E. coprostanoligenes, but its presence has not 
been demonstrated. When NADPH and FAD were used together, no significant 
effects were observed on cholesterol reductase activity. FADH2 might not be 
formed from NADPH, and NADPH itself did not affect cholesterol reductase 
activity either. The questions about how these cofactors work and what are the 
required cofactors for cholesterol reduction, however, can be answered only after a 
pure preparation of cholesterol reductase is available. 
Cholesterol 
FAD FADH2 •© 
\ / X 4-Cholesten-3-one /' N 
/ 
NADH NAD •© 
Coprostanol 
Figure 11. Proposed effect of NADH-FAD on cholesterol reduction. 
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The results from inhibitor experiments are also interesting. An oxidizing 
agent, iodoacetate, and metal-complexing agents, CN" and N3', did not affect 
cholesterol reductase significantly, whereas a metal-chelating agent, EDTA, 
significantly inhibited enzyme activity; and a heavy metal ion, Hg"*", abolished the 
activity completely. It seems that some metal ions such as those of Cu, Fe, Mo, 
Zn, and Mg may be required by the enzyme to reduce cholesterol to coprostanol. 
Again, however, elucidation of the mechanism of inhibition needs to wait until a 
pure preparation of the enzyme is available. 
Trials to prepare active cell-free extracts were not successful because of the 
great loss of activity when the bacterial cells are broken. The only other reported 
attempt to detect cell-free activity with cholesterol-reducing bacteria was made by 
Bjorkhem et al. (1973), which also resulted in negative results. Several reasons 
could account for the loss of activity: (1) Cholesterol reductase may require an 
intact membrane to be functional, (2) Cholesterol reductase may be composed of 
multiple subunits that are separated during cell disruption, (3) Some required 
cofactor(s) may not be formed when bacterial cells are broken, and (4) Cholesterol 
reductase may be extremely sensitive to oxygen when it is freed from intact cells. 
Future experiments should take these reasons into account for preparation of cell-
free extracts. Furthermore, cholesterol reductase does not seem to be a secretoiy 
protein. Its activity was associated with bacterial cells. The active site of the 
enzyme, however, may be located at the outer surface of the membrane, and 
substrate catalysis in vivo may occur externally to the cytoplasm because (a) the 
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rapid release of reduction products by resting cell action on cholesterol seemed to 
show a rapid and direct contact between the enzyme system and the substrate and 
(b) the enzyme activity could be measured by using whole cells, indicating that the 
substrate needs not intersect the cytoplasmic membrane for catalysis. Therefore, 
active cell-free enzyme preparation may be achieved by cell treatment with Triton 
X-100 or other nonionic detergents without cell disintegration. By using this 
method, Kreit et al. (1994) has extracted and purified cholesterol oxidase 
successfully from Rhodococciis sp. cells. 
Cholesterol oxidase gene was considered as a probe to screen for cholesterol 
reductase gene. It is hypothesized that the genes encoding cholesterol reductase 
and cholesterol oxidase would share some homology because they both must bind 
cholesterol and show similar catalytic functions. This hypothesis provides a 
potential method to isolate the cholesterol reductase gene from E. coprostanoligenes 
without the purification of cholesterol reductase. Unfortunately, no hybridization 
signal was observed after genomic DNA of E. coprostanoligenes was hybridized with 
P-labeled cho gene. The conditions for Southern hybridization, however, were 
not optimized in the experiment because only weak signals were seen with genomic 
DNA from B. sterolicum ATCC 21387, which produces cholesterol oxidase and has 
a cho gene that has been reported to have extensive homology in DNA sequence 
with the cho gene from Streptomyces sp. (Ohta et al. 1991). Similar experiments 
should be conducted in the future with other cholesterol-related genes, in addition 
to cho gene, as probes. Potential candidates include genes for sterol carrier 
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protein, cholesterol Ta-hydroxylase, steroid 5a:-reductase, and other cholesterol-
metabolizing enzymes. With the genomic expression library available, discovery of 
an appropriate probe would lead to the cloning of the cholesterol reductase gene 
before the enzyme protein is purified. 
Other potential methods to isolate cholesterol reductase and its gene(s) are 
under development. One method is to incorporated micellar cholesterol in the top 
agar when plating the genomic expression library with a lysogen such as E. coli 
strain Y1089. Production of the functional cholesterol reductase would convert 
cholesterol to coprostanol. Disappearance of cholesterol can be detected with a 
Sigma Cholesterol 100 Kit, which shows a pink color when cholesterol is present, 
and there is no color formation with coprostanol. Therefore, colonies or plaques 
with a colorless halo would be positive clones for cholesterol reductase. DNA 
inserts can be isolated from those clones, and the gene could be identified. 
Another potential method is focusing more on the enzyme protein itself. An 
assumption needs to be made that cholesterol reductase protein binds the substrate 
cholesterol, even though the cholesterol-reducing activity is lost by a purification 
procedure. A whole cellular protein can be prepared and separated by native 
polyaciylamide gel electrophoresis. The proteins can be transferred to a nylon 
membrane. The immobilized proteins can be incubated with a micellar cholesterol 
solution. After washing away the unbound cholesterol, the membrane will be 
treated with agents that recognize cholesterol, such as Sigma Cholesterol 100 Kit or 
radiolabeled or fluorescent-labeled antibodies against cholesterol. The protein that 
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binds cholesterol could be isolated this way. Further investigation with this protein 
may lead to the isolation of active cholesterol reductase. 
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HYPOCHOLESTEROLEMIC EFFECT OF 
EUBACTERIUM COPROSTANOLIGENES ATCC 51222 IN RABBITS 
A paper published in Letters in Applied Microbiology 
L. Li, K.K. Buhman, P.A. Hartman and D.C. Beitz 
Abstract 
Recently, a unique bacterium, Eubacterium coprostanoUgenes ATCC 51222, 
that reduces cholesterol to coprostanol was isolated. Because coprostanol is 
absorbed poorly, we hypothesized that oral administration of Eti. coprostanoUgenes 
might decrease cholesterol concentration in blood because the microorganisms will 
decrease the absorption of endogenous and dietary cholesterol by conversion to 
coprostanol. To test the hypothesis, three adult New Zealand White rabbits 
received 4 ml of Eu. coprostanoUgenes suspension {ca 2 x 10^ cells ml"^) daily per as 
for 10 days; three other adult New Zealand White rabbits received the same dosage 
of boiled bacterial suspension. Plasma cholesterol concentration of experimental 
rabbits (183.3 ± 11.0 mg dl'^ mean ± S.E.) was significantly lower {P < 0.001) 
than that of controls (248.8 ± 12.3 mg dl'^ mean ± S.E.). The coprostanol-to-
cholesterol ratios in contents of digestive tracts of experimental rabbits were 
greater than those of controls. The data indicate that oral administration of Eu. 
coprostanoUgenes caused a significant hypocholesterolemic effect in rabbits and that 
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this effect can be explained by the conversion of cholesterol to coprostanol in the 
intestine. 
Introduction 
Coronary heart disease is the leading cause of human mortality in the 
United States as well as in many other developed countries and is responsible for 
more deaths than all forms of cancer combined. For many years, it has been 
recognized that elevated serum cholesterol is a risk factor associated with 
atherosclerosis (Gotto et al 1990). Numerous cholesterol-lowering drugs, including 
the 3-hydroxy-3-methylglutaryl coen2yme A reductase inhibitors and drugs that 
increase net bile acid excretion, have been used to treat hypercholesterolemic 
individuals. The accompanying undesirable side effects of these drugs, however, 
have caused concerns about their therapeutic use (Erkelens et al. 1988). 
The identification of bacteria that convert cholesterol to coprostanol has 
provided a potential method to naturally decrease serum cholesterol in humans. 
Coprostanol, a saturated product of cholesterol, is absorbed poorly from the 
gastrointestinal system (Bhattacharyya 1986). Cholesterol-reducing bacteria have 
been isolated from feces of rats (Eyssen et al 1973), humans (Sadzikowski et al. 
1977), and baboons (Brinkley et al. 1982). Most of these previously isolated 
bacteria were difficult to grow in the laboratoiy. Recently, a unique cholesterol-
reducing bacterium designated Eubacteriiim coprostanoligenes ATCC 51222 was 
isolated and is much easier to grow in the laboratory (Freier et al. 1994). The 
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enzyme responsible for catalyzing the reduction of cholesterol to coprostanol has 
been named "cholesterol reductase" (Dehal et al 1991). 
Because coprostanol is absorbed poorly, we hypothesized that oral 
administration of Eu. coprostanoligenes would decrease cholesterol concentration in 
human blood because the microorganisms will decrease the absorption of 
endogenous {e.g. biliary) and dietary cholesterol by conversion to coprostanol in the 
small intestine. Therefore, the purpose of this study was to test the effect of orally 
administered Eu. coprostanoligenes on plasma cholesterol concentration by using 
rabbits as an animal model. 
Materials and Methods 
Animals and diets 
Six adult New Zealand White rabbits were fed Purina Rabbit Chow with 
0.05% cholesterol for 32 days and then 0.1% cholesterol for 57 days to raise their 
plasma cholesterol concentration. The dietarily induced hj^ercholesterolemic 
rabbits were divided randomly into two groups, the experimental group and the 
control group, with three rabbits in each group on day 50 of the 94-day experiment. 
The experimental group received 4 ml of Eu. coprostanoligenes suspension (ca 2 x 
10^ cells ml'^) daily through stomach tubing for 10 days; the control group received 
the same dosage of killed (boiled) bacterial suspension. 
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Cultivation of bacteria 
Eu. coprostanoligenes was grown in the medium containing the following 
components per liter: 10 g casitone (Difco, Detroit, MI), 10 g yeast extract, 5 g 
lactose, 5 g sodium pyruvate, 0.5 g sodium thioglycolate, 0.2 g cholesterol (ash-free, 
Sigma Chemical Co., St. Louis, MO), 0.1 g lecithin (type IV-S, Sigma), 0.1 g 
CaCl2 -21120 and 1 mg resazurin. The pH was adjusted to 7.5 with 3 N KOH. 
The Hungate technique was used for the anaerobic preparation of media and 
handling of the culture (Holdeman et al. 1977). Fresh medium was inoculated with 
1% of a 48-hour culture. After incubation for 48 hours at 37°C, the cultures were 
harvested by centrifugation (10,000 g, 10 min). The cell pellets were suspended in 
25 mmol 1'^ PIPES (piperazine-N,N'-bis-[2-ethanesulfonic acid]) buffer (pH 7.5) 
containing 5 mmol 1'^ sodium thioglycolate and 45 mmol 1'^ pyruvate before being 
fed to rabbits. 
Determination of plasma cholesterol concentrations 
Blood samples were taken from the rabbits through the ear artery 2-3 times 
a week; ethylenediaminetetraacetic acid (disodium salt) was used as an 
anticoagulant. The plasma cholesterol concentrations were determined in triplicate 
enzymatically with a Sigma cholesterol kit (Cholesterol 100, Sigma). 
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Determination of coprostanol-to-cholesterol ratios in the contents of digestive tract 
The contents of digestive tracts were collected from each rabbit at the end 
of the study. Lipids were extracted in duplicate (Lepage and Roy 1986), and the 
coprostanol-to-cholesterol weight ratios were determined in duplicate by gas-liquid 
chromatography by the method of Oles et al. (1990). The duplicate lipid extract 
from the samples was evaporated to dryness under nitrogen. Sterols in the residue 
were etherified with l,3-bis-(trimethylsilyl)trifluoroacetamide. A 5830A Hewlett 
Packard gas chromatograph was used. The glass column, 0.91 m x 4 mm ID, was 
packed with 3% SP-2250 on 100/120 Supelcoport. Operating conditions were: 
oven, 250-280°C; injector, 290°C; flame ionization detector (FID), 290°C; nitrogen 
flow rate, 20 ml min"^. 
Statistical analysis 
The data were analyzed by Student's t test for significance. 
Results 
Plasma cholesterol concentrations 
The plasma cholesterol concentrations of the rabbits are shown in Figure 1. 
The bacterial administration started when the plasma cholesterol concentration 
reached about 175 mg dl'^ at day 50. After 10 days of bacterial treatment, 
differences were observed between the two groups through the rest of the study. 
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Figure 1. The plasma cholesterol concentrations of the experimental and 
control (—A—) rabbits. Days of giving Eu. coprostanoligenes is 
indicated as Eubact. on the figure. Each data point represents the 
average of data from three rabbits. The plasma cholesterol 
concentration of the experimental group from day 61 through day 94 
was 183.3 ± 6.8 mg dl'^ (mean ± S.E.), which was significantly lower 
(P < 0.001) than that of the control group (248.8 ± 11.7 mg dl"^). 
The plasma cholesterol concentration of the experimental group from day 61 
through day 94 was 183.3 ± 6.8 mg dl"^ (mean ± S.E.), which was significantly 
lower {P < 0.001) than that of the control group (248.8 ± 11.7 mg dl"^). 
Coprostanol-to-cholesterol ratios 
The coprostanol-to-cholesterol ratios of the contents of rabbit digestive 
tracts at the end of the experiment (day 94) are shown in Table 1. In the 
duodenum, coprostanol was not detectable in either the experimental group or the 
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control group. In the jejunum, the coprostanol-to-cholesterol ratio of the 
experimental group was significantly (P = 0.05) greater than that of the control 
group. In the ileum, the ratio also was higher in the experimental group (P = 0.08). 
The trend continued in the cecum and colon. 
Table 1. Coprostanol-to-cholesterol weight ratios in contents of rabbit digestive 
tracts. 
Section Experimental Control P-Value 
Duodenum ND ND 
Jejunum 0.13 ± 0.04^ 0.01 ± 0.01 0.05 
Ileum 0.21 ± 0.08 0.02 ± 0.02 0.08 
Cecum 0.46 ± 0.12 0.14 ± 0.14 0.15 
Colon 0.48 ± 0.10 0.33 ± 0.13 0.39 
ND, not detectable. 
® Mean ± S.E., n = 3. 
Discussion 
In this study, we showed that orally administration of Eii. coprostanoligenes 
caused a significant decrease of plasma cholesterol concentration in dietarily 
induced hypercholesterolemic rabbits. The rabbits showed no adverse effects to 
being treated with the bacterial inocula. The mechanism by which Eu. 
coprostanoligenes decreases the plasma cholesterol concentration relies on the fact 
that Eu. coprostanoligenes converts readily absorbed cholesterol into poorly 
absorbed coprostanol (Freier et al. 1994; Bhattachaiyya 1986). Preliminary in vitro 
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experiments showed that Eu. coprostanoligenes could survive in simulated stomach 
acid conditions for at least 2 hours and retain its cholesterol-reducing activity when 
transferred to the regular growth medium (data not shown). The sources of 
cholesterol available for absorption in the intestine include exogenous (dietary) and 
endogenous (e.g. biliary) cholesterol (Gotto et al 1990). By conversion of 
cholesterol to coprostanol, Eu. coprostanoligenes, on one hand, could decrease the 
absorption of cholesterol so that less cholesterol will enter the body cholesterol 
pool, and, on the other hand, the bacterium may interrupt the enterohepatic 
circulation of biliary cholesterol so that the liver would partition more cholesterol 
into bile and less cholesterol into the bloodstream. 
The hypocholesterolemic effect of Eu. coprostanoligenes continued for at 
least 34 days after the last bacterial feeding. Colonization of Eu. coprostanoligenes 
in the digestive tracts of the rabbits can explain that sustained effect. Significantly 
greater coprostanol-to-cholesterol ratios in the contents of digestive tracts of the 
experimental group at the end of the experiment suggested that the bacteria 
colonized there were reducing cholesterol to coprostanol actively. When the 
intestinal contents were inoculated into the growth medium, Eu. coprostanoligenes 
and its cholesterol-reducing activity were recoved from the experimental group but 
not from the control group (data not shown). The presence of other indigenous 
coprostanol-producing bacteria in the digestive tracts of rabbits accounts for the 
relatively great coprostanol-to-cholesterol ratios in the contents of cecum and colon 
of the control group (Eyssen et al. 1973; Sadzikowski et al. 1977; Brinkley et al. 
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1982). These bacteria, however, exert little if any effects on cholesterol absorption 
because cholesterol absorption takes place primarily in the small intestine and not 
in the cecum and colon (Gotto et al. 1990). 
In conclusion, oral administration of Eu. coprostanoligenes significantly 
decreased plasma cholesterol concentrations in hypercholesterolemic rabbits, and 
the hypocholesterolemic effect can be explained by the conversion of cholesterol to 
coprostanol in the intestine. These results suggest a potential application of Eu. 
coprostanoligenes in humans to decrease serum cholesterol in hypercholesterolemic 
individuals. Before a human study becomes feasible, however, more animal 
experiments are needed to test variables such as bacterial dosage, length of time of 
bacterial administration and interaction of bacterial dosage with blood cholesterol 
concentration. 
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EFFECT OF ORALLY ADMINISTERED EUBACTERIUM 
COPROSTANOLIGENES ATCC 51222 ON PLASMA CHOLESTEROL 
CONCENTRATION IN LAYING HENS 
A paper prepared for submission to Poultry Science 
Ling Li, Carol A. Baumann, Daryl D. Meling, 
Jerry L. Sell, Paul A. Hartman, and Donald C. Beitz 
Abstract 
Thirty normocholesterolemic laying hens were used to investigate the effect 
of oral administration of Eubacterium coprostanoligenes on plasma cholesterol 
concentrations. Hens were divided randomly into three groups (active, inactive, 
and control) with 10 hens in each group. The active group received 0.5 ml of E. 
coprostanoligenes suspension {ca 2 x 10^ cells/ml) daily for 4 wk; the inactive group 
received the same dosage of killed (boiled) bacterial suspension; and the control 
group received no supplemental bacteria. After bacterial feeding, the coprostanol-
to-cholesterol ratio in feces of the active group was significantly higher than ratios 
of the inactive and control groups, indicating that E. coprostanoligenes was 
colonized in the intestine of hens and was converting intestinal cholesterol to 
coprostanol. Plasma cholesterol concentrations, however, were not affected by the 
bacterial treatment. 
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Introduction 
Eggs are a popular and highly nutritious food throughout the world. The 
amount of cholesterol contained in egg yolk, however, has caused immense 
concerns about consuming eggs because of the adverse effect of dietary cholesterol 
on coronary heart disease (Fraser 1994; Pyorala 1987). Great efforts have been 
made to decrease the cholesterol content of eggs through selective breeding and 
feeding or physical and chemical removal of egg cholesterol (Froning et al. 1990; 
Rossi et al. 1990; Michael Foods 1992). The "low-cholesterol" eggs are demanded 
by many consumers who love eggs as a food but are concerned about their daily 
cholesterol intake. 
A newly isolated bacterium, Eubacteiium coprostanoligenes ATCC 51222, 
converts cholesterol to coprostanol that is absorbed poorly by the gastrointestinal 
system (Freier et al. 1994). Previous studies have showed that oral administration 
of £. coprostanoligenes decreases the plasma cholesterol concentration significantly 
in hypercholesterolemic rabbits (Li et al. 1995). The hypothesis of this study is that 
E. coprostanoligenes will colonize in the intestine of laying hens after oral 
administration of the bacterium and that the bacterium in the intestine will convert 
exogenous (dietary) and endogenous (e.g., biliary) cholesterol to coprostanol so that 
less cholesterol will return to the liver through enterohepatic circulation. As a 
result, liver may partition more cholesterol into bile and less cholesterol into 
plasma. If plasma cholesterol was decreased markedly, less cholesterol probably 
would be incorporated into eggs of laying hens. 
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Materials and Methods 
Bacteriology 
E. coprostanoligenes was grown in the medium containing the following 
components per liter: 10 g casitone (Difco, Detroit, MI), 10 g yeast extract, 5 g 
lactose, 5 g sodium pyruvate, 0.5 g sodium thioglycolate, 0.2 g cholesterol (ash-free, 
Sigma Chemical Co., St. Louis, MO), 0.1 g lecithin (type IV-S, Sigma), 0.1 g 
CaCl2-2 H2O, and 1 mg resazurin. The pH was adjusted to 7.5 with 3 N KOH. 
The Hungate technique was used for the anaerobic preparation of media and 
handling of the culture (Holdeman et al. 1977). Fresh medium was inoculated with 
1% of a 48-h culture. After incubation for 48 h at 37°C, cultures were harvested 
by centrifugation (10,000 x g, 10 min). The cell pellets were suspended in 25 mM 
PIPES (piperazine-N,N'-bis-[2-ethanesulfonic acid]) buffer (pH 7.5) containing 5 
mM sodium thioglycolate and 45 mM pyruvate before being fed to hens. 
Management of hens 
Thirty Leghorn laying hens were placed in individual cages and provided ad 
libitum water and a corn-soy diet that was adequate in all nutrients. The hens were 
allowed one week to acclimate to the environment before experimental challenges 
were carried out. They were divided randomly into three groups with 10 hens in 
each group. Hens in the active group were fed once daily a gelatin capsule 
containing 0.5 ml of E. coprostanoligenes suspension (ca 2 x 10^ cells/ml) for 4 wk; 
an inactive group received the same dosage of killed (boiled) bacterial suspension; 
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and a control group received no supplemental bacteria. 
Determination of plasma cholesterol concentrations 
Blood samples were taken from the hens via the wing vein once a week; 
ethylenediaminetetraacetic acid (disodium salt) was used as an anticoagulant. The 
plasma cholesterol concentrations were determined enzymatically with a Sigma 
cholesterol kit (Cholesterol 100, Sigma). 
Determination of coprostanol-to-cholesterol ratios in feces 
The feces were collected from each hen after the last bacterial feeding. 
Lipids were extracted (Lepage and Roy 1986), and the coprostanol-to-cholesterol 
ratios (w/w) were determined by gas-liquid chromatography by the method of Oles 
et al. (1990). The lipid extract from the samples was evaporated to dryness under 
nitrogen. Sterols in the residue were etherified with 1,3-bis-
(trimethylsilyl)trifluoroacetamide. A 5830A Hewlett Packard gas chromatograph 
was used. The glass column, 0.91 m x 4 mm internal diameter, was packed with 
3% SP-2250 on 100/120 Supelcoport (Supelco Inc., PA). Operating conditions 
were; oven, 250-280°C; injector, 290°C; flame ionization detector, 290°C; and 
nitrogen flow rate, 20 ml/min. 
Statistical analysis 
The data were analyzed by Student's t test for significance. 
I l l  
Results 
The plasma cholesterol concentrations of the three groups of hens are 
shown in Figure 1. Great fluctuation was observed with plasma cholesterol 
concentrations in all groups. No difference (P > 0.05) was observed among groups 
during the experiment. Table 1 shows the coprostanol-to-cholesterol ratios in the 
feces of hens at 1, 2, and 4 d after the last bacterial feeding. A significantly higher 
ratio was seen in the feces of the active group at 4 d after last bacterial feeding. 
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Figure 1. The plasma cholesterol concentration of laying hens. The time of 
bacterial treatment is indicated as "Eubacterial Feeding". "Control, 
Inactive, and Active" refer to groups that received no, killed, and live 
bacterial feeding, respectively, during the bacterial treatment. The 
data are expressed as Mean ± SE. 
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Table 1. Coprostanol-to-cholesterol ratios in the feces of laying hens®. 
Time^ Active Inactive Control 
1 0.14 ± 0.02 0.14 ± 0.02 0.02 ± 0.01 
2 0.04 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
4 0.08 ± 0.02^ 0.03 ± O.Ol'^ 0.01 ± 0.003^^ 
® Mean ± SE, n=10. 
^ Days after last bacterial feeding. 
Means with different superscripts within a given time are different (P < 0.05). 
Discussion 
The role of intestinal bacteria in the regulation of cholesterol homeostasis 
has been studied by several investigators (Eyssen and Parmentier 1974; Martin et 
al. 1973; Tortuero et al. 1975; Wostmann 1973). Tortuero et al. (1975) studied the 
effect of cecectomy of laying hens on serum and egg cholesterol contents. The 
decrease in the number of the intestinal bacteria led to a significant increase in 
both serum and egg cholesterol concentrations. Eyssen and Parmentier (1974) did 
not observe a hj'pocholesterolemic effect after association of germ-free rats with a 
cholesterol-reducing bacterium, Eiibacterium ATCC 21408. The bacteria, however, 
were found to colonize only the cecum, where no cholesterol absorption takes 
place. Oral administration of E. coprostanoligenes to dietary-induced 
hypercholesterolemic rabbits caused a significant decrease of plasma cholesterol 
concentration because the cholesterol-reducing bacteria were found to colonize in 
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the jejunum and ileum, which are major sites for cholesterol absorption (Li et al. 
1995). 
In the present study, the coprostanol-to-cholesterol ratio in feces of both the 
inactive and the active groups were high 1 d after bacterial feeding, which was 
caused by the coprostanol contained in the bacterial preparation. Bacterial 
suspensions from cholesterol-containing cultures usually contain substantial 
amounts of coprostanol because the growing bacteria actively reduce cholesterol in 
the medium to coprostanol during cultivation (Freier et al. 1994). At 2 d after the 
last bacterial feeding, the dietary coprostanol had been flushed out, and fecal 
coprostanol-to-cholesterol ratios started to show a difference among groups. By 4 
d after the last bacterial feeding, a significantly higher fecal coprostanol-to-
cholesterol ratio was observed in the active group than those in the inactive and the 
control groups on day 4. No difference was found between the inactive and the 
control groups. The results suggest that the higher coprostanol-to-cholesterol ratio 
in the active group was caused by the live bacterial feeding. E. coprostanoligenes 
must have inhabited the intestine of hens and reduced cholesterol therein to 
coprostanol. The anatomical sites of bacterial colonization, however, were not 
determined. Plasma cholesterol concentrations of hens were not affected by the 
bacterial feeding, even though oral administration of E. coprostanoligenes did cause 
a significant hypocholesterolemic effect in hypercholesterolemic rabbits (Li et al. 
1995). Normocholesterolemic hens may have a mechanism to regulate the plasma 
cholesterol concentration so that it will not be subject to the changes of cholesterol 
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absorption in the intestine. Therefore, even though E. coprostanoligenes was 
reducing cholesterol to coprostanol and thereby caused less absorption of 
cholesterol in the intestine, the decreased absorption was not enough to reset the 
homeostasis for plasma cholesterol of hens. 
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Figure 2. Effect of culture temperatures on the growth and coprostanol 
production of E. coprostanoligenes. The cultures were incubated for 
48 h. The data are expressed as the mean ± standard error of 
triplicate samples. 
Moreover, the average body temperature of chickens is about 42°C. The 
growth of E. coprostanoligenes at 41°C was about half of that at 39°C (Figure 2). 
Conversion of cholesterol to coprostanol by E. coprostanoligenes was also much less 
at the high temperature. Presumably, the influence of temperature on grovrth and 
coprostanol production in the intestine of hens would be similar to that observed in 
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Figure 2. Also, the fecal transit time of hens is shorter than that of rabbits. E. 
coprostanoligenes may need more time to efficiently reduce cholesterol to 
coprostanol. Selection of heat-resistant strains of E. coprostanoligenes and 
increasing the bacterial dosage should be considered in the future experiments with 
hens. 
The effect of feeding E. coprostanoligenes on the cholesterol content in egg 
yolk was not determined in this study. No adverse effect of feeding E. 
coprostanoligenes was observed in laying hens on feed intake, egg production, body 
weight gain, and fecal consistency. 
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FEEDING OF EUBACTERIUM COPROSTANOLIGENES ATCC 51222 
TO GERM-FREE AND CONVENTIONAL MICE 
A paper prepared for submission to Applied and Environmental Microbiology 
Ling Li, Susan M. Batt, Lisa A. Hingtgen, 
Michael Wannemuehler, and Donald C. Beitz 
Abstract 
This study investigated the possibility of using germ-free and conventional 
mice as animal models to study the effect of orally administered Eubacterium 
coprostanoligenes ATCC 51222 on serum cholesterol concentrations. It was found 
that E. coprostanoligenes from cholesterol-containing cultures survived treatment 
with a simulated stomach solution better than did cholesterol-free cultures. Germ-
free mice had a serum cholesterol concentration that was two times higher than 
that of conventional mice, and their serum cholesterol also was more sensitive to 
dietary cholesterol. When fed a high cholesterol diet, germ-free mice increased 
their serum cholesterol concentration twice as much as did conventional mice. 
After oral inoculation of E. coprostanoligenes, the bacteria only lived temporarily in 
the intestine of germ-free mice. The positive oxidation-reduction potential in the 
intestine of germ-free mice might be responsible for the nonsurvival of the 
anaerobic bacterium. E. coprostanoligenes did not colonize in the intestine of 
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conventional mice either. The microflora in the intestine of conventional mice 
might have inhibited the growth and inhabitance of E. coprostanoUgenes. Further 
studies need to be designed to make the digestive ^stem of germ-free animals 
more suitable for growth of E. coprostanoUgenes. Preinoculation of a 
nonpathogenic facultative bacterium such as Bacteroides into the digestive tract of 
germ-free animals may facilitate growth of the anaerobic bacterium. 
Introduction 
Elevated serum cholesterol concentration has been recognized as a major 
risk factor for the development of atherosclerosis that leads to coronary heart 
disease (CHD) (Gotto et al. 1990), which remains the leading cause of human 
mortality in developed countries (Thom et al. 1992). There is substantial evidence 
that lowering serum cholesterol concentrations will decrease the incidence of CHD 
(Lipid Research Clinic Program 1988). Clinical trials have shown that cholesterol-
lowering therapy improves survival of patients with CHD (Scandinavian Simvastatin 
Survival Study Group 1994). 
A newly isolated bacterium, Eubacterium coprostanoUgenes ATCC 51222, 
converts cholesterol to coprostanol, which is absorbed poorly by the gastrointestinal 
system (Bhattacharyya 1986; Freier et al. 1994). Normally, coprostanol is excreted 
in the feces, and it is a major component of fecal sterols. Previous studies have 
showed that oral administration of E. coprostanoUgenes decreased the plasma 
cholesterol concentration significantly in hypercholesterolemic rabbits (Li et al. 
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1995a). The observation has provided a potential way to decrease serum 
cholesterol concentrations without involvement of drugs, with which undesirable 
side effects have caused concerns about their therapeutic use (Erkelens et al 1988). 
Before the cholesterol-reducing bacterium can be used in clinical cases, however, 
many animal experiments have to be conducted to support the application. 
The present study was designed to test the possibility of using mice as an 
alternative animal model to investigate the effect of feeding E. coprostanoligenes on 
serum cholesterol concentrations. The survivability of E. coprostanoligenes under 
stomach conditions was tested in vitro before the bacteria were fed to mice. The 
difference between germ-free and conventional mice was compared in terms of 
serum cholesterol concentrations, responses to dietary cholesterol, and colonization 
of E. coprostanoligenes after oral administration. 
Materials and Methods 
Cultivation of bacteria 
E. coprostanoligenes was cultured in a growth medium containing the 
following components per liter: 10 g casitone (Difco, Detroit, MI), 10 g yeast 
extract, 5 g lactose, 5 g sodium pyruvate, 0.5 g sodium thioglycolate, 0.2 g 
cholesterol (ash-free, Sigma Chemical Co., St. Louis, MO), 0.1 g lecithin (type IV-
S, Sigma), 0.1 g CaCl2*2 H2O, and 1 mg resazurin. Cholesterol was omitted to 
prepare a cholesterol-free medium. The pH of the medium was adjusted to 7.5 
with 3 N KOH. The Hungate technique was used for the anaerobic preparation of 
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media and handling of the culture (Holdeman et al. 1977). Fresh medium was 
inoculated with 1% of a 48-h culture and incubated at 37°C. 
Simulation of stomach conditions 
Simulated stomach solution (pH 1.0) contained 0.1 M HCl, 50 mM NaCl, 5 
mM KCl, 5 mM CaCl2, and 0.01% pepsin (Tennant and Hornbuckle 1989). 
Bacterial cells harvested after 2 d of incubation in a cholesterol-containing or 
cholesterol-free media were suspended in three volumes of 25 mM PIPES ( 
piperazine-N,N'-bis-[2-ethanesulfonic acid]) buffer (pH 7.5) containing 5 mM 
sodium thioglycolate and 45 mM sodium pyruvate or the stomach solution. After 2 
h of incubation, the mixtures were added to nine volumes of fresh cholesterol-
containing media and incubated at 37°C. After 5 d of incubation, the bacterial 
growth and coprostanol production were determined. PIPES buffer treatment was 
used as a control. 
Animals and diets 
A total of 24 Swiss germ-free and conventional mice (Taconic Laboratories), 
12 of each, were used in this study. Germ-free mice were living in a germ-free 
isolator and were fed Teklad mouse breeder sterilizable diet (Harlan Teklad Inc., 
WI) ad libitum. The serum cholesterol concentrations of mice were determined 
before the experiment started. A cholesterol diet (5%, diy matter basis) was made 
by dissolving cholesterol in ethyl ether and mixing with Teklad diet. After ether 
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was evaporated completely under N2, the cholesterol diet was fed to mice for 1 wk 
to determine their response to dietary cholesterol intake in terms of serum 
cholesterol. After the serum cholesterol concentrations were back to the normal 
range, mice were divided randomly into 2 groups—experimental and control groups-
-with 6 mice in each group. The experimental group received 0.5 ml of active E. 
coprostanoligenes culture (~ 0.5 mg bacterial protein) per os daily for 1 wk. The 
control group received the same dose of killed (boiled) bacteria. The same design 
was used for conventional mouse experiment except that the conventional mice 
were fed a 0.5% cholesterol diet instead of regular chow when bacterial feeding 
started. 
Determination of serum cholesterol concentrations 
Blood samples were drawn weekly from the orbital sinus after mice were 
anesthetized by peritoneal injection of ketamine and rompun solution (Fort Dodge 
Laboratories, lA) or by inhalation of halothane (Halocarbon Laboratories, SC). 
The serum cholesterol concentrations were determined in triplicate enzymatically 
with a Sigma cholesterol kit (Cholesterol 100, Sigma). 
Determination of bacterial growth 
The total cellular protein concentration was used as a indicator of bacterial 
growth. Bacterial cultures were harvested by centrifugation at 10,000 x g for 10 
min at 4°C usually after incubation. The cell pellets then were washed once and 
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suspended in 25 mM PIPES ( piperazine-N,N'-bis-[2-ethanesulfonic acid]) buffer 
(pH 7.5) containing 5 mM sodium thioglycolate and 45 mM sodium pyruvate. 
Total cellular protein was determined by the Bradford method with microtiter 
plates (Redinbaugh and Campbell 1985). A portion of the cell suspension was 
mixed with an equal volume of 2 N NaOH and incubated at 37®C overnight to 
solubilize the protein. Bovine serum albumin, treated in the same manner, was 
used as a standard. 
Quantitation of coprostanol and cholesterol 
Fresh fecal samples were collected from each mouse weekly to inoculate the 
cholesterol-containing medium for recovery of E. coprostanoligenes. Also, 
cholesterol-to-coprostanol ratios (wt/wt) of feces were determined by gas-liquid 
chromatography (Oles et al. 1990). Fecal lipids were extracted in duplicate as 
described by Lepage and Roy (1986). The duplicate lipid extract from the samples 
was evaporated to dryness under nitrogen. Sterols in the residue were etherified 
with l,3-bis-(trimethylsilyl)trif]uoroacetamide (Oles et al. 1990). A 5830A Hewlett 
Packard gas chromatograph was used. The glass column, 0.91 m x 4 mm internal 
diameter, was packed with 3% SP-2250 on 100/120 Supelcoport (Supelco Inc., PA). 
Operating conditions were: oven, 250-280°C; injector, 290°C; flame ionization 
detector, 290°C; nitrogen flow rate, 20 ml/min. At the end of the experiment, the 
mice were killed and the intestinal contents were inoculated into the cholesterol-
containing medium for recovery of E. coprostanoligenes. The cholesterol contents 
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of liver and leg skeletal muscle from germ-free mice were determined also. 
Statistical analysis 
The data were analyzed by Student's t  test for significance. 
Results 
Survival of bacteria from simulated stomach conditions 
Bacterial growth and coprostanol production were determined after 
treatment with the PIPES buffer (control) or the simulated stomach solution 
(Figure 1). Bacteria from cholesterol-containing cultures retained about 40% of 
growth and coprostanol production abilities when compared with controls. Bacteria 
from cholesterol-free cultures, however, only survived 10% after the treatment with 
simulated stomach conditions. Therefore, bacteria from cholesterol-containing 
cultures were fed to mice in this study. 
Comparison of normal serum cholesterol concentrations 
Normal serum cholesterol concentrations of germ-free and conventional 
mice were measured (Figure 2). It was found that serum cholesterol concentration 
of germ-free mice were two-fold higher than those of conventional mice. 
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Figure 2. Serum cholesterol concentrations of germ-free and conventional mice. 
Data are expressed as the mean ± standard error of 12 mice. 
Response to dietary cholesterol 
Germ-free and conventional mice were fed 5% cholesterol diets for 1 wk, 
and the serum cholesterol concentrations were determined before and after the 
cholesterol feeding (Fig. 3). The serum cholesterol concentration increased by 130 
mg/dL in germ-free mice, but only 62 mg/dL in conventional mice. Referring to 
the base values of serum cholesterol concentrations, however, the percentage of 
increase was similar in germ-free and conventional mice, which was about 70%. 
After the removal of cholesterol from the diet, serum cholesterol concentrations of 
conventional mice returned to normal. In germ-free mice, however, the serum 
cholesterol concentration declined but was still significantly higher than their 
normal value. 
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Figure 3. Effect of dietary cholesterol on serum cholesterol concentrations of 
germ-free and conventional mice. Mice were fed 5% cholesterol diet 
for the first week, and cholesterol was removed after the first week. 
Data are expressed as the mean ± standard error of 12 mice. 
Effects of bacterial feeding on serum cholesterol concentrations 
The serum cholesterol concentrations of germ-free and conventional mice 
are shown in Figure 4. In germ-free mice, after 1 wk of bacterial feeding, the 
serum cholesterol concentration of experimental mice tended to decrease to a 
greater extent compared with that of control mice. When the bacterial feeding 
stopped, however, no difference was observed between experimental and control 
groups afterwards. In conventional mice, the serum cholesterol concentration 
increased in the beginning of the experiment because mice were fed a 0.5% 
cholesterol diet. During the whole experiment, no significant difference (P > 0.05) 
was found in the serum cholesterol concentrations between experimental and 
control groups at any of measured times. 
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Figure 4. Effect of bacterial feeding on serum cholesterol concentrations of 
germ-free and conventional mice. Bacteria were fed between 3 to 4 
wk. Conventional mice were fed a 0.5% cholesterol diet beginning at 
wk 2. Data are expressed as the mean ± standard error of 6 mice. 
Coprostanol-to-cholesterol ratios in feces and fecal cultures 
Coprostanol-to-cholesterol ratios in feces of germ-free and conventional 
mice are shown in Table 1. In the feces of germ-free mice, there was no 
coprostanol detectable before the feeding of E. coprostanoligenes. Coprostanol 
content was increased significantly (P < 0.05) in the feces of the experimental mice 
after being fed E. coprostanoligenes for 1 wk. It declined, however, 1 wk after the 
last bacterial feeding and was not detectable thereafter. In conventional mice, 
coprostanol was detectable, but the coprostanol-to-cholesterol ratios were low 
throughout the experiment. No differences were observed between the 
experimental and control groups {P > 0.05). 
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Table 1. Coprostanol-to-cholesterol ratios in the feces of mice^. 
Group WK 1 W K 2  WK4'' W K 5  W K 6  
Germ-free mice 
Experimental ND'^ ND ND 0.29'^ 0.02 ND 
Control ND ND ND 0.04® 0.07 ND 
Conventional mice 
Experimental 0.03 0.03 0.04 0.03 0.04 0.02 
Control 0.02 0.02 0.03 0.04 0.02 0.04 
® Data are expressed as the average value of 6 mice. 
From wk 3 to 4, the experimental group received 0.5 ml of live E. 
coprostanoligenes (~ 0.5 mg of bacterial protein) per os daily and the control group 
received the same dose of killed (boiled) bacteria. 
^ ND = Not detectable. 
Means with different superscripts within a given time are different {P < 0.05). 
Table 2. Tissue cholesterol contents of germ-free mice. 
Tissue Cholesterol (mg/g dry tissue)® 
Skeletal muscle 
Experimental 3.95 ± 0.18 
Control 3.36 ± 0.17 
Liver 
Experimental 10.04 ± 0.58 
Control 10.69 ± 0.43 
^ Mean ± standard error, n=6. 
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E. coprostanoligenes was not recovered either from the cultures of fresh feces 
during the experiment or from the cultures of intestinal contents of the mice at the 
end of the experiment. Cholesterol contents of skeletal muscle and liver of germ-
free mice are shown in Table 2. No difference (P > 0.05) in cholesterol contents 
of either tissue was observed between the experimental and control groups. 
Discussion 
E. coprostanoligenes does not require cholesterol for growth but retains its 
cholesterol-reducing ability in the absence of cholesterol (Freier et al. 1994; Li et 
al. 1995b). It was planned originally to use bacteria from cholesterol-free cultures 
to feed mice. In vitro experiments, however, showed that bacteria from cholesterol-
free cultures did not survive the treatment with the simulated stomach solution, 
whereas bacteria from cholesterol-containing cultures had about 40% of growth 
and coprostanol production ability after the stomach solution treatment. Bacteria 
growing in cholesterol-containing media may have formed some capsule-like 
structures that partially protected the bacteria from the strong acid treatment of 
stomach solution. Therefore, bacteria from cholesterol-containing cultures should 
be used to feed animals for a bacterial feeding study. It would be ideal if bacteria 
from cholesterol-free cultures could be sealed in some sort of acid-proof capsules 
before oral administration so that the carry-over effect of cholesterol from the 
bacterial preparation of cholesterol-containing cultures would not be of concern. 
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Germ-free mice had much higher serum cholesterol concentrations than did 
conventional mice when fed the same diet. Similar observations have been 
reported with other animals (Kellogg and Wostmann 1969a; Wostmann 1973). 
Absence of intestinal microflora is responsible for the higher cholesterol 
accumulation in germ-free animals. It has been found that conventional animals 
excrete 50 to 100% more neutral sterols through feces than do germ-free animals 
(Evrard et al. 1964; Kellogg and Wostmann 1969b; Eyssen et al. 1974). 
Furthermore, cholesterol was more efficiently absorbed from the intestine of 
germfree rats, and germ-free rats had a 2 to 3 times higher liver cholesterol content 
than did conventional rats when moderate amounts of cholesterol with the diet 
were fed (Wostmann 1973). 
In the present study, germ-free mice were very sensitive to dietary 
cholesterol. Serum cholesterol concentrations were increased rapidly after 
initiation of cholesterol feeding. The amount of increase was double that of 
conventional mice. At 2 wk after replacement of the high cholesterol diet with a 
regular Teklad diet, serum cholesterol concentrations of conventional mice 
returned to normal. In germ-free mice, however, the serum cholesterol 
concentration declined but was still significantly higher than their normal value. 
Therefore, at least two mechanisms could account for the influence of the intestinal 
microflora on the cholesterol pools in the body: effects on elimination via direct 
microbial influences on bile acid excretion, and, indirectly, effects on dietaiy uptake 
of dietary cholesterol because of influences on the enterohepatic bile acid pools 
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supporting absorption. 
The results from the bacterial feeding study were somewhat disappointing. 
By using germ-free mice, the original attempt was to develop a monoassociated 
animal model with E. coprostanoligenes so that the mechanisms of the 
hypocholesterolemic effect can be investigated more specifically. After 1 wk of 
bacterial feeding, fecal coprostanol-to-cholesterol ratios were significantly higher in 
the experimental group than that in the control group, indicating that the bacteria 
did live in the digestive tract and reduced cholesterol to coprostanol. This effect, 
however, was only temporary because the ratios declined 1 wk after the last 
bacterial feeding, and coprostanol was not detectable thereafter as before bacterial 
feeding. This transient effect also was reflected in serum cholesterol 
concentrations. After 1 wk of bacterial feeding, the serum cholesterol 
concentration of the experimental group tended to decrease to a greater extent 
than that of controls. One wk after the last bacterial feeding, however, the serum 
cholesterol concentration were the same for both groups. 
Negative results from recoveiy of E. coprostanoligenes in the fresh feces or 
the intestinal contents also suggested that the bacteria did not colonize the 
intestine. £. coprostanoligenes is an anaerobic bacterium and grows only in 
anaerobic conditions, although it survives exposure to air for at least 48 h (Freier et 
al. 1994). In germ-free animals, the digestive tract is not colonized with facultative 
or any other bacteria that usually consume oxygen and facilitate the growth of 
anaerobic bacteria. The presence of substantial oxygen in the digestive tract of 
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germ-free mice might cause the nonsurvival of E. coprostanoligenes. 
Eyssen and Parmentier (1974) tried to establish a monoassociate with 
Eubacterium ATCC 21408, the first pure isolate of cholesterol-reducing bacterium, 
in the intestine of germ-free rats and failed because of a positive oxidation-
reduction potential. The colonization of E. ATCC 21408 was established by 
exposing rats to a ClosUidiiim species first and then to E. ATCC 21408. The 
hypocholesterolemic effect, however, was not observed in gnotobiotic rats 
associated with E. ATCC 21408 plus ClosUidiiim Cl-8 because the cholesterol-
reducing bacterium was colonized in the cecum and the large intestine, sites from 
which no cholesterol absorption takes place (Eyssen and Parmentier 1974). 
After oral administration of E. coprostanoligenes to rabbits, the bacteria 
colonized and reduced cholesterol in the jejunum and ileum, which are major sites 
for cholesterol absorption (Li et al. 1995b). A significant hypocholesterolemic 
effect was observed in dietary-induced hypercholesterolemic rabbits associated with 
E. coprostanoligenes. In the present study, E. coprostanoligenes failed to colonize 
the digestive tract of germ-free mice; therefore, the effect of the bacterium on 
serum cholesterol concentration could not be investigated. Future studies should 
focus on how to make the digestive system of germ-free animals suitable for growth 
of E. coprostanoligenes. Preinoculation of a nonpathogenic facultative bacteria such 
as Bacteroides into the digestive tract of germ-free animals may solve the problem. 
Only then would the study of impact of £. coprostanoligenes on serum cholesterol 
concentrations of germ-free animals be feasible. 
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Conventional mice were used also in this study because it was thought that 
the microflora in the intestine of conventional mice would facilitate the growth of 
E. coprostanoligenes. Surprisingly, the bacteria even did not show temporary growth 
in the intestine after oral inoculation. The fecal coprostanol-to-cholesterol ratios 
were low during the whole period of the experiment, and fresh fecal cultures did 
not result in recovery of the bacteria either. It seems that the environment in the 
intestine of mice is not suitable for the growth of E. coprostanoligenes. The 
microflora in the intestine of conventional mice may inhibit the growth and 
colonization of E. coprostanoligenes. Therefore, mice might not be a good animal 
model to study the effect of the bacterium on serum cholesterol concentration. 
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GENERAL SUMMARY 
Excess serum cholesterol is a major risk factor for the development of 
cardiovascular diseases. The identification of bacteria that convert cholesterol to 
coprostanol has provided a potential method to naturally decrease serum 
cholesterol in humans because coprostanol is absorbed poorly from the 
gastrointestinal system. In the present study, a novel cholesterol-reducing 
bacterium, Eiibacterium coprostanoligenes ATCC 51222, was characterized and 
tested for its hypocholesterolemic effect in animal models. 
E. coprostanoligenes did not require cholesterol for growth but retained its 
cholesterol-reducing ability. The enzyme, cholesterol reductase, seems to be 
synthesized constitutively by the bacterium. Lecithin was required for growth. 
Excess of lecithin in media, however, did not improve bacterial growth. Optimal 
growth and coprostanol production were achieved at pH 7.0 to 8.0 in the presence 
of pyruvate, lactose, and reducing agents in media incubated at 37°C to 39°C. 
Addition of a buffer system into media seemed unnecessary for bacterial growth 
but increased coprostanol production. Most antibiotics inhibit bacterial growth and 
coprostanol production at a final concentration of 50 ng/ml with the exception of 
tetracycline. The resistance to tetracycline was dose-dependent. Ethanol as a 
solvent for tetracycline showed no effect with a final concentration up to 1.3%. 
The mechanism for tetracycline resistance is unknown. 
A resting cell assay was developed to evaluate the cholesterol reductase 
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activity of E. coprostanoligenes. Washed bacterial cells rapidly reduced cholesterol 
to coprostanol with micellar cholesterol as a substrate. Optimal assay conditions in 
a 1-ml reaction mixture were determined to be up to 1 h of incubation and up to 
0.25 mg of bacterial protein per assay with at least 1 mM of cholesterol substrate. 
The cholesterol reductase activity in cells decreased as a function of storage time at 
22°C, 4°C, and -20°C. Filling the headspace of the reaction mixture with H2 
increased the cholesterol reductase activity about 20%. Optimal cholesterol 
reductase activity occurred at pH 7.5 in sodium phosphate buffer. Pyruvate and 
reducing agents in the buffer increased the cholesterol reductase activity. 
E. coprostanoligenes was shown to be a Gram-positive coccobacilloid 
bacterium by use of the electron microscope. The cells were 0.5 to 0.7 ^im in 
diameter and 0.7 to 1.0 nm in length and occurred singly and in pairs. The 
bacterium reduced cholesterol through an indirect metabolic pathway. 
Intermediates, 4-choIesten-3-one and coprostanone, were detected in resting cell 
assays even though no accumulation of intermediates were observed in actively 
growing cultures with cholesterol. E. coprostanoligenes seemed to have a broad 
specificity for substrates. The bacterium converted all the intermediates to 
coprostanol, and it metabolized pregnenolone, progesterone, androstenediol, and 
etienic acid. In resting cell assays, NADH or FAD increased cholesterol reductase 
activity, but the activity was inhibited when NADH and FAD were added together 
to the reaction mixture. lodoacetate, NaCN, and NaN3 did not affect the en^one 
activity significantly, whereas EDTA inhibited the activity, and HgCl^ abolished the 
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cholesterol reductase activity completely. 
The en^one activity was found to be associated with bacterial cells. 
Attempts to achieve active cell-free extracts were not successful because a great 
loss of activity occurred after the bacterial cells were disrupted by sonication, 
passage through a French pressure cell, freezing and thawing, liquid N2 freezing 
and pulverizing, or en2ymatic digestion. Addition of different cofactors did not 
recover the cholesterol reductase activity. The genomic expression library of E. 
coprostanoligenes was constructed in an expression vector, bacteriophage X vector 
Xgtll. Much effort was made to develop a screening technique for detection of 
positive clones for cholesterol reductase. The cholesterol oxidase gene (cho) was 
considered a possible probe, the preliminary experiment, however, did not show 
hybridization of the gene with the genomic DNA of E. coprostanoligenes. Other 
cholesterol-related genes should be considered as potential probes. 
Effect of orally administered E. coprostanoligenes on plasma or serum 
cholesterol concentrations were investigated in rabbits, laying hens, and germ-free 
and conventional mice. E. coprostanoligenes caused a significant decrease of plasma 
cholesterol concentrations in dietaiy-induced hypercholesterolemic rabbits. The 
hypocholesterolemic effect was explained by the conversion of cholesterol to 
coprostanol by colonized E. coprostanoligenes in the intestine. 
In laying hens, the bacterium did not grow well in the intestine because of 
the high body temperature of hens. Even though orally administered bacteria did 
convert cholesterol to coprostanol in the intestine, plasma cholesterol 
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concentrations of hens were not affected. Normocholesterolemic hens may have a 
mechanism to regulate the plasma cholesterol concentration so that it will not be 
subject to the changes of cholesterol absorption in the intestine, or the conversion 
of cholesterol to coprostanol in the intestine may not been enough to reset 
cholesterol homeostasis mechanisms of hens. 
In germ-free mice, E. coprostanoligenes only survived temporarily in the 
intestine. The serum cholesterol concentrations were affected also transiently. The 
positive oxidation-reduction potential in the intestine of germ-free mice might be 
responsible for the dying-off of the anaerobic bacterium. E. coprostanoligenes did 
not colonize in the intestine of conventional mice either. The microflora in the 
intestine of conventional mice might have inhibited the growth and inhabitance of 
E. coprostanoligenes. Coinoculation of a nonpathogenic bacterium with E. 
coprostanoligenes in germ-free mice or modification of intestinal microflora in 
conventional mice would allow the colonization of the cholesterol-reducing 
anaerobic bacterium. Only then would the study of the impact of E. 
coprostanoligenes on serum cholesterol concentrations of mice be feasible. 
In conclusion, E. coprostanoligenes has many unique characteristics that 
make the bacterium more amenable than previously isolated cholesterol-reducing 
bacteria to be used for decreasing cholesterol content of foods and for lowering 
serum cholesterol concentrations of hypercholesterolemic individuals. More studies 
need to be conducted, however, before the cholesterol-reducing bacterium can be 
applied in the food-processing and pharmaceutical industries. 
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